<SEC-DOCUMENT>0001829126-23-003245.txt : 20230510
<SEC-HEADER>0001829126-23-003245.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510171836
ACCESSION NUMBER:		0001829126-23-003245
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nexalin Technology, Inc.
		CENTRAL INDEX KEY:			0001527352
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				275566468
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41507
		FILM NUMBER:		23907731

	BUSINESS ADDRESS:	
		STREET 1:		26072 MERIT CIRCLE, SUITE 106
		CITY:			LAGUNA NIGUEL
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		949-260-8090

	MAIL ADDRESS:	
		STREET 1:		26072 MERIT CIRCLE, SUITE 106
		CITY:			LAGUNA NIGUEL
		STATE:			CA
		ZIP:			92653
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nexalintechno_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:NXL="http://nexalin.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_NXL_nexalin.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001527352 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCentralIndexKey">0001527352</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonFraction name="NXL:PatentNetOfAmortization" contextRef="AsOf2022-12-31" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:LoanPayableOfficer" contextRef="AsOf2023-03-31" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:GainOnSaleOfShorttermInvestments" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:UnrealizedGainFromShorttermInvestments" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:GainOnSaleOfShorttermInvestments" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireTradingSecuritiesHeldforinvestment" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:PurchaseOfPatents" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:PaymentsOnLoanPayableShareholder" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:PaymentsOnNotesPayableOfficer" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:UnrealizedGainOnShorttermInvestments" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:RouAssetAndLeaseLiabilityRecorded" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_custom_DeviceSalesMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_country_CN" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0690" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0692" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0694" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0696" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0698" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NXL:WeightedAverageExercisePriceWarrantsExpiredOrCancelled" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0700" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nxl-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NXL:CommonStockParValue0.001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NXL:WarrantsExercisableForOneShareOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-20_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-20_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_DeviceSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:DeviceSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_DeviceSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:DeviceSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_LicensingFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:LicensingFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LicensingFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:LicensingFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-21_custom_PotentialJointVentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">NXL:PotentialJointVentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-012018-05-09_custom_USAsianConsultingGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-01</xbrli:startDate>
        <xbrli:endDate>2018-05-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NXL:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_USAsianConsultingGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-22_custom_MrOsserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NXL:MrOsserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-302021-11-02_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-30</xbrli:startDate>
        <xbrli:endDate>2021-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-02_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012018-10-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_LoansPayableOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NXL:LoansPayableOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LoansPayableOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NXL:LoansPayableOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-11_custom_LegacyVenturesInternationalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-012017-09-11_custom_LegacyVenturesInternationalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-01</xbrli:startDate>
        <xbrli:endDate>2017-09-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_LegacyVenturesInternationalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LegacyVenturesInternationalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_LegacyVenturesInternationalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LegacyVenturesInternationalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_AnInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:AnInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_AnInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:AnInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_VariousConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:VariousConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Range1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_Range1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Range2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_Range2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_SixCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:SixCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OneCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:OneCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ThreeCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:ThreeCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FourCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:FourCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerDMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerEMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerFMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527352</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM&#160;<span id="xdx_90F_edei--DocumentType_c20230101__20230331_z0JSqQvygub8"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--DocumentQuarterlyReport_c20230101__20230331_zK2tAD6bZsu1"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
<b>QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Quarterly Period Ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20230101__20230331_z9F7aEI2hOBb"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentTransitionReport_c20230101__20230331_z5URpMeD7pp3"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from _______ to _______.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span style="text-decoration: underline"><span id="xdx_90B_edei--EntityFileNumber_c20230101__20230331_zMNhvpMEJF5h"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityFileNumber">001-41507</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20230101__20230331_zuC8m2cPDShk"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityRegistrantName">NEXALIN TECHNOLOGY, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20230101__20230331_zdDAdFsn1Ld8"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20230101__20230331_zbAHUrC88dHg"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">27-5566468</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20230101__20230331_zXgAJZyedb36"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine1">1776 Yorktown</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20230101__20230331_zZpQa1hVksxd"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine2">Suite 550</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20230101__20230331_zyinO66VmYy3"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressCityOrTown">Houston</ix:nonNumeric></span>,
    <span id="xdx_909_edei--EntityAddressStateOrProvince_c20230101__20230331_zvbRlDOfPdMl"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressStateOrProvince">TX</ix:nonNumeric></span> 77056&#160;</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20230101__20230331_z4HYWp6z1Wv8"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressPostalZipCode">77056</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90A_edei--CityAreaCode_c20230101__20230331_zATyixbzmrx2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CityAreaCode">(832)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20230101__20230331_zgriC5qoMp19"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:LocalPhoneNumber">260-0222</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.001PerShareMember_zB6PNDNqzAxk"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember" name="dei:Security12bTitle">Common
    stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.001PerShareMember_zaPXeMOg2u23"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember" name="dei:TradingSymbol">NXL</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_908_edei--SecurityExchangeName_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.001PerShareMember_zbTseH0mleak"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--WarrantsExercisableForOneShareOfCommonStockMember_z4e5flxAcyM3"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember" name="dei:Security12bTitle">Warrants,
    exercisable for one share of Common Stock</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--WarrantsExercisableForOneShareOfCommonStockMember_zjYT0TBZuq2b"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember" name="dei:TradingSymbol">NXLIW</ix:nonNumeric></span></span></p>
    </td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_903_edei--SecurityExchangeName_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--WarrantsExercisableForOneShareOfCommonStockMember_zGLVVSpHLyEk"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746; <span id="xdx_90C_edei--EntityCurrentReportingStatus_c20230101__20230331_zpLMH93Yowfe"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#160;&#160;&#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). &#9746; <span id="xdx_906_edei--EntityInteractiveDataCurrent_c20230101__20230331_zTV6XhTZ1gs2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#160;&#160;&#9744;
No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging
growth company in Rule&#160;12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Accelerated Filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    Filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityFilerCategory_c20230101__20230331_z3SY5AALZhQl"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-Accelerated Filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    Reporting Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntitySmallBusiness_c20230101__20230331_z8941Al0iqLi"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20230101__20230331_zcg3FOf8fvb7"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <span id="xdx_902_edei--EntityExTransitionPeriod_c20230101__20230331_z9U8M6baoH39"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#9744; Yes&#160;&#160;&#160;&#9746;
<span id="xdx_909_edei--EntityShellCompany_c20230101__20230331_zArhj6QZCe71"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 8, 2023, there were <span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20230508_zNldaTYhx9yk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-05-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,286,562</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Registrant&#8217;s common stock
outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NEXALIN
TECHNOLOGY, INC. AND SUBSIDIARY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM&#160;10-Q</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Quarter Ended March&#160;31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td colspan="3" style="vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I. FINANCIAL INFORMATION</a></b></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="background-color: White">
    <td colspan="3" style="vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">ITEM&#160;1.</a></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Financial Statements</a></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">1</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Condensed Consolidated Balance Sheets at March&#160;31,2023 (unaudited) and December&#160;31, 2022</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Condensed
    Consolidated Statements of Operations and Comprehensive Gain (Loss) (unaudited) for the three months ended March&#160;31,2023 and
    2022</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) (unaudited) for the three months ended March&#160;31,2023 and 2022</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March&#160;31,2023 and 2022</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Notes to Unaudited Condensed Consolidated Financial Statements</a> </span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">5</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">ITEM&#160;2.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">ITEM&#160;3.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">ITEM&#160;4.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Controls and Procedures</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_011">PART II. OTHER INFORMATION</a></b></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td colspan="3" style="vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">ITEM&#160;1.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Legal Proceedings</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">ITEM&#160;1A.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Risk Factors</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">ITEM&#160;2.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">ITEM&#160;3.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Defaults Upon Senior Securities</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">ITEM&#160;4.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">ITEM&#160;5.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">ITEM&#160;6.</a></span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Exhibits</a></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">33</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_019">SIGNATURES</a></b></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">35</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_001"></span>PART I&#8212;FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_002"></span>ITEM 1. Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEXALIN
TECHNOLOGY, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zqH8opbIqE7h" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20230331" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221231" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March,&#160;31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December,&#160;31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_z4pbCDJfnX43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">ASSETS</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_znLJylIwLJN3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzrI6_zsznxwa9EeFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,961</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,743</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermInvestments_i02I_maCzrI6_zpseNHPuX36k" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,297,658</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,831,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzrI6_zw1AUIpC4Ur" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_i02I_maCzrI6_zngtjrAMkXei" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,270</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzrI6_zy72VeWyF1qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,330</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,282</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtCzrI6_maCzO3I_z8LCD70qYc5d" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,875,769</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,425,462</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzO3I_zJOqZjkCtCIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">ROU Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,171</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzO3I_z3vc3eBX4Aj2" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Equipment, net of accumulated depreciation of $<span id="xdx_900_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c20230331_pp0p0" title="Accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,315</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c20221231_pp0p0" title="Accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,181</ix:nonFraction></span>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PatentNetOfAmortization_i02I_maCzO3I_z7m76bg3lfmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Patent, net of amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NXL:PatentNetOfAmortization" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,536</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i02TI_mtCzO3I_zlp3UssqVd02" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,930,473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,432,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z4OmhZnyJljd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zQJAI106RBy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_maCz8fN_zr3ttQLBNQ2" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: 400; font-style: normal; text-align: left">Accounts payable (Includes related party of $<span id="xdx_90D_ecustom--AccountsPayableRelatedParty_c20230331_pp0p0" title="Accounts payable related party"><ix:nonFraction name="NXL:AccountsPayableRelatedParty" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--AccountsPayableRelatedParty_c20221231_pp0p0" title="Accounts payable related party"><ix:nonFraction name="NXL:AccountsPayableRelatedParty" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></span>, respectively)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">658,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz8fN_znZUUysjQwId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">597,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCz8fN_zGKd4bnkRmVa" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Lease liability, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,026</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LoanPayableOfficer_i02I_maCz8fN_zsY029KcG7W4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Loan payable - officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NXL:LoanPayableOfficer" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NotesPayableCurrent_i02I_maCz8fN_zwObGdjcAMF1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Note payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02TI_mtCz8fN_maCzd5v_zPSkJtCBkRA1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,195,444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,948,986</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_z0k7qgwbGgkg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Long-term Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzd5v_zomYsi9xr75d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Lease liability, net of current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,463</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtCzd5v_maCzjyw_z45SUNmUIv36" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,195,444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,953,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommitmentsAndContingenciesDisclosureAbstract_i01B_zzt94wYHD0jc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Commitments and Contingencies (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquityAbstract_i01B_zgMUOIIpZhp3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Stockholders&#8217; Equity (Deficit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_pp0p0_maCzFn9_zV0e9BHJcvZ4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_pdd" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20221231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20230331_pdd" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20230331_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20230331_pdd" title="Common stock, shares outstanding"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20221231_pdd" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,286,562</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2023 and December 31, 2022,&#160;&#160;respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCzFn9_zhfCqoGsjFCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i02I_maCzFn9_z8UUX3aXSnz9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,824,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,824,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzFn9_zjCT1RaFvVQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,137,754</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">72,389,340</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_i02TI_mtCzFn9_maCzjyw_zKf6MNr0V4i8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,735,029</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,478,687</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtCzjyw_zAlzRXFnvhfa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,930,473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,432,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>NEXALIN
TECHNOLOGY, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS)<br />
(Unaudited)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_zviyfRMKmV05" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230101_20230331" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220101__20220331_zA6OPmLP2qql" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br />
March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_maCzHv8_z6Sqr9z1NfP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: 400; font-style: normal; text-align: left">Revenues, net (Includes related party of $<span id="xdx_902_ecustom--RevenuesFromRelatedParties_c20230101__20230331_pp0p0" title="Revenue from related parties"><ix:nonFraction name="NXL:RevenuesFromRelatedParties" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_900_ecustom--RevenuesFromRelatedParties_c20220101__20220331_pp0p0" title="Revenue from related parties"><ix:nonFraction name="NXL:RevenuesFromRelatedParties" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,499</ix:nonFraction></span> for the three months ended March 31, 2023 and March 31, 2022, respectively)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">323,322</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_msCzHv8_zOWQoEQm0dYk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,110</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,015</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzHv8_maCzH5x_zMJ36co1iaEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,307</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB_zY3tExgCaX8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfessionalFees_i01_maCzJfD_z59KbAhWIOK5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LaborAndRelatedExpense_i01_maCzJfD_zfmB719V68Jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,594</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzJfD_z4nV54qtiOtc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,953</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,374</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_i01T_mtCzJfD_msCzH5x_zkvAKkEmhEq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">802,876</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">652,424</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01T_mtCzH5x_maCzZt5_z4qHHDrTuCRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">779,426</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">375,117</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z92uZJmNvPS1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense), net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestExpense_i01N_pp0p0_di_msCzG5d_zDo71rkpwJLd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,837</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,132</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--GainOnSaleOfShorttermInvestments_i01_pp0p0_maCzG5d_z4DTGKVCswK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on sale of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NXL:GainOnSaleOfShorttermInvestments" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,772</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherIncome_i01_maCzG5d_zsTfQNBWNWni" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzG5d_maCzZt5_zIsZcyTX0kK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,012</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,132</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01T_mtCzZt5_maCzuBE_zoWcPjRcFxYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">748,414</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">393,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossTaxAbstract_iB_zMdQGUmPJG97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--UnrealizedGainFromShorttermInvestments_i01_maCzuBE_zivYoMtslSd6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Unrealized gain from short-term investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NXL:UnrealizedGainFromShorttermInvestments" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,069</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCzuBE_zAhmfz0rZOfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">707,345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">393,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted_zoNcNg2X8ePd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share attributable to common stockholders - Basic and Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="NXL:NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="NXL:NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WeightedAverageSharesOutstanding_zXemrwvMshw9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted Average Shares Outstanding - Basic and Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NXL:WeightedAverageSharesOutstanding" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,286,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NXL:WeightedAverageSharesOutstanding" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,888,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br />
</span></p>



<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEXALIN
TECHNOLOGY, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br />
(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zJmE4kk9iOV5" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zn1HaZfuAxhk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zdIKmJkrET6a" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z0bQUh94cO7k" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zcA5ZiBg7Hmd" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_zSVKxcqC96C6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated Other Comprehensive Gain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br />
Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> (Loss) on ST</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> Equity </td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Investments</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_435_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zMQBsEXKVir" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance as January 1, 2022</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh0Dt8wH2BUk" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,879,923</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,880</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,004,703</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,691,524</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,681,941</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Stock issued for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Stock compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">393,249</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">393,249</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zfnVmz8yc033" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance as of March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNuIm04tUtmb" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,107,278</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,084,773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,972,590</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated Other Comprehensive Gain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br />
Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> (Loss) on ST</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> Equity </td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Investments</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_433_c20230101__20230331_eus-gaap--StockholdersEquity_iS_z0nBeXwpZJul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance as of January 1, 2023</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJJ1rRsWZQa7" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,286,562</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,287</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,313</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,824,427</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">72,389,340</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,478,687</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_iP3us-gaap--SharesOutstanding_ztziPKNlD4n7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other comprehensive gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,756</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zHjO9Sh4vw9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">748,414</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">748,414</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zZLecN67gnXd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance as of March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrppe3uMPpfg" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,286,562</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,069</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,824,427</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,137,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,735,029</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>



<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEXALIN
TECHNOLOGY, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_301_112_zM6ph4r88VO6" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20230101__20230331_z2ukATKRxQ2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220101_20220331" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br />
March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: red; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zHGFY4xIV8x7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_maCzXJN_zLu9CXbXocAf" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net Loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">748,414</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">393,249</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zrASV1y3E5Za" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maCzXJN_z6ZRUfEiWU81" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Depreciation_i02_maCzXJN_zeiaxZnrxGH6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AcquisitionCosts_i02_maCzXJN_z1g37vCOWt" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AcquisitionCosts" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNoncashExpense_i02_maCzXJN_zcI5wQjqsVBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,371</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--GainOnSaleOfShorttermInvestments_i02N_di_msCzXJN_zEyQxe43gbQ4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on sale of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NXL:GainOnSaleOfShorttermInvestments" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,772</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zCEpxbb0kl89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msCzXJN_zdzqToJk4oi1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,540</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzXJN_z7Pt3Urr61Bh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,671</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msCzXJN_zBYvd4Eb5iae" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,900</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_i02_maCzXJN_zo0XWbU8YwGe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzXJN_zgUK3IjSIwd1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">353,609</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,386</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzXJN_zIbMAfe82sy7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,838</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,675</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_maCzXJN_zV9P8umafMH7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzXJN_zpBBMfWEXNI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,234</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,087</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzXJN_maCzRUg_zGaChYoV3Dk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,314,649</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">203,271</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z3Z8CjQexJ3b" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromSaleOfShortTermInvestments_maCzCYL_zTzeOKVaWFu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Sale of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,599,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsToAcquireTradingSecuritiesHeldforinvestment_iN_di_msCzCYL_zzTYvmVlFV78" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchase of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireTradingSecuritiesHeldforinvestment" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,022,293</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--PurchaseOfPatents_iN_di_msCzCYL_zhzRQT5qetyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Purchase of patents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NXL:PurchaseOfPatents" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,196</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_pp0p0_mtCzCYL_maCzRUg_z3pPPtWYndnc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash provided by investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,526,867</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zfJU517L0u41" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzmZf_zwGGfMF0soQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Sale of common stock for cash, net of financing fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--PaymentsOnLoanPayableShareholder_i01N_di_msCzmZf_zxiGHaDxjc17" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Payments on loan payable - shareholder</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NXL:PaymentsOnLoanPayableShareholder" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--PaymentsOnNotesPayableOfficer_i01_maCzmZf_zSehZHN0vGeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Payments on notes payable - officer</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NXL:PaymentsOnNotesPayableOfficer" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">200,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0p0_mtCzmZf_maCzRUg_zDStPy6q5rFl" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">200,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzRUg_zTPBltflYeT6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,218</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">203,171</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cash and cash equivalents - beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">661,778</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents - end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">174,961</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">458,607</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zxWe8GzzG0hd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--UnrealizedGainOnShorttermInvestments_i01_zs3yO7H4d9Xj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Unrealized gain on short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NXL:UnrealizedGainOnShorttermInvestments" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--RouAssetAndLeaseLiabilityRecorded_i01_za9KyZzDshi8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">ROU asset and lease liability recorded</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NXL:RouAssetAndLeaseLiabilityRecorded" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,359</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>



<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEXALIN
TECHNOLOGY, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_801_eus-gaap--NatureOfOperations_zDAdXvSwT9ul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; <span id="xdx_82D_zyeb6O7vrhU9">NATURE OF THE ORGANIZATION AND BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nexalin
Technology, Inc. (&#8220;NV Nexalin&#8221;) was formed on October&#160;19, 2010 as a Nevada corporation. The Company&#8217;s principal
offices are located at 1776 Yorktown, Suite 550, Houston, Texas 77056.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;6, 2019, Neuro-Health International, Inc. (&#8220;Neuro-Health&#8221;), a Nevada corporation, a wholly owned subsidiary
of NV Nexalin, was formed. Neuro-Health had no activity from December&#160;6, 2019 (Inception) through March&#160;31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November&#160;22, 2021, NV Nexalin entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Nexalin Technology,
Inc., a Delaware corporation (&#8220;Nexalin&#8221;, or the &#8220;Company&#8221;). Pursuant to the Merger Agreement, NV Nexalin merged
with and into Nexalin with all shareholders of NV Nexalin receiving one common share of Nexalin in exchange for twenty shares of NV Nexalin
held at the time of the Merger Agreement. NV Nexalin treated the transaction as a corporate reorganization with the historical consolidated
financial statements of NV Nexalin becoming the historical consolidated financial statements of Nexalin. Nexalin had nominal assets and
liabilities and did not conduct any operations prior to the reorganization other than its incorporation. NV Nexalin has retroactively
applied the 20-for-1 exchange, effective on November&#160;22, 2021, to share and per share amounts on the unaudited condensed consolidated
financial statements for the three months ended March&#160;31, 2023 and 2022. NV Nexalin&#8217;s authorized shares of common stock were
not affected as a result of the Merger Agreement. As a result of the Merger Agreement, NV Nexalin was dissolved, and Neuro-Health became
a subsidiary of Nexalin. The Company completed its initial public offering on September&#160;16, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial public offering consisted of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zo5FUboLWCk7" title="Shares issued during the period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-09-012022-09-20_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,315,000</ix:nonFraction></span> units consisting of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued during the period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-09-012022-09-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,315,000</ix:nonFraction></span> shares of Common Stock and <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU1seVF8r347" title="Shares issued during the period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-09-012022-09-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,315,000</ix:nonFraction></span> accompanying warrants
to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220920_pdd" title="Warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-20" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,315,000</ix:nonFraction></span> shares of common stock. Each share of common stock was sold together with one Warrant, each to purchase one
share of common stock with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220920_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-09-20" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></span> per share at a combined offering price of $4.15, for gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220901__20220920_pp0p0" title="Proceeds from issuance of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-09-012022-09-20" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,607,250</ix:nonFraction></span>,
before deducting underwriting discounts and offering expenses. In addition, the underwriters purchased <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zOvzs5cvnJlb" title="Shares issued during the period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-09-012022-09-20_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">347,250</ix:nonFraction></span> warrants for net proceeds
of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pp0p0" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-09-012022-09-20_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,473</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares and warrants began trading on the Nasdaq Capital Market tier of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) on September&#160;16,
2022, under the symbols &#8220;NXL&#8221; and &#8220;NXLIW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this report, the terms &#8220;Nexalin,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and the &#8220;Company&#8221; refer
to Nexalin Technology, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic.
We developed an easy-to-administer medical device &#8212; referred to as Generation 1 or Gen-1 &#8212; that utilizes bioelectronic medical
technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy
stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) as a Class II device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we continue providing services to medical professionals to support patients&#8217; use of the Gen-1 devices which were in operation
prior to December&#160;2019, we are not making new sales or new marketing efforts of Gen-1 devices. We continue to derive revenue
from devices which we sold or leased prior to the FDA&#8217;s December&#160;2019 reclassification announcements. This revenue
consists of monthly licensing fees and payments for the sale of electrodes. We have suspended marketing efforts for new sales of
devices related to the Gen-1 device for treatment of anxiety and insomnia in the United States until the Nexalin regulatory team
makes a decision on amending our existing 510(k) application at 4 milliamps. A new pre-sub document in preparation of a new 510(k)
for our Gen-3 Halo headset at 15 milliamps was filed with the FDA in January of 2023. Formal comments to our pre-sub document filing
were received in March of 2023. A formal meeting to address FDA comments is scheduled for May of 2023.&#160;&#160;</span></p>

<ix:exclude><p id="xdx_231_ziPTxODjbEH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div id="xdx_23C_z1uEBFnsaS49" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zSG1SMMEVHie" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zlcYll9wbSK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have designed and developed a new advanced wave form technology to be emitted at 15 milliamps through new and improved medical devices
referred to as Generation 2 or Gen-2 and Generation 3 or Gen-3. Gen-2 is a clinical use device with a modern enclosure to emit the new
15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual
clinic setting similar to existing Tele-health platforms. Preliminary data provided by the University of California San Diego supports
the safety of utilizing our 15 milliamp waveform technology, however the determination of safety and efficacy of medical devices in the
United States is subject to clearance by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are currently designing clinical trial strategies for the use of Gen-3 for the treatment of substance use disorders including opiate,
cocaine, and alcohol abuse. Recently the Gen-2 device was tested in pilot trials in China for the treatment of Alzheimer&#8217;s disease,
and dementia. Continued pilot testing for Alzheimer&#8217;s and dementia, cognition and memory, and neurotransmitter changes is planned
in China in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Emerging
Growth Company</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and approval of any golden parachute payments not previously approved. Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither
an emerging growth company, nor an emerging growth company which has opted out of using the extended transition period, difficult or
impossible because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
continues to evaluate the impact of the economy and the capital markets and has concluded that, while it is reasonably possible that
events could have negative effects on the Company&#8217;s financial position and results of its operations, the specific impacts are
not readily determinable as of the date of these consolidated financial statements. The unaudited condensed consolidated financial statements
do not include any adjustments that might result from the outcome of uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may
also have a direct impact on the Company&#8217;s operating results and financial position in the future. The ultimate duration and magnitude
of the impact and the efficacy of government interventions on the economy has and may continue to indirectly impact the Company because
of its current dependence upon its distributor relationship with Wider Come Limited. Wider Come Limited acts as a distributor for the
Company&#8217;s devices in China and Asia. Because of significant restrictions imposed by the Chinese government during the COVID-19
pandemic through calendar year 2022 and into 2023, Wider&#8217;s ability to market and sell the Company&#8217;s devices has been negatively
impacted, resulting in decreased revenue to the Company. Patients and salespeople have been restricted in their movements resulting in
a significant slowdown in the medical and other sectors. Significant efforts and funds expended by our Chinese distributor has led to
regulatory approval in China in both depression and insomnia thus far which has allowed for sales of our devices in China in 2022, and
into 2023. The extent of future impact is dependent on future developments, including future activities by the Chinese government and
other possible events which are highly uncertain and not in the Company&#8217;s control, including new information which may emerge concerning
the spread and severity of COVID-19, or any of its variants, and actions taken to address its impact, among others. The repercussions
of this health crisis could have a material adverse effect on the Company&#8217;s business, financial condition, liquidity and operating
results.</span></p>

<ix:exclude><p id="xdx_23D_zvM6EfMO1Ih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_23F_zi4o5Def9i0e" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zzZqhyyLNLPj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zKNDNcez0axc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z31oT8cXpmc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; <span id="xdx_824_z9mHyOKMXo7a">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern,
which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At March&#160;31, 2023,
we had a significant accumulated deficit of approximately $73.1<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230331_zr0dGuvM81Sg" title="Accumulated deficit" style="display: none"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">73,137,754</ix:nonFraction></span> million. For the three months ended March&#160;31, 2023, we had a loss
from operations of approximately $779<span id="xdx_90E_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_c20230101__20230331_zHXNgDOU5SS1" title="Loss from operation" style="display: none"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">779,426</ix:nonFraction></span> thousand and negative cash flows used in operations of approximately $1.3<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20230101__20230331_zwAry1sZw8We" title="Cash flows from operations" style="display: none"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,314,649</ix:nonFraction></span> million. While we had
a working capital surplus as of March&#160;31, 2023 of approximately $<span id="xdx_90D_ecustom--WorkingCapitalDeficit_iI_pn3n3_dm_c20230331_z4EDNLOKO0Ci" title="Working capital deficit"><ix:nonFraction name="NXL:WorkingCapitalDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million, our operating activities consume most of our cash
resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur operating losses as we execute our development plans, as well as undertaking other potential strategic and
business development initiatives through 2023 and through the twelve months from the date of this report. In addition, we have had and
expect to have negative cash flows from operations, at least into the near future. We have previously funded these losses primarily through
the sale of equity and issuance of convertible notes. The accompanying unaudited consolidated financial statements do not include any
adjustments that might be necessary should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue as a going concern will be dependent upon our ability to execute on our business plan, including the ability to generate
revenue from the proposed joint venture and obtain U.S. approval for the sale of our devices in the United States, and, if necessary,
our ability to raise additional capital. Although no assurances can be given as to our ability to deliver on our revenue plans or that
unforeseen expenses may arise, management has evaluated the significance of the conditions as of March&#160;31, 2023 and has concluded
that due to the receipt of the net proceeds from the completion of the Initial Public Offering, we have sufficient cash and short-term
investments on hand to satisfy its anticipated cash requirements for the next twelve months from the issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zVTZsUtZX1hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8212; <span id="xdx_82F_zJdfPqCglvkb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ziwgyhRgJr29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zCEbVvtgn9z9">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial information has been prepared in accordance with Generally Accepted Accounting
Principles (&#8220;GAAP&#8221;) for interim financial information. In the opinion of management, such financial information includes
all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company&#8217;s
financial position and the operating results and cash flows. Operating results for the three months ended March&#160;31, 2023 and 2022
are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant
to the rules of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). These unaudited condensed consolidated financial
statements and related notes should be read in conjunction with the Company&#8217;s audited consolidated financial statements for the
year ended December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_ztxBpm3wVJH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zoJyURshDri3">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Nexalin and its wholly owned subsidiary Neuro-Health. Intercompany accounts
and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zVMkEAgoER8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zu2QFZ1AvS8b">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at
the date of the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<ix:exclude><p id="xdx_237_z0tr4kJPlwua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_237_zfWTy4zhtUF7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_23D_zuMkWiV53Cc4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zP3wCBc1Jfw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zmmdLmF1qRMb">Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company
determines if the contract is within the scope of ASC Topic 606 and then evaluates the contract using the following five steps: (1) identify
the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.
These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements
are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its
acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer
of the Company&#8217;s electrodes will pay a royalty to the Company for a three-year period beginning January&#160;1, 2022. The amount
of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Streams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives revenues from its license agreements by charging a monthly licensing fee for the duration of the agreement. The Company
derives revenues from equipment by selling additional individual electrodes to customers for use with the Nexalin Device. The Company
receives revenue from the sale in China of its Devices to its acting distributor and from the sale of products relating to the use of
those Devices. The Company derives revenue as a royalty fee from the China-based manufacturer for electrodes ordered in connection with
the Company&#8217;s China sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied as long as the
licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time
in which the invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that the Company&#8217;s equipment and Device revenue has one performance obligation. That performance obligation is satisfied
when the equipment and Devices are shipped. The Company recognizes revenue at a point in time in which the electrodes and Devices are
shipped to the customer. The Company does not offer a warranty on the electrodes and Devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of
individual treatments on patients by customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that royalty revenue has one performance obligation. The performance obligation is satisfied at the time the Electrode manufacturer
invoices the acting distributor for the sale to the acting distributor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify; border-collapse: collapse">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
Financing Component &#8212; the Company does not adjust the promised amount of consideration for the effects of a significant financing
component since the Company expects, at contract inception, that the period between when the Company transfers a promised goods or services
to the customer and when the customer pays for that service will be one year or less.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
    Performance Obligations &#8212; all performance obligations related to contracts with a duration of less than one year, the Company
    has elected to apply the optional exemption provided in ASC Topic 606 and therefore, is not required to disclose the aggregate amount
    of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting
    period.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
    and Handling Activities &#8212; the Company elected to account for shipping and handling activities as a fulfilment cost rather than
    as a separate performance obligation.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to Invoice &#8212; the Company has a right to consideration from a customer in an amount that corresponds directly with the value
    to the customer of the Company&#8217;s performance completed to date the Company may recognize revenue in the amount to which the
    entity has a right to invoice.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_236_zvpIRxUgXf21" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_znPEyk3fhBM2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zGrgXaHCyfyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregated
Revenues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Revenue Streams</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
consists of the following by service offering:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zKXKMNzW1PKb" style="display: none">Schedule of disaggregation of revenue</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Device Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" title="Total" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" title="Total" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31_custom_DeviceSalesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Licensing Fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_custom_LicensingFeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31_custom_LicensingFeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_custom_OtherMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">290</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31_custom_OtherMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,679</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Geographic Locations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">U.S. Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" title="Total" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" title="Total" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">China Sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31_country_CN" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,499</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zhxXaSYjMQDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contract
Modifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no contract modifications during the three months ended March&#160;31, 2023 and 2022. Contract modifications are not routine in
the performance of the Company&#8217;s contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives payment for equipment and devices in advance of shipping. The Company recognizes the revenue as being earned upon shipment.
<span id="xdx_906_eus-gaap--DeferredRevenue_iI_pdp0_do_c20230331_za0NdTo1G8y1" title="Deferred revenue"><span id="xdx_902_eus-gaap--DeferredRevenue_iI_pp0p0_do_c20221231_zuh5FH9Q2wq2" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2023-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> deferred revenue was recognized as of March&#160;31, 2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmOBQHnAe6B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zUHANBYlCnsg">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through,
as well as maintaining cash balances, with major financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="NXL:ShortTermInvestmentsPolicyTextBlock"><p id="xdx_841_ecustom--ShortTermInvestmentsPolicyTextBlock_zWieSHVRS2m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zVP5jxNasouc">Short-Term
Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance
sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value
is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or
liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in accumulated other comprehensive
income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income
(expense), net. For declines in the fair values of equity securities that are considered other-than-temporary, impairment losses are
charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments,
including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments on March&#160;31,
2023 and December&#160;31, 2022, respectively.</span></p>

<ix:exclude><p id="xdx_23E_zXKgM5RWKAt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_231_zA76KGR6RL2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zr16Zu3ud1u6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zfs6vQT0JHt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zT4W6RK5rK4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zN12aHCf3Uf5">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivables are reported at their outstanding unpaid principal balances, net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#8217;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. Payments are generally due within 30 days of invoice. The Company writes off accounts receivable against
the allowance for doubtful accounts when a balance is determined to be uncollectible. During the three months ended March&#160;31, 2023
and 2022, the Company did <span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pp0p0_do_c20230101__20230331_z1pga6fdJSQe" title="Writeoff accounts receivable"><span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pdp0_do_c20220101__20220331_zqKYSXNGmcK7" title="Writeoff accounts receivable"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2023-01-01to2023-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2022-01-012022-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t write off accounts receivable. The Company did <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20230331_zljQzIUit65g" title="Allowance for doubtful accounts"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20221231_zSaymtCYV9og" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2023-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t record an allowance for doubtful accounts on March&#160;31,
2023 and December&#160;31, 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zy8yXrzUygx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zAajoedepadc">Inventory</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods and components stated at the lower of cost or net realizable value with cost determined on a first-in first-out
basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete, slow-moving, quantities
in excess of demand, or otherwise non-saleable items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zasktAHwlD87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zdEHP5BzTYGa">Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
is recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally
five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance
and repairs are charged to expense as incurred. The Company capitalizes costs attributable to the betterment of property and equipment
when such betterment enhances the functionality of the asset or extends the useful life of the asset. Should an asset be disposed of
before the end of its useful life, the cost and accumulated depreciation at that date is removed from the consolidated balance sheets,
with the resulting gain or loss, if any, reflected in operations in that period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="NXL:PatentsPolicyTextBlock"><p id="xdx_844_ecustom--PatentsPolicyTextBlock_zOzG5NGCjWui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zkG0LVSPscje">Patents</span></i>&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was
$<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20230101__20230331_znJU6uuKZbtf" title="Amortization expense"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20220101__20220331_z9xTxJ8RBtp4" title="Amortization expense"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> for the three months ended March&#160;31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zN3dnVivAMF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zXYsMlXZIYKa">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets
and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax
bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are
expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. At March&#160;31, 2023 and December&#160;31, 2022, the Company had a full valuation allowance applied
against its net tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcXCxj3XCBul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span><span id="xdx_86D_zguvg96Hkg0d">Fair
Value Measurements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, <i>Fair Value Measurements and Disclosures</i>, fair value is the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about
risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or
generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<ix:exclude><p id="xdx_235_zu2qNzzWOove" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_232_zh5dooJNc7v1" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zz3ZCvDXql1i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zFouC1Kn34ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1: Quoted prices are available in active markets for identical assets or liabilities as of
                                            the reporting date. Active markets are those in which transactions for the asset or liability
                                            occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2: Pricing inputs are other than quoted prices in active markets included in Level 1, which
                                            are either directly or indirectly observable as of the reported date. Level 2 includes those
                                            financial instruments that are valued using models or other valuation methodologies. These
                                            models are primarily industry-standard models that consider various assumptions, including
                                            quoted forward prices for commodities, time value, volatility factors and current market
                                            and contractual prices for the underlying instruments, as well as other relevant economic
                                            measures. Substantially all of these assumptions are observable in the marketplace throughout
                                            the full term of the instrument, can be derived from observable data or are supported by
                                            observable levels at which transactions are executed in the marketplace.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3: Pricing inputs include significant inputs that are generally less observable from objective
                                            sources. These inputs may be used with internally developed methodologies that result in
                                            management&#8217;s best estimate of fair value. The significant unobservable inputs used
                                            in the fair value measurement for nonrecurring fair value measurements of long-lived assets
                                            include pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRVlNQryVQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zV52sLvBiGKd">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, short-term investments, accounts receivable, inventory, prepaids, accounts payable and accrued expenses, and
other current liabilities approximate their fair values based on the short-term maturity of these instruments. The carrying amount of
the loans payable approximates the estimated fair value for this financial instrument as management believes that such debt and interest
payable on the note approximates the Company&#8217;s incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the amortized cost, unrealized gains and the fair value at March&#160;31, 2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zs3t7FXsNSp9" style="display: none">Schedule of amortized cost, unrealized gains</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gain</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" title="Amortized Cost" style="width: 9%; text-align: right"><ix:nonFraction name="NXL:AmortizedCost" contextRef="AsOf2023-03-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,256,589</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" title="Unrealized Gain" style="width: 9%; text-align: right"><ix:nonFraction name="NXL:UnrealizedGain" contextRef="From2023-01-012023-03-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,069</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" title="Fair Value" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-03-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,297,658</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" title="Amortized Cost" style="text-align: right"><ix:nonFraction name="NXL:AmortizedCost" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,256,589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" title="Unrealized Gain" style="text-align: right"><ix:nonFraction name="NXL:UnrealizedGain" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" title="Fair Value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,297,658</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" title="Amortized Cost" style="text-align: right"><ix:nonFraction name="NXL:AmortizedCost" contextRef="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,794,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" title="Unrealized Gain" style="text-align: right"><ix:nonFraction name="NXL:UnrealizedGain" contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" title="Fair Value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,831,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" title="Amortized Cost" style="text-align: right"><ix:nonFraction name="NXL:AmortizedCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,794,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" title="Unrealized Gain" style="text-align: right"><ix:nonFraction name="NXL:UnrealizedGain" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" title="Fair Value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,831,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zgTFJ0y0id8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the carrying value and fair value of the Company&#8217;s financial assets measured at fair value as of March&#160;31,
2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B3_zCQv7SG86EE6" style="display: none">Schedule of fair value, assets measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" title="Financial assets" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,297,658</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Financial assets" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,297,658</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" title="Financial assets" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" title="Financial assets" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" title="Financial assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,831,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" title="Financial assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,831,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" title="Financial assets" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" title="Financial assets" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zHJhhT0qg8Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_23B_zx8OzfKeFGj9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zoAgAJlA639a" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zcm4pj7HVmx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zWmitsjX5Ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zL6qrgolIYrg">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
The dilutive effect, if any, of warrants is calculated using the treasury stock method. These shares were included in the basic and diluted
net loss per common share on the unaudited condensed consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including
these potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than
the most recent fair value of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B1_zLU5zHzGbeWe" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br />
March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left">Warrants</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Total" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,662,250</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Total" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,662,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zcswmzwYtBwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlC9wDc6glwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zFnBIzw03kOf">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 718, <i>Compensation &#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;), which requires the
measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in
the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASU 2018-07 Compensation &#8212; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the
Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation
methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="NXL:WarrantAccountingPolicyTextBlock"><p id="xdx_84D_ecustom--WarrantAccountingPolicyTextBlock_z3UGM7qS0ERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zwUktMJPX3o7">Warrant
Accounting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued private and public warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815-40,
Derivatives and Hedging: Contracts in Entity&#8217;s Own Equity (&#8220;ASC 815-40&#8221;). The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is assessed as part of this evaluation. During the
reporting periods the Public Warrants were outstanding, they were precluded from liability classification, being equity-classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zxeAWPBgERL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zm3EYQPjFwl2">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
research and development costs are charged to operations as incurred. For the three months ended March&#160;31, 2023 and 2022, the Company
recorded $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,833</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,565</ix:nonFraction></span>, respectively, in selling, general and administrative expenses on the unaudited condensed consolidated statements
of operations.</span></p>

<ix:exclude><p id="xdx_231_zIe2Cf6ZPgnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23C_ziDKuJeUIplh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zhdf2griClFc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_ztJy6fcR2iR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LessorLeasesPolicyTextBlock"><p id="xdx_84E_eus-gaap--LessorLeasesPolicyTextBlock_ziXIOmBL8Lmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zM5Iphrt0J28">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease is defined as an agreement that conveys the right to control the use of identified property, plant or equipment (right of use asset
or &#8220;ROU asset&#8221;) for a period of time in exchange for consideration. The Company accounts for its leases in accordance with
ASC 842, Leases, which requires that an ROU asset identified in a lease to be recorded as a noncurrent asset with a related liability.
The Company does not record ROU assets for those agreements of a twelve-month duration or less. The Company recognized a ROU asset and
corresponding lease liability on its balance sheets related to its office lease agreement. See Note 9, Leases, for further discussion,
including the impact on the Company&#8217;s unaudited condensed consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets include any initial direct costs and prepaid lease payments and exclude any lease incentives. Lease expense for minimum lease
payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate the lease
if it is reasonably certain that the Company will exercise that option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zk24gkl5K1N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zPZI23trzxol">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February&#160;2020, the FASB issued ASU 2020-02,
Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting
Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments are in effect
for the Company for interim and annual periods in fiscal years beginning after December&#160;15, 2022. The adoption on January 1, 2023
modified the way the Company analyzes financial instruments, but it did not have a&#160;material impact on our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80A_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zgs8QBaY3Q63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8212; <span id="xdx_823_zO5DBgQn13o8">ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consist of the following amounts:</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zWGpl1Uc50x2" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B2_zB0TmldCVjSd" style="display: none">Schedule of accrued expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230331_zwdMPITlfCCi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20221231_zQdRn0BzFWSc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAUCzJ3A_zw7745EclQu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued interest</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,501</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,501</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_zrDMDyBIp372" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued &#8211; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,321</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SettlementLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_z9P6h78x3sld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued settlement liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">336,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">336,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpense_iI_pp0p0_maAUCzJ3A_znBHmHpZLGF6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accrued research and development expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NXL:AccruedResearchAndDevelopmentExpense" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NXL:AccruedResearchAndDevelopmentExpense" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0p0_mtAUCzJ3A_zML3qxSxolBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedUtilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedUtilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">539,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPzBYTBKyOu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8212; <span id="xdx_824_zDOIujGOFkS4">NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Joint Venture</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;21, 2018, the Company entered into the first of a series of agreements providing for the establishment of a joint venture
(&#8220;JV&#8221;) agreement (the &#8220;JV Agreement&#8221;) with Wider Come Limited, a China company (&#8220;Wider&#8221;) for the
purpose of marketing, sale and distribution of the Company&#8217;s proprietary devices for the treatment of (i) anxiety, depression and
insomnia (&#8220;ADI&#8221;) and (ii) Alzheimer&#8217;s and dementia (&#8220;AD&#8221;) in the applicable territories. Wider has an experienced
medical technology team in China and when formed, the JV will design and implement a comprehensive business model and distribution plan
for our devices in China, Hong Kong, Macau and Taiwan. The JV will be formed following the completion of certain funding, clinical study,
and publication milestones, which Wider has agreed to undertake but not yet completed, as well as resolution of potential regulatory
concerns in China. Following its formation, the JV will design and implement a comprehensive business model and distribution plan for
our devices in China, Hong Kong, Macau and Taiwan.</span></p>

<ix:exclude><p id="xdx_237_zfVO301l45ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_23E_zwWWoQlzFXja" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zzzpkZUaQTJa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_z2csxqI2cd44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
originally contemplated, each of the parties to the JV would hold a <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20180921__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PotentialJointVentureMember_z1Q4coRZBaC1" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2018-09-21_custom_PotentialJointVentureMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% interest in the equity, profits and losses, shareholder voting,
management control and rights to use production capacity of the facility. The Company will provide an Asian territory exclusive distribution
license for ADI treatment to the JV and Wider. As originally contemplated the JV, if completed, will be controlled by an equally represented
Board of Directors in which neither entity has sole decision-making ability over day-to-day or significant operational decisions. The
parties may determine to alter the equity interest or board composition of the Joint Venture or other economic terms as they move closer
to its implementation. As of March&#160;31, 2023, the JV has not been established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&#160;22, 2019, the Company entered into a supplementary agreement to the JV Agreement (the &#8220;Supplementary Agreement&#8221;).
At the time of the May&#160;2019 Supplementary Agreement, the parties desired to expand the scope of the JV to include and address the
pain management opportunities for our devices and technology. Pursuant to the Supplementary Agreement, Wider was to fund the JV within
thirty days of execution of the JV Agreement with $600,000 in cash to be used for clinical trials and other activities related to pain
management utilization of our devices and technology in China. Within thirty days of the funding, the Company was to issue 5% of the
Company in common stock to Wider&#8217;s shareholders. As of the date of this report the JV has yet to be formally established and therefore
the $600,000 has not been funded. Further, the parties have determined not to proceed with the pain management scope of the JV and have
decided to terminate the May&#160;2019 Supplementary Agreement. The parties may elect to proceed with a similar arrangement in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&#160;6, 2020, the Company entered into a three-year service agreement with Wider, pursuant to which Wider agreed to perform clinical
trials associated with the possible formation of the future JV. In consideration, the Company and certain designated Wider shareholders
entered into stock issuance agreements for the issuance of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200401__20200406_pdd" title="Issuance of common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2020-04-012020-04-06" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, and simultaneously with
the execution of this service agreement, Wider contributed $<span id="xdx_901_ecustom--RelatedPartyContribution_c20180921_pp0p0" title="Related party contribution"><ix:nonFraction name="NXL:RelatedPartyContribution" contextRef="AsOf2018-09-21" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span> to the Company. During the year ended December&#160;31, 2020, the
Company issued <span id="xdx_903_eus-gaap--SharesIssued_c20201231_pdd" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares to affiliates of Wider in satisfaction of the obligation. The fair value of the 150,000 shares issued (less
the contributed $200,000 in cash) resulted in a charge to stock-based compensation of $<span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200101__20201231_pp0p0" title="Stock-based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">550,000</ix:nonFraction></span> and was recorded in selling, general and
administrative expenses on the statement of operations. <span id="xdx_900_ecustom--RemainingSharesIssuedDescription_c20200401__20200406" title="Remaining shares issued, description"><ix:nonNumeric contextRef="From2020-04-012020-04-06" name="NXL:RemainingSharesIssuedDescription">The remaining 300,000 shares will be issued in accordance with the following
schedule upon Wider&#8217;s successful completion of the following milestones (i) 50% upon successful completion of the fourth of four
clinical trials pursuant to the terms and conditions of the Service Agreements and (ii) 50% upon all four trials being submitted for
publication in international medical journals satisfactory to the Company.</ix:nonNumeric></span> As of March&#160;31, 2023, these milestones have not been
met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March&#160;2022, we entered into a second supplement
to the JV Agreement with Wider, whereby the parties confirmed that the JV had not yet been established and is subject to further review
and analysis of regulatory issues in China and the United States, trade and political issues between the two countries and potential changes
in the use and market for the Company&#8217;s products and technology. Pursuant to the second supplement, the parties agreed to use their
commercial efforts to complete documentation by September&#160;30, 2022. Wider has continued its work with respect to undertaking and
establishing clinical trials. In light of general economic conditions in China and the United States and the continued impact of regulatory
issues in China and the United States and trade and political issues between the two counties, the parties determined to further extend
the time frame to complete establishment of the JV to September 30, 2023 and entered into a supplement 3 to the JV Agreement to memorialize
such extension. The parties intend to continue to work together to complete the establishment prior to such extended time, however, the
ramifications of the continued COVID pandemic, especially in China, and the Chinese government&#8217;s regulatory approach to the pandemic
have adversely affected Wider&#8217;s ability to distribute our current products. As a result, the JV may be further delayed or we and
Wider may determine to re-structure the business terms (which changes may include timing and the scope of the intended operations and
trial studies) of the proposed JV.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2023 and 2022, the Company recorded $<span id="xdx_90D_ecustom--RevenuesFromRelatedParties_pp0p0_c20230101__20230331_znUdncemGc02" title="Revenue from Related Parties"><ix:nonFraction name="NXL:RevenuesFromRelatedParties" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--RevenuesFromRelatedParties_pp0p0_c20220101__20220331_zHdiFFtKRW0e" title="Revenue from Related Parties"><ix:nonFraction name="NXL:RevenuesFromRelatedParties" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,499</ix:nonFraction></span> in revenue, respectively, from Wider on the
unaudited condensed consolidated statements of operations.</span></p>

<ix:exclude><p id="xdx_23E_zXrCfKs8AvTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_233_zeT8RgBmSDmk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zEMs4ptp6R1j" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zQ1KNKkLAtSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Asian Consulting Group, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&#160;9, 2018, the Company entered into a five-year consulting agreement with U.S. Asian Consulting Group, LLC (&#8220;U.S. Asian&#8221;).
The two members of U.S. Asian are shareholders in the Company and include Marilyn Elson who is the Chief Financial Officer of the Company.
Pursuant to the consulting agreement, U.S. Asian will provide consulting services to the Company with regard to, among other things,
corporate development and financing arrangements. The Company is to pay U.S. Asian $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pp0p0" title="Monthly payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2018-05-012018-05-09_custom_USAsianConsultingGroupLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> per month for services rendered and, on October&#160;24,
2018, the Company issued <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pdd" title="Issuance of common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2018-05-012018-05-09_custom_USAsianConsultingGroupLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">249,750</ix:nonFraction></span> shares of the Company&#8217;s common stock to U.S. Asian. The Company recorded consulting expenses related
to the consulting agreement of $<span id="xdx_908_ecustom--ConsultingExpenses_c20230101__20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_pp0p0" title="Consulting expenses"><ix:nonFraction name="NXL:ConsultingExpenses" contextRef="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> for each of the three months ended March&#160;31, 2023&#160;&#160; and 2022 on the Company&#8217;s
unaudited consolidated statements of operations. At December&#160;31, 2022, U.S. Asian was owed $<span id="xdx_90D_eus-gaap--OtherBorrowings_c20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pp0p0" title="Balance owed for accrued,unpaid services and expenses"><ix:nonFraction name="us-gaap:OtherBorrowings" contextRef="AsOf2023-03-31_custom_USAsianConsultingGroupLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></span> for accrued and unpaid services.
<span id="xdx_90A_ecustom--OwedBalancePaymentDescription_c20230101__20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember" title="Owed balance payment, description"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember" name="NXL:OwedBalancePaymentDescription">A payment of $250,000 was made to U.S. Asian on March&#160;17, 2023.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;22, 2021, the Company entered into a one-year agreement with Leonard Osser to serve on the Company&#8217;s Board of Advisors.
The agreement may be, but has not yet been, extended for an additional one-year term upon agreement of both parties. As consideration
Mr. Osser was entitled to $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211201__20211222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserMember_pp0p0" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2021-12-012021-12-22_custom_MrOsserMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></span> in shares of the Company&#8217;s common stock which was waived by Mr. Osser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;11, 2022, the Company entered into an employment agreement with Marilyn Elson to serve as Chief Financial Officer of the
Company for a three-year term with an option for the Company and Ms. Elson to extend the term for an additional two years. Ms. Elson
is the spouse of Leonard Osser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Payable &#8211; Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November&#160;1, 2021, the Company received $<span id="xdx_908_ecustom--LoansFromRelatedParty_c20211030__20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Loans from related party"><ix:nonFraction name="NXL:LoansFromRelatedParty" contextRef="From2021-10-302021-11-02_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>
&#160;&#160;as a loan from the Company&#8217;s Chief Executive Officer. The loan had a principal of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-11-02_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>,
an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20211030__20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zla7wWBIkbbh" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-10-302021-11-02_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9</ix:nonFraction></span>%,
and a maturity date of the earlier of (i) <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20181001__20181025_zfBcOw1kekK6" title="Maturity date"><ix:nonNumeric contextRef="From2018-10-012018-10-25" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">October
31, 2022</ix:nonNumeric></span> or (ii) the date of the consummation of the initial public offering. The note was amended as of
January&#160;1, 2023 to extend the due date to March&#160;17, 2023 and to provide that interest payable on the maturity date will be
$<span id="xdx_909_ecustom--InterestPayableCurrents_iI_c20230317_z311nlY3MCGh"><ix:nonFraction name="NXL:InterestPayableCurrents" contextRef="AsOf2023-03-17" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction></span>
less any interest payments previously made. Total interest expense on this note was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LoansPayableOfficerMember_pp0p0" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-03-31_custom_LoansPayableOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></span>
and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0p0_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--LoansPayableOfficerMember_z0bjApEueQeg" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2022-01-012022-03-31_custom_LoansPayableOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,500</ix:nonFraction></span> for the three months ended March&#160;31, 2023 and 2022, respectively. The December&#160;31, 2022 outstanding principal
balance of $<span id="xdx_902_ecustom--OutstandingAmount_iI_c20230517_zDX6M7Uz9KX3" title="Outstanding amount"><ix:nonFraction name="NXL:OutstandingAmount" contextRef="AsOf2023-05-17" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>
was satisfied by a payment on March&#160;17, 2023. The March&#160;31, 2023 outstanding interest balance of $<span id="xdx_908_ecustom--OutstandingInterest_iI_c20230426_zkq6qHtkM1O7" title="Outstanding interest"><ix:nonFraction name="NXL:OutstandingInterest" contextRef="AsOf2023-04-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,500</ix:nonFraction></span>
was satisfied by a payment on April&#160;26, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principle executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056. Under ASC 842 &#8220;<i>Leases</i>&#8221;, we
have two separate sub-leases (through IIcom Strategic Inc. controlled and owned by our Chief Executive Officer) totalling approximately
4,000 square feet of office space under operating leases. Management and supporting staff are hosted at this location. Our lease payments
for fiscal year 2022 were $54,000. Our lease costs for each of the three months ended March&#160;31, 2023 and 2022 were $13,500.&#160;&#160;
The sub-leases are due to expire in 2024. Pursuant to the sublease, we pay the third-party landlord (not the sub landlord) all direct
and indirect rent costs under the primary lease directly for the leased premises. No additional payments are made to the Chief Executive
Officer or the entity controlled by him.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zNfHcaYfEQr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8212; <span id="xdx_829_zAcXptiFc996">LOANS PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legacy
Ventures International, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;11, 2017, the Company issued a promissory note (the &#8220;Promissory Note&#8221;) in favor of Legacy Ventures International,
Inc. (&#8220;Legacy&#8221;) as part of a commercial transaction with Legacy that was never consummated. The Promissory Note was issued
in the original principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zQcurheG7qok"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2017-09-11_custom_LegacyVenturesInternationalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>, with interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20170901__20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zhpJoN3DCkTg" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2017-09-012017-09-11_custom_LegacyVenturesInternationalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% per annum and a maturity date of <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20170901__20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zDJ6PhAf4JE5" title="Maturity date"><ix:nonNumeric contextRef="From2017-09-012017-09-11_custom_LegacyVenturesInternationalIncMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 31, 2017</ix:nonNumeric></span>. As of March&#160;31,
2023, this promissory note is in default. The Company recorded $<span id="xdx_90E_eus-gaap--InterestExpense_pp0p0_c20230101__20230331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zeDNuTBRbupc" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-03-31_custom_LegacyVenturesInternationalIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20220331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_z2l8b1vGMNXk" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-03-31_custom_LegacyVenturesInternationalIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span> of interest expense for the three months ended March&#160;31,
2023 and 2022, respectively. The amount outstanding at March&#160;31, 2023 and December&#160;31, 2022 was $<span id="xdx_903_ecustom--OutstandingAmount_iI_c20230331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zpXMLg3FuMl5" title="Outstanding amount"><span id="xdx_90C_ecustom--OutstandingAmount_iI_c20221231__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zzLGXLlzWaUl" title="Outstanding amount"><ix:nonFraction name="NXL:OutstandingAmount" contextRef="AsOf2023-03-31_custom_LegacyVenturesInternationalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="NXL:OutstandingAmount" contextRef="AsOf2022-12-31_custom_LegacyVenturesInternationalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></ix:nonFraction></span></span>.</span></p>

<ix:exclude><p id="xdx_231_zqqRQjWtfMPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div id="xdx_23F_zMh9HWupPCJl" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z27k7pcYraGb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zyQKfbcWkI31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_za5wyz67nUJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8212; <span style="text-transform: uppercase"><span id="xdx_82F_zN6WaLyl8tIe">STOCKHOLDERS&#8217; EQUITY (Deficit)</span></span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2022, the Company issued <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zPpxRjgBfSF7" title="Number of common stock issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-03-31_custom_AnInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850</ix:nonFraction></span> shares of common stock to an investor for cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zNqSfPY2dc32" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-03-31_custom_AnInvestorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,100</ix:nonFraction></span>
with a fair value of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zHjt86ROyPEd" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-03-31_custom_AnInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2022, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_pdd" title="Stock issued for services rendered, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-03-31_custom_VariousConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,390</ix:nonFraction></span> shares of common stock to a consultant for services rendered in
lieu of cash for an aggregate compensation charge of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_pp0p0" title="Stock Issued During Period, Value, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-03-31_custom_VariousConsultantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span>, of which $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_zzt3jlE8TMp2" title="Share based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_VariousConsultantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,500</ix:nonFraction></span> was expensed during the three months ended March&#160;31,
2022, in the unaudited condensed consolidated statement of operations. In addition, $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20220331_zWRAV4w6tRwf" title="Stock compensation expenses"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span> was expensed as stock compensation related
to shares to be issued to advisors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2023, the Company issued no shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of warrants to purchase shares of the Company&#8217;s common stock are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbEInnHdAiy2" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BF_zm5mnQQWXNkc" style="display: none">Schedule of warrants</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of<br />
warrants</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">Outstanding December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331_zBVoI2Rc0AZb" title="Number of Warrants Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,662,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331_z3YUardUvLFg" title="Weighted Average Exercise Price, Warrants Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331_pdd" title="Warrants Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" title="Weighted Average Exercise Price, Warrants Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_pdd" title="Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" title="Weighted Average Exercise Price, Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230331_pdd" title="Warrants Expired or cancelled" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpiredOrCancelled_c20230101__20230331_pdd" title="Weighted Average Exercise Price, Warrants Expired or cancelled" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331_zPtNq21ceaol" title="Number of Warrants Outstanding at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,662,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331_zLMbz8dfVqFf" title="Weighted Average Exercise Price, Warrants Outstanding at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zOsuExpRFWYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants to purchase shares of the Company&#8217;s common stock outstanding and exercisable
at March&#160;31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="NXL:SummaryInformationAboutWarrantsToPurchaseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--SummaryInformationAboutWarrantsToPurchaseTableTextBlock_zfJ930USVG78" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_z9B5eNsqGR3l" style="display: none">Summary information about warrants to purchase</span></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Outstanding<br /> Number of<br /> Warrants</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br /> Remaining Life<br />
    In Years</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br /> Exercise Price</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Exercisable<br /> Number of<br /> Warrants</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" title="Exercise Price" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_custom_Range1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" title="Outstanding Number of Warrants" style="width: 17%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_custom_Range1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,315,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_zgBMUlIwzbI4" title="Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_Range1Member" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" title="Weighted Average Exercise Price" style="width: 17%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_Range1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" title="Exercisable Number of Warrants" style="width: 17%; text-align: right"><ix:nonFraction name="NXL:ExercisableNumberOfWarrants" contextRef="From2023-01-012023-03-31_custom_Range1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,135,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" title="Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_custom_Range2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" title="Outstanding Number of Warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_custom_Range2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">347,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_zLtUlvkJYGzd" title="Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_Range2Member" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.5</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" title="Weighted Average Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_Range2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" title="Exercisable Number of Warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NXL:ExercisableNumberOfWarrants" contextRef="From2023-01-012023-03-31_custom_Range2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">347,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331_pdd" title="Outstanding Number of Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,662,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331_zN6b0O8QSvLh" title="Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.75</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331_pdd" title="Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331_pdd" title="Exercisable Number of Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="NXL:ExercisableNumberOfWarrants" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,662,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zKBDginqzdva" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation expense attributed to the issuance of the warrants, if required to be recognized on the nature of the transaction, was recognized
as they vested/earned. These warrants are exercisable up to three years from the date of grant. All are currently exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zQzMjcwCWYh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8212; <span id="xdx_82B_zNOWUm4a744c">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
Claims</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material pending legal proceedings in which the Company or any of its subsidiaries is a party or in which any director, officer
or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of its voting securities, or security holder
is a party adverse to us or has a material interest adverse to the Company other than the following:</span></p>

<ix:exclude><p id="xdx_231_z5spt5q3a29f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div id="xdx_23E_znRnbVT2iel8" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zEQ3ZPBkfZ64" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zYsvlJuRrh74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sarah
Veltz v. Nexalin Technology, Inc. et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plaintiff,
Sarah Veltz, filed a lawsuit in this matter on January&#160;20, 2021 in Orange County Superior Court (Case No. 30-2021-01180164-CU-WT-CJC)
(the &#8220;Complaint&#8221;) naming the Company and others as defendants. In her Complaint, Plaintiff contends that she was employed
by defendants, including Nexalin, and has not been paid all wages, including overtime wages and other benefits allegedly due her. Plaintiff
also contends that, during her employment, she was subjected to sexual harassment by the Company&#8217;s then Chief Executive Officer.
Plaintiff seeks both compensatory and punitive damages. On March&#160;12, 2021, the Company filed its answer to the Complaint. Although
the parties are seeking mediation, the court has set a trial in this matter for March&#160;18, 2024. Management&#8217;s intent
is to contest the allegations vigorously and, as of the date of this report, is unable to provide an evaluation of the potential outcome
of the litigation within the probable or remote range or to provide an estimate of the amount of or a range of potential loss that might
be incurred by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Development Department</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently engaged in settlement discussions with the Employment Development Department (EDD) of the state of California. This
matter involves issues related to our previous management&#8217;s classification of certain work provided to or on behalf of the Company&#8217;s
business as contract labor instead of employee labor. The total amount involved is approximately $300,000. Management has petitioned
for reassessment and believes the hired workers at issue were indeed actual contractors and not employees. We have no business in California
other than one part time and one full time worker residing in California. An initial hearing before an EDD magistrate was held on April&#160;15,
2022. A second hearing was held in June of 2022. We are now in negotiations with the EDD for a final settlement. The Company believes
its potential exposure to be approximately $<span id="xdx_900_ecustom--AccruedAmount_iI_c20221231_zXpYMzZtR1z1" title="Accrued amount"><span id="xdx_90B_ecustom--AccruedAmount_iI_c20230331_zKLlCUnvmuw" title="Accrued amount"><ix:nonFraction name="NXL:AccruedAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="NXL:AccruedAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></ix:nonFraction></span></span> and, as such, has accrued this amount on the consolidated balance sheets as of March&#160;31,
2023 and December&#160;31, 2022 and believes it has adequately accrued for this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Demand
Letter from The University of Arizona</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;8, 2022, the Company received a demand letter from the University of Arizona seeking payment of $111,094 purportedly due
on an Investigator Initiated Cooperative Study Agreement, dated as of September&#160;25, 2017 (the &#8220;2017 Study&#8221;). The Company
believes that the 2017 Study was not completed and no payment was due. In fact, for a number of months prior to receipt of the demand
letter, the Company had had discussions with the person at the University of Arizona who was to conduct the 2017 Study concerning updating
the 2017 Study and completing an updated study and related work. After receipt of the demand letter, the Company has had discussions
with the University of Arizona concerning resuming an updated study and receipt of credit for some or all the monies claimed to be due
for the 2017 Study. Such discussions are ongoing, and no resolution has been reached but the Company hopes to achieve a consensual resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zB8hJXem1pZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8212; <span id="xdx_826_zovszaVFmax1">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the adoption of ASC 842, operating lease agreements are required to be recognized on the balance sheet as ROU assets and corresponding
lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;1, 2022, the Company exercised its right to lease an additional 400 square feet of office space and an increase of monthly
rent of $500. In accordance with ASC 842 management accounted for this as a separate lease and, as a result, recorded an ROU asset and
lease liability of $<span id="xdx_90A_ecustom--LeaseLiability_iI_c20220102_zY4DHYGVYSf8"><ix:nonFraction name="NXL:LeaseLiability" contextRef="AsOf2022-01-02" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,359</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at January&#160;1, 2022. The weighted average incremental borrowing rate applied was <span id="xdx_90A_ecustom--WeightedAverageIncrementalBorrowingRate_dp_c20230101__20230331_zYkRs2FjZjVb"><ix:nonFraction name="NXL:WeightedAverageIncrementalBorrowingRate" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9</ix:nonFraction></span>%.</span></p>

<ix:exclude><p id="xdx_23B_zMYxlvkXOt13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div id="xdx_23D_zjyUXXXl7Pee" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zWxjfgGNDkT" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zFVnEC9NFz98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
leases are included in the consolidated balance sheets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zm9yV6pGBAd9" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B0_z9y3yuQHCM2d">Schedule of Operating leases</span></span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Lease assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1pt">Operating lease cost ROU assets</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 37%; text-align: center; padding-bottom: 1pt">Assets</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20230331_pp0p0" title="Operating lease cost ROU assets" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,800</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_c20221231_pdp0" title="Operating lease cost ROU assets" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,171</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--TotalLeaseAssets_c20230331_pp0p0" title="Total lease assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="NXL:TotalLeaseAssets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--TotalLeaseAssets_c20221231_pdp0" title="Total lease assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="NXL:TotalLeaseAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: center">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20230331_pp0p0" title="Operating lease liabilities, current" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,026</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20221231_pp0p0" title="Operating lease liabilities, current" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20230331_pp0p0" title="Operating lease liabilities, non-current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20221231_pp0p0" title="Operating lease liabilities, non-current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,463</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20230331_pp0p0" title="Total lease liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20221231_pp0p0" title="Total lease liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,260</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A8_zmgagEbqQoA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease costs, which are included in income from operations in our unaudited condensed consolidated statements of operations,
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z93w3u9sqdvb" summary="xdx: Disclosure - LEASES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BF_zCaqrjlnfcHd">Schedule
    of lease cost</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Leases costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Operating lease costs</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230331_zD8L1pqUktEe" title="Operating lease costs" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,500</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20220331_zxPemt28nPq5" title="Operating lease costs" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,500</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LeaseCost_pp0p0_c20230101__20230331_zNFzN48KmJ83" title="Total lease costs" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LeaseCost_pp0p0_c20220101__20220331_znFZj38zqeoh" title="Total lease costs" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zfyOFcOdsCMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancellable leases for operating leases for the remaining terms of the leases following the three months ended
March&#160;31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMJce7mbudu2" summary="xdx: Disclosure - LEASES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_z6rabcvfOcI1" style="display: none">Future minimum payments under non-cancelable leases for operating leases</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230331_zXpNELAJW1Ma" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating<br />
Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 88%">Remainder of 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,304</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,496</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zV2GRPFLZ74g" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zYjMRwbd27h4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information related to leases is presented as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="NXL:ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_zvGp0GjQqYHc" summary="xdx: Disclosure - LEASES (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span><span id="xdx_8BC_zFles555rNB5" style="display: none">Schedule of additional information related to leases</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br /> 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted average remaining lease term</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zSXvjrdi0fnd" title="Weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2023-03-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.75</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zTzb0dW7T2dj" title="Weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.00</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230331_zi8EARkc03Z1" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_znIbbghubL9b" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AE_zd03Tzay9aYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div id="xdx_236_zlbo8H8aryqh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_z4xwPDE3mQFg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zg2CQpACJFXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_802_eus-gaap--ConcentrationRiskDisclosureTextBlock_zUMVSatOzCke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8212; <span id="xdx_821_zoMDeMDoQQVd">CONCENTRATION OF CREDIT RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
customers accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--SixCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znnltBfHkO7e" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_SixCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">94</ix:nonFraction></span>% of revenues for the three months ended March&#160;31, 2023, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z7Fi5DMylUp7" summary="xdx: Disclosure - CONCENTRATION OF CREDIT RISK (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B0_z81OUXVNplM2" style="display: none">Concentration of credit risk</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbEAUv4QHoSj" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBxqhhryJecb" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvOq3rqOShIe" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhV5UiU86HZ7" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerDMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer E</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmI8tzKCedea" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerEMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmZx8itKW0Rc" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerFMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
customer, a related party, accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZhKOwdmzyv3" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_custom_OneCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span>% of revenue for the three months ended March&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
customers accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEuAhvsn5QQ9" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_ThreeCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91</ix:nonFraction></span>% of accounts receivable at March&#160;31, 2023, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXvItKA0wnG7" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZikiWyMYAX7" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5fHJCTVXRa" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlT5Oj9Wdfae" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_FourCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84</ix:nonFraction></span>% of accounts receivable at December&#160;31, 2022, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br />
Year Ended<br />
December&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2T22LTDqV84" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOLbwMDeRZp8" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdW8hhsp8T08" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zunwLJIAVGQl" title="Revenue, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zuiN6gqlmNq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_237_zzZPWlSSXyrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div id="xdx_230_zJ6lPs8dePp7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zNwXwHnBAZn1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zEalpAKu6eJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zWgm55rIv9v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8212; <span id="xdx_82D_zwtfW1TTljb2">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated subsequent events and transactions that occurred after the balance sheet date, up to the date that the unaudited financial
statements were issued. Based upon this review management did not identify any subsequent events that would have required adjustment
or disclosure in the unaudited consolidated condensed financial statements.</span></p>

</ix:nonNumeric><p id="xdx_81D_zDF9F42a0bMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_008"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;2.
MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Note Regarding Forward-Looking Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the following discussion and analysis of financial condition and operating results together with our financial statements
and the related notes and other financial information included elsewhere in this quarterly report on Form&#160;10-Q, as well as our audited
consolidated financial statements and related notes as disclosed in included in our Annual Report on Form&#160;10-K for the year ended
December&#160;31, 2022, which was filed with the Securities and Exchange Commission, or SEC on March&#160;27, 2023. References in this
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; to &#8220;us,&#8221; &#8220;we,&#8221;
&#8220;our,&#8221; and similar terms refer to Nexalin Technology, Inc. This discussion contains forward-looking statements as that term
is defined within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange
Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are subject to the &#8220;safe harbor&#8221; created by those sections.
The events described in forward-looking statements contained in this discussion may not occur. Generally, these statements relate to
business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated
benefits from acquisitions that may be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating
results. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; and &#8220;continue,&#8221; and their opposites and similar expressions,
are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or
events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence
the accuracy of the statements and the projections upon which the statements are based. Reference is made to &#8220;Risk Factors &#8220;in
this quarterly report on Form&#160;10-Q as well as the risk factors set forth in the section titled &#8220;Risk Factors&#8221; included
in our Registration Statement for our initial public offering as filed with the Securities and Exchange Commission (SEC File number 333-26198),
Our actual results may differ materially from those anticipated in these forward-looking statements. For convenience of presentation
some of the numbers have been rounded in the text below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic.
We developed an easy-to-administer medical device &#8212; referred to as Generation 1 or Gen-1 &#8212; that utilizes bioelectronic medical
technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy
stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) as a Class II device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
professionals in the United States have utilized the Gen-1 device to administer to patients in clinical settings. While the Gen-1 device
had been cleared by the FDA to treat depression, anxiety, and insomnia, three prevalent and serious diseases, because of the FDA&#8217;s
December&#160;2019 reclassification of CES devices, the Gen-1 device was reclassified as a Class II device for the treatment of anxiety
and insomnia. We are required to file a new application under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act (&#8220;510(k)
Application&#8221;) to be approved by the FDA for the sales and marketing of our devices for the treatment of anxiety and insomnia. In
the FDA&#8217;s December&#160;2019 reclassification ruling, the treatment of depression with our device will require a Class III certification
and require a new PMA (premarket approval) application to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we continue providing services to medical professionals to support patients&#8217; use of the Gen-1 devices which were in operation prior
to December&#160;2019, we are not making new sales or new marketing efforts of Gen-1 devices in the United States. We continue to derive
revenue from devices which we sold or leased prior to the FDA&#8217;s December&#160;2019 reclassification announcements. This revenue
consists of monthly licensing fees and payments for the sale of electrodes and patient cables. We have suspended marketing efforts for
new sales of devices related to the Gen-1 device for treatment of anxiety and insomnia in the United States until the Nexalin regulatory
team makes a decision on amending our existing 510(k) application at 4 milliamps. A new pre-sub document in preparation of a new 510K
for our Gen-3 Halo headset at 15 mAmps was filed with the FDA in January of 2023. Formal comments to our pre-sub document filing were
received in March of 2023. A formal meeting to address FDA comments is scheduled for May of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices
referred to as Generation 2 or Gen-2 and Generation 3 or Gen-3. Gen-2 is a clinical use device with a modern enclosure to emit the new
15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual
clinic setting similar to existing Tele-health platforms. The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3
devices can penetrate deeper into the brain and stimulate associated structures of mental illness, which we believe will generate enhanced
patient response without any risk or unpleasant side effects. The Nexalin regulatory team has made a strategic decision to develop strategies
for pilot trials in various mental health disease states. In addition, a new PMA application in the United States is in development for
the treatment of depression utilizing both Gen-2 and Gen-3. The new Gen-3 device is also scheduled for additional pilot trials for anxiety
and insomnia in the United States and China beginning in the third quarter of 2023. Preliminary data provided by the University of California
San Diego supports the safety of utilizing our 15 milliamp waveform technology. However, the determination of safety and efficacy of
medical devices in the United States is subject to clearance by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are currently designing clinical trial strategies for the use of Gen-3 for the treatment of substance use disorders including opiate,
cocaine, and alcohol abuse. Recently the Gen-2 device was tested in pilot trials in China for the treatment of Alzheimer&#8217;s disease
and dementia. Continued pilot testing for Alzheimer&#8217;s and dementia is planned in China in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
part due to increasing incidence attributed to the devastating impacts of the COVID-19 pandemic, mental health and cognitive disorders
are widespread across the globe and cause substantial health, social and economic losses, and hardships accordingly. Our focus is on
the continued development of our innovative bioelectronic medical technologies and rapid regulatory approval. We intend to help reverse
these losses, and hardships of these losses, by safely and effectively treating various mental health disorders associated with post
Covid and long Covid mental disease states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
our products are non-invasive, safe, undetectable to the human body and can provide relief to those afflicted with mental health issues
without adverse side effects. We have a proprietary design that eliminates voltage while stabilizing currents, electromagnetic fields,
and various frequencies &#8212; referred to collectively as waveform - particularly our proprietary, 15 milliamp patented symmetrical
waveform. Our devices generate a high frequency carrier wave that is charge balanced. It is applied to the brain with an array of electrodes
on the forehead and behind each ear at the mastoid. The features of this proprietary waveform and the array of electrodes allow the application
of the waveform to the entire brain rather than a small, targeted area of the brain. By increasing the power, our waveform can penetrate
deeper into the brain and stimulate deep mid-brain structures associated with mental illness. Our research and clinical teams believe
that a more powerful waveform will create a stronger response in the brain. A stronger response creates a higher level of efficacy. This
entire proprietary technique allows Nexalin to provide a safe and comfortable treatment that is more powerful than any stimulation device
in the market. Current pilot study protocols and randomized clinical trials have been designed and submitted to the FDA to provide feedback
on final reports and data sets for the purpose of safety and efficacy evaluations in the future. Determinations of the safety and efficacy
of our devices are solely within the authority of the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the waveform that comprises the basis of Gen-2 and new Gen-3 headset devices has been tested in research settings to develop safety data
that has been submitted for review by the FDA for safety evaluation and eventual marketing in the United States and around the world.
Determinations of the safety and efficacy of our devices in the United States are solely within the authority of the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that an additional barrier to treatment in today&#8217;s mental health treatment landscape -- beyond the concerns about safety,
efficacy and side-effects that have been associated with conventional mental health treatments such as ECT (shock therapy), drugs and
psychotherapy -- is stigma. We have received industry reports and feedback that many patients that struggle with mood disorders have
the stigma of embarrassment associated with psychiatrists and psychotherapy (e.g., counselling with a therapist). Additional stigmas
and other issues are associated with the side effects of medication prescribed by psychiatrists. When we researched the current pharmaceuticals
model, public information highlighted the many side effects associated with these medications. Frequently, patients would stop taking
the medication because of the uncomfortable side effects. Additional public information mentions dependency and withdrawal issues associated
with medication for psychiatric disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address the embarrassment stigma, we are developing a new virtual clinic that will allow the physician to diagnose a mental health issue
in the privacy of a tele-psychiatry virtual platform. After diagnosis, the physician will prescribe the Nexalin Gen-3 headset to the
patient for treatment. Next, the Gen-3 device will be shipped to the patient&#8217;s home. After patient receives the device, they will
pair the headset device with an app in the patient&#8217;s smart phone. The app will communicate with the Nexalin cloud servers to authorize
the device for treatment according to the protocol designed by the physician. The physician will monitor treatment compliance and other
health related issues in a private physician dashboard that connects through the Nexalin app and cloud servers. We believe that to preserve
product safety and integrity for home use, the headset device will require physician oversight that will include a prescription for use
with a monthly authorization provided by the physician after a monthly virtual visit. All appointments will be in a virtual setting to
provide privacy and convenience for the physician and patient. The Nexalin virtual clinic will be provided in a proprietary virtual platform
currently in the design stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
China Gen-2 15 milliamp device was recently approved in China by the NMPA for the treatment of insomnia and depression in China. This
device and all other clinical devices will include a single use electrode for long term revenue streams. The USA Gen-2 device will have
a fresh and modern appearance that meets the technology standards of the digital tech world of 2023. Early adopters of the Gen-1 device
will be able to access additional firmware upgrades which are planned to enhance the previously purchased devices to the new symmetric15-milliamp
waveform. Our Gen-2 device will be equipped with RFID technology that exchanges electrode usage data with a reader in the main device.
The purpose of RFID is to track and maintain control of the proprietary single use electrode. Our electrode chip will be programmed to
exchange data with the device and allow activation for a single treatment with a new electrode only. This ensures a recurring revenue
stream on the device and protects against any generic knockoffs designed to avoid treatment costs. This upgrade in technology also ensures
the proprietary nature of the electrodes that support treatment outcomes are sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
we believe that our advanced waveform, technological upgrades and the development of a modern headset monitored with our IT management
platform will position us with the opportunity to disrupt the traditional mental health treatment model. Our mission is to remove the
stigma of expensive psychotherapy or pharmaceuticals with the attendant side effects and dependency issues and replace such stigma with
clinically proven and cost-effective technology that is easily accessible in the privacy of the patient&#8217;s home and monitored by
licensed healthcare providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have generated significant losses; we expect to continue to incur significant expenses and increasing operating losses
for at least the next two years. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned
clinical trials and expenditures for other research and development activities. We expect our expenses will increase substantially over
time as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
    the ongoing and planned preclinical and clinical development of our products; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and analyse the value of amending our previous 510(k) Application for anxiety and insomnia in accordance with the FDA and seek other
    regulatory approvals for any future products that successfully complete clinical trials;&#160;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">arrange
    for a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any product
    candidate for which we may obtain regulatory approval and intend to commercialize on our own; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
    additional clinical, scientific, manufacturing and controls personnel; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    additional information systems including personnel to support our product development and planned future commercialization efforts;
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor
relations and other expenses that we did not incur as a private company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Developments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Completion
of Initial Public Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed its initial public offering on September&#160;16, 2022. The initial public offering consisted of 2,315,000 units consisting
of 2,315,000 shares of its Common Stock and 2,315,000 accompanying warrants to purchase up to 2,315,000 shares of common stock. Each
share of common stock was sold together with one warrant, each to purchase one share of common stock with an exercise price of $4.15
per share at a combined offering price of $4.15, for gross proceeds of $9,607,250 before deducting underwriting discounts and offering
expenses. In addition, Nexalin granted the underwriters a 45-day option to purchase up to an additional 347,250 shares of common stock
and/or warrants to purchase up to 347,250 shares of common stock to cover over-allotments at the initial public offering price, less
the underwriting discount. The underwriters exercised their option to purchase 347,250 warrants for net proceeds of $3,473.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration statement on Form S-1 (File No. 333-261989) for our initial public offering was filed with the Securities and Exchange Commission
(&#8220;SEC&#8221;) and became effective on September&#160;15, 2022. A final prospectus relating to the offering was filed with the SEC
and is available on the SEC&#8217;s website at <span style="text-decoration: underline">http://www.sec.gov</span>. The offering was being made only by means of a prospectus forming
part of the effective registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares and warrants began trading on the Nasdaq Capital Market tier of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) in September&#160;2022,
under the symbols &#8220;NXL&#8221; and &#8220;NXLIW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID-19 Pandemic</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to be indirectly impacted by the Covid-19 pandemic because of our current dependence upon our distributor relationship with
Wider Come Limited (&#8220;Wider&#8221;.) Wider acts as a distributor for the Company&#8217;s devices in China and Asia. Because of significant
restrictions imposed by the Chinese government during the Covid pandemic, Wider&#8217;s ability to market and sell the Company&#8217;s
devices has been negatively impacted, resulting in decreased revenue to the Company. Patients and salespeople are restricted in their
movements resulting in a significant slowdown in the medical and other sectors. Fortunately, our Chinese distributor continues our strategy
of multiple clinical studies in the major institution in Beijing in an array of brain related diseases. Very significant efforts and
funds expended by our Chinese distributor has led to regulatory approval in China in both depression and insomnia thus far which has
allowed for sales of our devices in China the past year. The extent of future impact will depend on future developments, including future
activities by the Chinese government and other possible events which are highly uncertain and not in the Company&#8217;s control, including
new information which may emerge concerning the spread and severity of COVID-19, or any of its variants, and actions taken to address
its impact, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components
or raw materials on a timely basis. Such events may result in a period of business and manufacturing disruption, and in reduced operations,
any of which could materially affect our business, financial condition and results of operations. The extent to which the coronavirus
impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information
which may emerge concerning the severity of COVID-19 and the actions to contain the coronavirus or treat its impact, among other things.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Joint Venture; China Related Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September&#160;2018, we entered into an agreement with Wider Come Limited, a company formed under the laws of the People&#8217;s Republic
of China (&#8220;Wider&#8221;), pursuant to which we and Wider have agreed to investigate the formation of a joint venture entity to
be domiciled in Hong Kong (the &#8220;potential Joint Venture&#8221;) to conduct additional clinical research and implement a business
distribution plan for our devices in China, Macau, Hong Kong, and Taiwan. We do not have any existing operations in China and will not
in the future. We do have current distribution in China through Wider, our potential Joint Venture partner. As of the date of this Quarterly
Report on Form&#160;10-Q, (i) our operations are carried on outside of China; and (ii) the potential Joint Venture does not maintain
any variable interest entity structure or operate any data center in China. However, because of the intended formation of the potential
Joint Venture, we may become subject to laws of The People&#8217;s Republic of China (PRC or China) relating to, among other topics,
data security and restrictions over foreign investments. Further, as a result of the complexity and vagaries of the legal system in the
PRC and recent statements and regulatory actions by the PRC government relating to data security, our ability to operate the potential
Joint Venture may be adversely affected or subject to change and adversely impact our ability to offer or continue to offer securities
to investors, with the result that our securities may significantly decline or be worthless. There can be no assurance that regulators
in China will not take a contrary view or will not subsequently require us to undergo the approval procedures and subject us to penalties
for non-compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2022, we entered into a second supplement to the Joint Venture agreement with Wider whereby the parties confirmed that the
potential Joint Venture had not yet been established and is subject to further review and analysis of regulatory issues in China and
the United States. Pursuant to the second supplement, the parties agreed to use their commercial efforts to complete documentation by
September&#160;30, 2022. In light of general economic conditions in China and the United States, the continued impact of regulatory issues
within China and the United States and trade and political issues between the two counties, the parties determined to further extend
the time frame to complete establishment of the joint venture to September&#160;30, 2023 and entered into a Supplement 3 to the potential
Joint Venture Agreement to memorialize such extension. The parties intend to continue to work together to complete the establishment
prior to such extended time. Further, the parties agreed that all references within the Joint Venture agreements to funding and formation
were amended from December&#160;21, 2018 to be September&#160;30, 2023. We anticipate that the Joint Venture will be formed by the third
quarter of 2023. However, that will be dependent on the situation at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
and if the Joint Venture is formed and Wider completes sales of our devices in China on behalf of the potential Joint Venture, we believe
that there are no regulatory or other restrictions that would restrict either (i) the transfer from China of any proceeds resulting from
such sales by Wider to the potential Joint Venture in Hong Kong, other than standard compliance with China&#8217;s State Administration
of Foreign Exchange (&#8220;SAFE&#8221;) policies and approval process, or (ii) our receipt of our share of such proceeds from Hong Kong
to us in the United States, which is not subject to SAFE&#8217;s policies and approval process. The Company does not currently believe
any of the Company&#8217;s scientific data resulting from activities in China by the potential Joint Venture would fall within the Measures
for the Management of Scientific Data promulgated by the General Office of the PRC State Council. In the event any existing or new laws
or regulations or detailed implementations and interpretations are modified or promulgated, we and the potential Joint Venture will take
all actions to remain in compliance with any such laws or regulations or detailed implementations and interpretations thereof. Neither
we nor our potential Joint Venture Partner can at this point speak to any future changes in rules, regulations or the commercial and
potentials situation that lies ahead which could affect the formation of the Joint Venture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September of 2021, the China National Medical Products Administration (NMPA), the equivalent of the United States FDA, approved the Gen-2
device for marketing and sale in China for the treatment of insomnia and depression. These treatment indications and clearances from
the NMPA have allowed Wider to market and sell the Gen-2 device in China for the treatment of insomnia and depression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Quarters ended March&#160;31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial results for the quarter ended March&#160;31, 2023 and 2022 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: normal; text-align: center">Change<span style="font: normal 700 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="padding-bottom: 1pt; font-weight: bold; font-style: normal">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">%</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Revenues, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">323,322</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(292,762</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(91</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,110</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">46,015</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(38,905</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">(85</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,450</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">277,307</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(253,857</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">(92</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(136,856</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">299,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">344,953</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">218,374</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">126,579</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">802,876</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">652,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150,452</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(779,426</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(375,117</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(404,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">108</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other (income) expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,837</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,132</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,295</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gain on sale of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,077</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,077</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total other (income) expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">31,012</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(18,132</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,144</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">271</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(748,414</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(393,249</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(355,165</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">90</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Unrealized gain from short-term investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,069</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,069</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(707,345</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(393,249</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(314,096</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->





<table cellpadding="0" cellspacing="0" style="font-family: Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify; border-collapse: collapse">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentages
                                            may not foot due to rounding.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March&#160;31, 2023 and 2022, we generated $30,560 and $323,322 respectively, of revenue primarily from the sale
of devices, supplies and from the reimbursement of costs. In addition, we generated income from licensing and treatment fee agreements
with our customers by charging a monthly licensing fee for the duration of the agreement. We also generated revenue from treatment fee
agreements by collecting fees based on the number of treatments per month the customer performs. In addition, we derived revenue from
equipment by selling electrodes and patient cables to customers for use with our device. The decrease in revenue for 2023 compared to
2022 was primarily due to the decrease in Device sales as a result of the difficulties encountered by our distribution network given
the Covid restrictions in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cost
of Revenues and Gross Profit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March&#160;31, 2023 and 2022, cost of revenues was $7,110 and $46,015, respectively, yielding a gross profit of
$23,450 and $277,307 respectively, or 77% and 86%, respectively. Such decrease in gross margin was due to the change in our sources of
revenue. Our revenue for the three months ended March&#160;31, 2022 was primarily from the sale of Devices. The cost of that revenue
in 2022 was low because a portion of such costs were included in research and developments costs in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
operating expenses for the three months ended March&#160;31, 2023 and 2022 were $802,876 and $652,424, respectively.
Professional fees decreased by approximately $137,000 primarily due to large fees in 2022 relating to the public offering. The increase
of approximately $161,000 in salaries and benefits was due to the hiring of our CFO and other staff. The increase
in selling, general and administrative expenses was due primarily to an increase in research and development costs of approximately $54,000,
an increase in insurance of approximately $74,000, an increase in taxes of $40,000, and an increase in travel expense of approximately
$43,000. These items were offset by a decrease stock based compensation expense of $97,500. The increases in research and development
and consulting costs are attributable to the development of our Gen-2 and Gen-3 devices. The increase in insurance is a result of being
a public company. The increase in taxes was due to franchise tax as a result of an increase in authorized shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
Income (Expense), net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net, for the three months ended March&#160;31, 2023 and 2022 were $31,012 and ($18,132), respectively, consisting of
interest and dividend income and gain on the sale of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Capital Resources</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
Capital </b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,875,769</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,425,462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,195,444</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,948,986</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Working capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,680,325</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,476,476</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets decreased for the three months ended March&#160;31, 2023 primarily a result of funding operations and the paydown of debt. Cash&#160;&#160;
and cash equivalents increased approximately $12,000. Short-term investments decreased approximately $1,534,000, and prepaid and other
current assets decreased approximately $31,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities decreased for the three months ended March&#160;31, 2023 primarily as a result of the reduction of accounts payable and repayment
of a loan payable to an officer of the Company. Accounts payable decreased approximately $604,000, accrued expenses increased approximately
$58,000, lease liability &#8211; current portion decreased approximately $8,000, and loan payable - officer decreased by $200,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our consolidated cash flows for the three months ended March&#160;31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br />
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,314,649</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(203,271</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,526,867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net cash provided by (used in) financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(200,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Cash Used In Operating Activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $1,314,649 for the three months ended March&#160;31, 2023, as compared to $203,271 for the respective
period in 2022, primarily due to the net loss of $748,414 &#160;&#160;and $393,249, respectively, as well as decreases in accounts payable
of approximately $603,000&#160;&#160; in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Cash Provided By Investing Activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities during the three months ended March&#160;31, 2023, and 2022 was $1,526,867 and $0 respectively,
which was due to the net sales and purchases of&#160;&#160; short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Cash Provided by (used In) Financing Activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by (used in) financing activities during the three months ended March&#160;31, 2023 and 2022 was ($200,000) and $100 respectively,
which was primarily due to payment of note payable to an officer of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Uses
and Availability of Additional Funds</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and
development services, manufacturing development costs, legal and other regulatory expenses, and general administrative costs. Although
we have produced Gen-2, which is selling in China where it is approved for certain utilizations by medical practitioners, the successful
development of our future products is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and estimated
costs of the efforts that will be necessary to complete the clinical development of Gen-3 and obtain regulatory approvals. We are also
unable to predict when, if ever, net cash inflows from revenues will enable us to be cash flow positive. This is due to the numerous
risks and uncertainties associated with developing products, including, among others, the uncertainty of:&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    enrolment in, and completion of clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performing
preclinical studies and clinical trials in compliance with the FDA or any comparable regulatory authority requirements;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ability of collaborators to manufacture sufficient quantity of product for development, clinical trials and/ or potential commercialization;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent, trademark and trade secret protection for our products; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
arrangements with third parties for manufacturing;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scaling
the commercial sales of products, if and when approved, whether alone or in collaboration with others;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
of existing therapies, and future therapies, if and when approved, by healthcare providers, physicians, clinicians, patients and third-party
payors;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with other therapies; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
and maintaining healthcare coverage and adequate reimbursement;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protecting
our rights in our intellectual property portfolio; and</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of our products following approval. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Capital Resources</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March&#160;31, 2023, the Company had a significant accumulated deficit of $73.1 million. For the three months ended March&#160;31, 2023,
the Company had a loss from operations of $779 thousand and negative cash flows from operations of $1.3 million. The Company&#8217;s
operating activities consume the majority of its cash resources. The Company will continue to service existing customers in the United
States. The Company sold devices in China to its acting distributor. The Company anticipates that it will continue to incur operating
losses as it executes its development plans through 2023, as well as other potential strategic and business development initiatives.
In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. The Company
previously funded these losses primarily through the sale of equity and issuance of convertible notes. The accompanying unaudited condensed
consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as
a going concern. As of the March&#160;31, 2023, the Company had cash and cash equivalents on hand of approximately $175 thousand and
short-term investments of approximately $5.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the closing on September&#160;16, 2022, the Company sold 2,315,000 Units and 347,250 of Warrants in an Initial Public Offering (the &#8220;Initial
Public Offering&#8221;) at a price of $4.15 per Unit and $0.01 per Warrant for a total of $9,610,723. The Company incurred offering costs
of $1,067,078, consisting of $878,858 of underwriting fees and expenses and $188,220 of costs related to the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
no assurances can be given as to the Company&#8217;s ability to deliver on its revenue plans or that unforeseen expenses may arise, management
has evaluated the significance of the conditions and has concluded that because of the completion of our initial public offering in September&#160;2022,
the Company has sufficient cash and investments on hand to satisfy its anticipated cash requirements for the next twelve months from
the issuance date of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Accounting Policies and Significant Judgments and Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unaudited condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the
United States. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent
assets and liabilities in our unaudited condensed consolidated financial statements. We base our estimates on historical experience,
known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate
our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in Note 3 to our unaudited condensed consolidated financial statements
appearing elsewhere in this Form&#160;10-Q, we believe that the following accounting policies are those most critical to the judgments
and estimates used in the preparation of our unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company
determines if the contract is within the scope of ASC Topic 606 and then evaluates the contract using the following five steps: (1) identify
the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.
These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements
are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its
acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer
of the Company&#8217;s electrodes will pay a royalty to the Company for a three-year period beginning January&#160;1, 2022. The amount
of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Streams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives revenues from its license agreements by charging a monthly licensing fee for the duration of the agreement. The Company
derives revenues from equipment by selling additional individual electrodes and patient cables to customers for use with the Nexalin
Device. The Company receives revenue from the sale in China of its Devices to its acting distributor and from the sale of products relating
to the use of those Devices. The Company derives revenue as a royalty fee from the China-based manufacturer for electrodes ordered in
connection with the Company&#8217;s China sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied as long as the
licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time
in which the invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that our equipment revenue has one performance obligation. That performance obligation is satisfied when the electrodes and
devices are shipped to the customer. We do not offer a warranty on the electrodes or devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of
individual treatments on patients by customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that our royalty fee has one performance obligation. The performance obligation is satisfied as long as the royalty agreement
remains valid and is not terminated. The royalty revenue is invoiced when the manufacturer advises the Company that the invoice has been
sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
Financing Component &#8212; we do not adjust the promised amount of consideration for the effects of a significant financing component
since we expect, at contract inception, that the period between when we transfer a promised goods or services to the customer and when
the customer pays for that service will be one year or less.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
                                                                              Performance Obligations &#8212; for all performance obligations related to contracts with a duration of less than one year, we have
                                                                              elected to apply the optional exemption provided in ASC Topic 606 and therefore, are not required to disclose the aggregate amount
                                                                              of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the
                                                                              reporting period.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and Handling Activities &#8212; we elected to account for shipping and handling activities as a fulfilment cost rather than as a separate
performance obligation.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to invoice &#8212; we have the right to consideration from a customer in an amount that corresponds directly with the value to the
    customer of our performance completed to date we may recognize revenue in the amount to which the entity has a right to invoice.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February&#160;2020, the FASB issued ASU 2020-02,
Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting
Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments are in effect
for the Company for interim and annual periods in fiscal years beginning after December&#160;15, 2022. The adoption on January 1, 2023
modified the way the Company analyzes financial instruments, but it did not have a material impact on our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contractual
Obligations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 &#8211; Commitments and Contingencies in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item&#160;1
of this Form&#160;10-Q for a summary of our contractual obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Emerging
Growth Company Status</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend
to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging
growth companies. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions.
If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and
our share price may be more volatile. We may take advantage of these exemptions until the last day of our fiscal year following the fifth
anniversary of the completion of this offering. However, if any of the following events occur prior to the end of such five-year period,
(i) our annual gross revenue exceeds $1.07 billion, (ii) we issue more than $1.0 billion of non-convertible debt in any three-year period
or (iii) we become a &#8220;large accelerated filer,&#8221; (as defined in Rule&#160;12b-2 under the Exchange Act), we will cease to
be an emerging growth company prior to the end of such five-year period. We will be deemed to be a &#8220;large accelerated filer&#8221;
at such time that we (a) have an aggregate worldwide market value of common equity securities held by non-affiliates of $700 million
or more as of the last business day of our most recently completed second fiscal quarter, (b) have been required to file annual and quarterly
reports under the Exchange Act, for a period of at least twelve months and (c) have filed at least one annual report pursuant to the
Exchange Act. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221;
which would allow us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or revised accounting standards
and, therefore, will be subject to the same new or revised accounting standards as other public companies that are emerging growth companies.
As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance
or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;3.
Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable. As a smaller reporting company, we are not required to provide the information required by this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item&#160;4.
Disclosure Controls and Procedures</b>&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Exchange Act Rules&#160;13a-15(f) and 15d-15(f). Internal control over financial reporting is a process designed by, or under the
supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected
by our board of directors to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes
those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that
could have a material effect on the financial statements. Our management evaluated, with the participation of our chief executive officer
and chief financial officer (our &#8220;Certifying Officers&#8221;), the effectiveness of our disclosure controls and procedures as of
March&#160;31, 2023, &#160;&#160;pursuant to Rule&#160;13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers
concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
                                            of sufficient resources necessary to provide adequate segregation of duties related to the
                                            preparation and review of financial information used in financial reporting and review of
                                            controls over the financial reporting process, including documentation of review/approval
                                            of journal entries and reconciliations; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insufficient
                                            IT controls which are effectively designed and implemented, specifically related to user/superuser
                                            access to the Company&#8217;s financial reporting system.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deficiencies described above if not remedied, could result in a misstatement of one or more account balances or disclosures in our annual
or interim consolidated financial statements that would not be prevented or detected, and, accordingly, we determined that these control
deficiencies constitute a material weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address our material weakness, we intend to engage an outside firm to advise on our financial reporting processes and intend to implement
new financial accounting controls and processes. We intend to continue to take steps to remediate the material weakness described above
through implementing enhancements and controls within our accounting systems, subject to budget limitations. We will not be able to remediate
these control deficiencies until these steps have been completed and have been operating effectively for a sufficient period of time
and Management has concluded, through testing, that the controls are operating effectively. The redesign and implementation of improvements
to our accounting and proprietary systems and controls may be costly and time consuming and the cost to remediate may impair our results
of operations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those
systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as such term is defined in Rules&#160;13a-15(f) and 15d-15(f) of the
Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>PART
II&#8212;OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item&#160;1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
    Proceedings</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Item&#160;1A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    Factors.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
material risk factors are disclosed in &#8220;Risk Factors&#8221; in our Registration Statement on Form S-1 (SEC File Number 333-261989)
as declared effective by the Securities and Exchange Commission on September&#160;15, 2022 and the Prospectus contained therein, as updated
in our Form&#160;10-K filed on March&#160;27, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes from the risk factors previously disclosed in such filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>Item&#160;2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Equity Securities and Use of Proceeds from Registered Securities</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>Item&#160;3.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Defaults
    Upon Senior Securities</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>Item&#160;4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mine
    Safety Disclosures</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>Item&#160;5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Information</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>Item&#160;6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exhibits
and Financial Statement Schedules.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify; border-collapse: collapse">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Document</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622017011/nexalintech_ex4-1.htm">Underwriting
    Agreement dated as of September&#160;15, 2022 between the Registrant and maxim Group LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex3-1.htm">Certificate
    of Incorporation, as amended and as currently in effect.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex3-2.htm">Amended
    and Restated Bylaws.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000089109222000235/e14909ex4-1.htm">Form
    of Specimen stock certificate evidencing shares of common stock.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex4-2.htm">Warrant
    Agreement between the Company and Continental Stock Transfer and Trust company as warrant agent dated as of September&#160;16, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex4-2.htm">Form
    of Warrant Certificate (filed as part of Exhibit 4.2)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622008910/nexalintechnology_ex5-1.htm">Opinion
    of Warshaw Burstein, LLP as to legality of the shares.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-1.htm">potential
    Joint Venture Agreement between the Company and Wider Limited, and Supplement thereto, dated as of September&#160;21, 2018, as supplemented
    by Supplement Number 1.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-2.htm">Employment
    Agreement between the Company and Mark White dated as of February&#160;15, 2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-3.htm">Agreement
    between the Company and David Owens, M.D. dated as of February&#160;15, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-4.htm">Quality
    Assurance Agreement between the Company and Apical Instruments dated December&#160;31, 2020.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-5.htm">Advisor
    Agreement with Leonard Osser dated as of December&#160;22,2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-6.htm">Advisor
    Agreement with Tucker Anderson dated as of December&#160;24, 2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000117494722000015/e14815ex10-7.htm">Advisor
    Agreement with Gian Domenico Trombetta dated December&#160;24, 2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000089109222000235/e14909ex10-8.htm">Employment
    Agreement between the Company and Marilyn Elson dated as of January&#160;11, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex10-9.htm">Amendment
    and Deferral Agreement dated as of March&#160;30, 2022 to Consulting Agreement between the Company and US Asian Consulting Group
    LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex10-10.htm">Supplement
    Number 2 to potential Joint Venture Agreement dated as of March&#160;1, 2022 between the Company and Wider Come Limited.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex10-11.htm">Amendment
    to Employment Agreement with David Owens, M.D.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex10-12.htm">Form
    of Lock-Up Agreement.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex10-13.htm">Consulting
    Agreement dated as of May&#160;9, 2018 as amended between the Company and US Asian Consulting Group, LLC, as amended on January&#160;2,
    2019 and March&#160;4, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14****</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="nexalintechno_ex10-14.htm">Amended and Restated Promissory Note in favor of Mark White dated as of January 1, 2023.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622008910/nexalintechnology_ex10-15.htm">Distribution
    Authorization Agreement dated as of May&#160;1, 2019 with Wider Come Limited.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016885/nexalintech_ex23-1.htm">Consent
    of Friedman LLP, independent registered public accounting firm.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527352/000182912622008910/nexalintechnology_ex5-1.htm">Consent
    of Warshaw Burstein, LLP (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1****</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="nexalintechno_ex31-1.htm">Certification of the Chief Executive Officer pursuant to Rule&#160;13a-14(a) or Rule&#160;15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2****</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="nexalintechno_ex31-2.htm">Certification of the Chief Financial Officer pursuant to Rule&#160;13a-14(a) or Rule&#160;15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1****</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="nexalintechno_ex32-1.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2****</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="nexalintechno_ex32-2.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex99-1.htm">Code
    of Ethics</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex99-2.htm">Audit
    Committee Charter</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex99-3.htm">Compensation
    Committee Charter</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex99-4.htm">Nominating
    and Corporate Governance Committee Charter</a></span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to Form S-1 as declared effective by the SEC on September&#160;15, 2022 (SEC File Number 333-261989).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to Form&#160;8-K as filed with the SEC on September&#160;20, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to Form&#160;8-K/A as filed with the SEC on September&#160;20, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">****</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed
    as an exhibit to this Form&#160;10-Q.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form&#160;10-Q to be signed
on its behalf by the undersigned thereunto duly authorized on the 10<sup>th</sup> day of May, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEXALIN
    TECHNOLOGY, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark White&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark White</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Marilyn Elson&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marilyn Elson</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>

    <!-- Field: /Page -->
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>nexalintechno_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.14</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED PROMISSORY NOTE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; width: 50%; font-size: 10pt; layout-grid-mode: line; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of January 1, 2023</FONT></TD>
    <TD STYLE="padding: 0pt; width: 50%; font-size: 10pt; layout-grid-mode: line; text-align: right; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Value Received, <B>NEXALIN TECHNOLOGY, INC.</B>, a Delaware corporation (the &ldquo;<U>Maker</U>&rdquo;) promises to pay to the order
of <FONT STYLE="text-transform: uppercase"><B>MARK WHITE</B></FONT> (the &ldquo;<U>Payee</U>&rdquo;) the principal sum of <B>TWO HUNDRED
THOUSAND DOLLARS ($200,000)</B> (the &ldquo;<U>Loan</U>&rdquo;). The entire unpaid balance and interest thereon of the Loan as set forth
below shall be due and payable on March 17, 2023 (the &ldquo;<U>Maturity Date</U>&rdquo;), unless payment is accelerated as herein provided,
by reason of the occurrence of an &ldquo;Event of Default&rdquo; as set forth and defined below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amended and Restated Promissory Note amends and restates and is executed and delivered in substitution and replacement of, but not in
payment of, the Promissory Note of the Maker to the Payee dated November 1, 2021 (as heretofore amended, restated, supplemented, replaced,
renewed or otherwise modified, the &ldquo;<U>Prior Note</U>&rdquo;). This Amended and Restated Promissory Note does not cancel or satisfy
the Maker&rsquo;s payment obligations under the Prior Note and is not a novation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
shall be payable on the principal amount of the Loan in an amount equal to Thirty Nine Thousand Dollars ($39,000), payable on the Maturity
Date, when the entire unpaid principal balance of the Loan and such interest (less any interest payments made to the Payee by the Maker
prior to the Maturity Date) shall be due and payable. In no event shall interest exceed the maximum legal rate permitted for the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
any payment hereunder is due on a day which is a holiday in the State of New York, such payment shall be made on the next succeeding
business day. All payments by the Maker on account of principal, interest or fees hereunder shall be made in lawful money of the United
States of America, in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maker agrees that if an attorney is retained to enforce or collect this Note or any other obligations by reason of non-payment of this
Amended and Restated Promissory Note when due or made due hereunder, a reasonable attorneys&rsquo; fee shall be paid in addition, which fee
shall be the reasonable value of the attorneys&rsquo; services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amended and Restated Promissory Note may be prepaid in whole or in part at any time, without premium or penalty of any kind. All prepayments
of this Amended and Restated Promissory Note shall be applied first to accrued and unpaid interest, and then to the outstanding principal
amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence and continuance of any one or more of the following events with respect to the Maker will constitute an event of default hereunder
(each an &ldquo;<U>Event of Default</U>&rdquo;): (i) any failure by the Maker to make a payment of principal or interest under this Amended
and Restated Promissory Note; (ii) the making of an assignment for the benefit of the Maker&rsquo;s creditors, unless such assignment
is dismissed within ninety (90) days; (iii)&nbsp;the appointment of a trustee, receiver or liquidator for the Maker or for any of its
property, unless such appointment is dismissed within ninety (90) days; (iv) the commencement of any proceedings by the Maker under any
bankruptcy, reorganization, arrangement of debt, insolvency, readjustment of debt, or receivership, law or statute, unless such proceedings
are dismissed within ninety (90) days; or (v) the commencement of any such proceedings without the consent of the Maker, unless such
proceedings are dismissed within ninety (90) days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence of an Event of Default (unless such Event of Default has been waived by the Payee), all sums owing under this Amended
and Restated Promissory Note, if not then due or payable, shall become due and payable immediately without demand or notice and the Payee
or holder hereof shall have the right to exercise any and all rights and remedies available to it under applicable law, including, without
limitation, the right to collect from the Maker all sums due under this Amended and Restated Promissory Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amended and Restated Promissory Note shall be governed by the laws of the State of Delaware. <B>The Payee and the Maker hereby irrevocably
consent to the jurisdiction of any Delaware State or Federal court located in Delaware over any action or proceeding arising out of any
dispute between them. </B>The Payee or any holder may accept late payments, or partial payments, even though marked &ldquo;payment in
full&rdquo; or containing words of similar import or other conditions, without waiving any of its rights. No amendment, modification,
or waiver of any provision of this Amended and Restated Promissory Note nor consent to any departure by the Maker therefrom shall be
effective, irrespective of any course of dealing, unless the same shall be in writing and signed by the Payee, and then such waiver or
consent shall be effective only in the specific instance and for the specific purpose for which given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amended and Restated Promissory Note shall be binding upon the Maker and the Maker&rsquo;s successors and assigns and shall inure to
the benefit of and be enforceable by each person who shall be the holder of this Note from time to time and each such person&rsquo;s
successors, assigns, heirs, executors and administrators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and remedies of the Payee provided for hereunder are cumulative with the rights and remedies of the Payee available under any
other instrument or agreement or under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEXALIN TECHNOLOGY, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 0pt 1pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark White&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt">Mark White</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address:&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1776
    Yorktown Street, Suite 550A</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; layout-grid-mode: line; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
    TX 77056</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>nexalintechno_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;302
OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(18
U.S.C. SECTION&nbsp;1350)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Mark White, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this quarterly report on Form&nbsp;10-Q of Nexalin Technology, Inc.:</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s
most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing
the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 10, 2023</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEXALIN
    TECHNOLOGY, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark White&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark White</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>nexalintechno_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;302
OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(18
U.S.C. SECTION&nbsp;1350)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Marilyn Elson, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this quarterly report on Form&nbsp;10-Q of Nexalin Technology, Inc.:</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s
most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing
the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Date: May 10, 2023</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEXALIN
    TECHNOLOGY, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marilyn Elson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marilyn Elson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>nexalintechno_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, in his capacity as an officer of NEXALIN TECHNOLOGY, INC., that, to his or her knowledge, the Quarterly Report Nexalin Technology,
Inc. on Form&nbsp;10-Q for the period ended March&nbsp;31, 2023 fully complies with the requirements of Section&nbsp;13(a) of the Securities
Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition
and results of operation of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section&nbsp;906 has been provided to NEXALIN TECHNOLOGY, INC and will be retained
by NEXALIN TECHNOLOGY, INC and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Date: May 10, 2023</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEXALIN
    TECHNOLOGY, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark White&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark White</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>nexalintechno_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, in his capacity as an officer of NEXALIN TECHNOLOGY, INC., that, to his or her knowledge, the Quarterly Report of Nexalin Technology,
Inc. on Form&nbsp;10-Q for the period ended March&nbsp;31, 2023 fully complies with the requirements of Section&nbsp;13(a) of the Securities
Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition
and results of operation of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section&nbsp;906 has been provided to NEXALIN TECHNOLOGY, INC and will be retained
by NEXALIN TECHNOLOGY, INC and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 10, 2023</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEXALIN
    TECHNOLOGY, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
</FONT>Marilyn Elson</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marilyn Elson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nxl-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nexalin.com/role/Cover" xlink:href="nxl-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nxl-20230331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="nxl-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusiness" xlink:href="nxl-20230331.xsd#NatureOfOrganizationAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Liquidity" xlink:href="nxl-20230331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpenses" xlink:href="nxl-20230331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:href="nxl-20230331.xsd#Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LoansPayable" xlink:href="nxl-20230331.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficit" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CommitmentsAndContingencies" xlink:href="nxl-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Leases" xlink:href="nxl-20230331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRisk" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SubsequentEvents" xlink:href="nxl-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpensesTables" xlink:href="nxl-20230331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitTables" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesTables" xlink:href="nxl-20230331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskTables" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" xlink:href="nxl-20230331.xsd#NatureOfOrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LiquidityDetailsNarrative" xlink:href="nxl-20230331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpensesDetails" xlink:href="nxl-20230331.xsd#AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:href="nxl-20230331.xsd#Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LoansPayableDetailsNarrative" xlink:href="nxl-20230331.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails1" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nxl-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails" xlink:href="nxl-20230331.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails1" xlink:href="nxl-20230331.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails2" xlink:href="nxl-20230331.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails3" xlink:href="nxl-20230331.xsd#LeasesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetailsNarrative" xlink:href="nxl-20230331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PatentNetOfAmortization" xlink:label="loc_NXLPatentNetOfAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_NXLPatentNetOfAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoanPayableOfficer" xlink:label="loc_NXLLoanPayableOfficer" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_NXLLoanPayableOfficer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_GainOnSaleOfShorttermInvestments" xlink:label="loc_NXLGainOnSaleOfShorttermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_NXLGainOnSaleOfShorttermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGainFromShorttermInvestments" xlink:label="loc_NXLUnrealizedGainFromShorttermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_NXLUnrealizedGainFromShorttermInvestments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaapAcquisitionCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAcquisitionCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_GainOnSaleOfShorttermInvestments" xlink:label="loc_NXLGainOnSaleOfShorttermInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NXLGainOnSaleOfShorttermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfShortTermInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:label="loc_us-gaapPaymentsToAcquireTradingSecuritiesHeldforinvestment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PurchaseOfPatents" xlink:label="loc_NXLPurchaseOfPatents" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_NXLPurchaseOfPatents" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PaymentsOnLoanPayableShareholder" xlink:label="loc_NXLPaymentsOnLoanPayableShareholder" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NXLPaymentsOnLoanPayableShareholder" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PaymentsOnNotesPayableOfficer" xlink:label="loc_NXLPaymentsOnNotesPayableOfficer" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NXLPaymentsOnNotesPayableOfficer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/NatureOfOrganizationAndBusiness" xlink:title="00000008 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Liquidity" xlink:title="00000009 - Disclosure - LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:title="00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:title="00000012 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LoansPayable" xlink:title="00000013 - Disclosure - LOANS PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficit" xlink:title="00000014 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Leases" xlink:title="00000016 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRisk" xlink:title="00000017 - Disclosure - CONCENTRATION OF CREDIT RISK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpensesTables" xlink:title="00000021 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitTables" xlink:title="00000022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskTables" xlink:title="00000024 - Disclosure - CONCENTRATION OF CREDIT RISK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LiquidityDetailsNarrative" xlink:title="00000026 - Disclosure - LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:title="00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpensesDetails" xlink:title="00000032 - Disclosure - ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="loc_us-gaapAccruedUtilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedUtilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedUtilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedUtilitiesCurrent" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccruedResearchAndDevelopmentExpense" xlink:label="loc_NXLAccruedResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedUtilitiesCurrent" xlink:to="loc_NXLAccruedResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LoansPayableDetailsNarrative" xlink:title="00000034 - Disclosure - LOANS PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetails" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetails1" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails" xlink:title="00000039 - Disclosure - LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails1" xlink:title="00000040 - Disclosure - LEASES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails2" xlink:title="00000041 - Disclosure - LEASES (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails3" xlink:title="00000042 - Disclosure - LEASES (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetailsNarrative" xlink:title="00000043 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" xlink:title="00000044 - Disclosure - CONCENTRATION OF CREDIT RISK (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" xlink:title="00000045 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nxl-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nexalin.com/role/Cover" xlink:href="nxl-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nxl-20230331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="nxl-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusiness" xlink:href="nxl-20230331.xsd#NatureOfOrganizationAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Liquidity" xlink:href="nxl-20230331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpenses" xlink:href="nxl-20230331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:href="nxl-20230331.xsd#Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LoansPayable" xlink:href="nxl-20230331.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficit" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CommitmentsAndContingencies" xlink:href="nxl-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Leases" xlink:href="nxl-20230331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRisk" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SubsequentEvents" xlink:href="nxl-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpensesTables" xlink:href="nxl-20230331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitTables" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesTables" xlink:href="nxl-20230331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskTables" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" xlink:href="nxl-20230331.xsd#NatureOfOrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LiquidityDetailsNarrative" xlink:href="nxl-20230331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpensesDetails" xlink:href="nxl-20230331.xsd#AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:href="nxl-20230331.xsd#Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LoansPayableDetailsNarrative" xlink:href="nxl-20230331.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails1" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nxl-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails" xlink:href="nxl-20230331.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails1" xlink:href="nxl-20230331.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails2" xlink:href="nxl-20230331.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails3" xlink:href="nxl-20230331.xsd#LeasesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetailsNarrative" xlink:href="nxl-20230331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CommonStockParValue0.001PerShareMember" xlink:label="loc_NXLCommonStockParValue0.001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NXLCommonStockParValue0.001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WarrantsExercisableForOneShareOfCommonStockMember" xlink:label="loc_NXLWarrantsExercisableForOneShareOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NXLWarrantsExercisableForOneShareOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/NatureOfOrganizationAndBusiness" xlink:title="00000008 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/Liquidity" xlink:title="00000009 - Disclosure - LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:title="00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:title="00000012 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LoansPayable" xlink:title="00000013 - Disclosure - LOANS PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficit" xlink:title="00000014 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/Leases" xlink:title="00000016 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRisk" xlink:title="00000017 - Disclosure - CONCENTRATION OF CREDIT RISK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpensesTables" xlink:title="00000021 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitTables" xlink:title="00000022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskTables" xlink:title="00000024 - Disclosure - CONCENTRATION OF CREDIT RISK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LiquidityDetailsNarrative" xlink:title="00000026 - Disclosure - LIQUIDITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DeviceSalesMember" xlink:label="loc_NXLDeviceSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NXLDeviceSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LicensingFeeMember" xlink:label="loc_NXLLicensingFeeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NXLLicensingFeeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OtherMember" xlink:label="loc_NXLOtherMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NXLOtherMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:title="00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaapScheduleOfInvestmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapScheduleOfInvestmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapShortTermInvestmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AmortizedCost" xlink:label="loc_NXLAmortizedCost_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_NXLAmortizedCost_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGain" xlink:label="loc_NXLUnrealizedGain_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_NXLUnrealizedGain_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpensesDetails" xlink:title="00000032 - Disclosure - ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PotentialJointVentureMember" xlink:label="loc_NXLPotentialJointVentureMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_NXLPotentialJointVentureMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_USAsianConsultingGroupLLCMember" xlink:label="loc_NXLUSAsianConsultingGroupLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_NXLUSAsianConsultingGroupLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ConsultingAgreementMember" xlink:label="loc_NXLConsultingAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NXLConsultingAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_MrOsserMember" xlink:label="loc_NXLMrOsserMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NXLMrOsserMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoansPayableOfficerMember" xlink:label="loc_NXLLoansPayableOfficerMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NXLLoansPayableOfficerMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RelatedPartyContribution" xlink:label="loc_NXLRelatedPartyContribution_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLRelatedPartyContribution_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharesIssued_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RemainingSharesIssuedDescription" xlink:label="loc_NXLRemainingSharesIssuedDescription_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLRemainingSharesIssuedDescription_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RevenuesFromRelatedParties" xlink:label="loc_NXLRevenuesFromRelatedParties_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLRevenuesFromRelatedParties_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ConsultingExpenses" xlink:label="loc_NXLConsultingExpenses_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLConsultingExpenses_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherBorrowings" xlink:label="loc_us-gaapOtherBorrowings_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherBorrowings_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OwedBalancePaymentDescription" xlink:label="loc_NXLOwedBalancePaymentDescription_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLOwedBalancePaymentDescription_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoansFromRelatedParty" xlink:label="loc_NXLLoansFromRelatedParty_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLLoansFromRelatedParty_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_InterestPayableCurrents" xlink:label="loc_NXLInterestPayableCurrents_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLInterestPayableCurrents_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingAmount" xlink:label="loc_NXLOutstandingAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLOutstandingAmount_210" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingInterest" xlink:label="loc_NXLOutstandingInterest_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLOutstandingInterest_210" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LoansPayableDetailsNarrative" xlink:title="00000034 - Disclosure - LOANS PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LegacyVenturesInternationalIncMember" xlink:label="loc_NXLLegacyVenturesInternationalIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NXLLegacyVenturesInternationalIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingAmount" xlink:label="loc_NXLOutstandingAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NXLOutstandingAmount_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetails" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetails1" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_Range1Member" xlink:label="loc_NXLRange1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_NXLRange1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_Range2Member" xlink:label="loc_NXLRange2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_NXLRange2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ExercisableNumberOfWarrants" xlink:label="loc_NXLExercisableNumberOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_NXLExercisableNumberOfWarrants_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AnInvestorMember" xlink:label="loc_NXLAnInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_NXLAnInvestorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_VariousConsultantsMember" xlink:label="loc_NXLVariousConsultantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_NXLVariousConsultantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails" xlink:title="00000039 - Disclosure - LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails1" xlink:title="00000040 - Disclosure - LEASES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails2" xlink:title="00000041 - Disclosure - LEASES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails3" xlink:title="00000042 - Disclosure - LEASES (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetailsNarrative" xlink:title="00000043 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" xlink:title="00000044 - Disclosure - CONCENTRATION OF CREDIT RISK (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerAMember" xlink:label="loc_NXLCustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerBMember" xlink:label="loc_NXLCustomerBMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerBMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerCMember" xlink:label="loc_NXLCustomerCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerDMember" xlink:label="loc_NXLCustomerDMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerDMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerEMember" xlink:label="loc_NXLCustomerEMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerEMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerFMember" xlink:label="loc_NXLCustomerFMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerFMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_140" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" xlink:title="00000045 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_SixCustomerMember" xlink:label="loc_NXLSixCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLSixCustomerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OneCustomerMember" xlink:label="loc_NXLOneCustomerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLOneCustomerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ThreeCustomerMember" xlink:label="loc_NXLThreeCustomerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLThreeCustomerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_FourCustomerMember" xlink:label="loc_NXLFourCustomerMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLFourCustomerMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_50" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nxl-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CommonStockParValue0.001PerShareMember" xlink:label="NXL_CommonStockParValue0.001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CommonStockParValue0.001PerShareMember" xlink:to="NXL_CommonStockParValue0.001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CommonStockParValue0.001PerShareMember_lbl" xml:lang="en-US">Common stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WarrantsExercisableForOneShareOfCommonStockMember" xlink:label="NXL_WarrantsExercisableForOneShareOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_WarrantsExercisableForOneShareOfCommonStockMember" xlink:to="NXL_WarrantsExercisableForOneShareOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_WarrantsExercisableForOneShareOfCommonStockMember_lbl" xml:lang="en-US">Warrants, exercisable for one share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DeviceSalesMember" xlink:label="NXL_DeviceSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_DeviceSalesMember" xlink:to="NXL_DeviceSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_DeviceSalesMember_lbl" xml:lang="en-US">Device Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LicensingFeeMember" xlink:label="NXL_LicensingFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_LicensingFeeMember" xlink:to="NXL_LicensingFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_LicensingFeeMember_lbl" xml:lang="en-US">Licensing Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OtherMember" xlink:label="NXL_OtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_OtherMember" xlink:to="NXL_OtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_OtherMember_lbl" xml:lang="en-US">Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US">Short-Term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PotentialJointVentureMember" xlink:label="NXL_PotentialJointVentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PotentialJointVentureMember" xlink:to="NXL_PotentialJointVentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_PotentialJointVentureMember_lbl" xml:lang="en-US">Potential Joint Venture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_USAsianConsultingGroupLLCMember" xlink:label="NXL_USAsianConsultingGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_USAsianConsultingGroupLLCMember" xlink:to="NXL_USAsianConsultingGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_USAsianConsultingGroupLLCMember_lbl" xml:lang="en-US">U S Asian Consulting Group L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ConsultingAgreementMember" xlink:label="NXL_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_ConsultingAgreementMember" xlink:to="NXL_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_MrOsserMember" xlink:label="NXL_MrOsserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_MrOsserMember" xlink:to="NXL_MrOsserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_MrOsserMember_lbl" xml:lang="en-US">Mr Osser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoansPayableOfficerMember" xlink:label="NXL_LoansPayableOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_LoansPayableOfficerMember" xlink:to="NXL_LoansPayableOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_LoansPayableOfficerMember_lbl" xml:lang="en-US">Loans Payable Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LegacyVenturesInternationalIncMember" xlink:label="NXL_LegacyVenturesInternationalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_LegacyVenturesInternationalIncMember" xlink:to="NXL_LegacyVenturesInternationalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_LegacyVenturesInternationalIncMember_lbl" xml:lang="en-US">Legacy Ventures International Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AnInvestorMember" xlink:label="NXL_AnInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_AnInvestorMember" xlink:to="NXL_AnInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_AnInvestorMember_lbl" xml:lang="en-US">An Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_VariousConsultantsMember" xlink:label="NXL_VariousConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_VariousConsultantsMember" xlink:to="NXL_VariousConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_VariousConsultantsMember_lbl" xml:lang="en-US">Various Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_Range1Member" xlink:label="NXL_Range1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_Range1Member" xlink:to="NXL_Range1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_Range1Member_lbl" xml:lang="en-US">Range 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_Range2Member" xlink:label="NXL_Range2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_Range2Member" xlink:to="NXL_Range2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_Range2Member_lbl" xml:lang="en-US">Range 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_SixCustomerMember" xlink:label="NXL_SixCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_SixCustomerMember" xlink:to="NXL_SixCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_SixCustomerMember_lbl" xml:lang="en-US">Six Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OneCustomerMember" xlink:label="NXL_OneCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_OneCustomerMember" xlink:to="NXL_OneCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ThreeCustomerMember" xlink:label="NXL_ThreeCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_ThreeCustomerMember" xlink:to="NXL_ThreeCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_ThreeCustomerMember_lbl" xml:lang="en-US">Three Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_FourCustomerMember" xlink:label="NXL_FourCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_FourCustomerMember" xlink:to="NXL_FourCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_FourCustomerMember_lbl" xml:lang="en-US">Four Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerAMember" xlink:label="NXL_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CustomerAMember" xlink:to="NXL_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerBMember" xlink:label="NXL_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CustomerBMember" xlink:to="NXL_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerCMember" xlink:label="NXL_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CustomerCMember" xlink:to="NXL_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerDMember" xlink:label="NXL_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CustomerDMember" xlink:to="NXL_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerEMember" xlink:label="NXL_CustomerEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CustomerEMember" xlink:to="NXL_CustomerEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CustomerEMember_lbl" xml:lang="en-US">Customer E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerFMember" xlink:label="NXL_CustomerFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_CustomerFMember" xlink:to="NXL_CustomerFMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_CustomerFMember_lbl" xml:lang="en-US">Customer F [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">ROU Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment, net of accumulated depreciation of $2,315 and $2,181, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PatentNetOfAmortization" xlink:label="NXL_PatentNetOfAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PatentNetOfAmortization" xlink:to="NXL_PatentNetOfAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_PatentNetOfAmortization_lbl" xml:lang="en-US">Patent, net of amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable (Includes related party of $10,000 and $260,000, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoanPayableOfficer" xlink:label="NXL_LoanPayableOfficer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_LoanPayableOfficer" xlink:to="NXL_LoanPayableOfficer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_LoanPayableOfficer_lbl" xml:lang="en-US">Loan payable - officer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 7,286,562 shares issued and outstanding at March 31, 2023 and December 31, 2022,&#160;&#160;respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccountsPayableRelatedParty" xlink:label="NXL_AccountsPayableRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_AccountsPayableRelatedParty" xlink:to="NXL_AccountsPayableRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_AccountsPayableRelatedParty_lbl" xml:lang="en-US">Accounts payable related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues, net (Includes related party of $0 and $300,499 for the three months ended March 31, 2023 and March 31, 2022, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salaries and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense), net:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_GainOnSaleOfShorttermInvestments" xlink:label="NXL_GainOnSaleOfShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_GainOnSaleOfShorttermInvestments" xlink:to="NXL_GainOnSaleOfShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_GainOnSaleOfShorttermInvestments_lbl" xml:lang="en-US">Gain on sale of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGainFromShorttermInvestments" xlink:label="NXL_UnrealizedGainFromShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_UnrealizedGainFromShorttermInvestments" xlink:to="NXL_UnrealizedGainFromShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_UnrealizedGainFromShorttermInvestments_lbl" xml:lang="en-US">Unrealized gain from short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" xlink:label="NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" xlink:to="NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WeightedAverageSharesOutstanding" xlink:label="NXL_WeightedAverageSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_WeightedAverageSharesOutstanding" xlink:to="NXL_WeightedAverageSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_WeightedAverageSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Shares Outstanding - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RevenuesFromRelatedParties" xlink:label="NXL_RevenuesFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_RevenuesFromRelatedParties" xlink:to="NXL_RevenuesFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_RevenuesFromRelatedParties_lbl" xml:lang="en-US">Revenue from related parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionCosts_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_GainOnSaleOfShorttermInvestments" xlink:to="NXL_GainOnSaleOfShorttermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NXL_GainOnSaleOfShorttermInvestments_2_lbl" xml:lang="en-US">Gain on sale of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Accounts payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Sale of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:label="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:to="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment_lbl" xml:lang="en-US">Purchase of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PurchaseOfPatents" xlink:label="NXL_PurchaseOfPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PurchaseOfPatents" xlink:to="NXL_PurchaseOfPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NXL_PurchaseOfPatents_lbl" xml:lang="en-US">Purchase of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Sale of common stock for cash, net of financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PaymentsOnLoanPayableShareholder" xlink:label="NXL_PaymentsOnLoanPayableShareholder" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PaymentsOnLoanPayableShareholder" xlink:to="NXL_PaymentsOnLoanPayableShareholder_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NXL_PaymentsOnLoanPayableShareholder_lbl" xml:lang="en-US">Payments on loan payable - shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PaymentsOnNotesPayableOfficer" xlink:label="NXL_PaymentsOnNotesPayableOfficer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PaymentsOnNotesPayableOfficer" xlink:to="NXL_PaymentsOnNotesPayableOfficer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_PaymentsOnNotesPayableOfficer_lbl" xml:lang="en-US">Payments on notes payable - officer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents - end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGainOnShorttermInvestments" xlink:label="NXL_UnrealizedGainOnShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_UnrealizedGainOnShorttermInvestments" xlink:to="NXL_UnrealizedGainOnShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_UnrealizedGainOnShorttermInvestments_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RouAssetAndLeaseLiabilityRecorded" xlink:label="NXL_RouAssetAndLeaseLiabilityRecorded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_RouAssetAndLeaseLiabilityRecorded" xlink:to="NXL_RouAssetAndLeaseLiabilityRecorded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_RouAssetAndLeaseLiabilityRecorded_lbl" xml:lang="en-US">ROU asset and lease liability recorded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF THE ORGANIZATION AND BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">LOANS PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (Deficit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="NXL_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_DisclosureLeasesAbstract" xlink:to="NXL_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATION OF CREDIT RISK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ShortTermInvestmentsPolicyTextBlock" xlink:label="NXL_ShortTermInvestmentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_ShortTermInvestmentsPolicyTextBlock" xlink:to="NXL_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_ShortTermInvestmentsPolicyTextBlock_lbl" xml:lang="en-US">Short-Term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PatentsPolicyTextBlock" xlink:label="NXL_PatentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PatentsPolicyTextBlock" xlink:to="NXL_PatentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_PatentsPolicyTextBlock_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WarrantAccountingPolicyTextBlock" xlink:label="NXL_WarrantAccountingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_WarrantAccountingPolicyTextBlock" xlink:to="NXL_WarrantAccountingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_WarrantAccountingPolicyTextBlock_lbl" xml:lang="en-US">Warrant Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of disaggregation of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of amortized cost, unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value, assets measured on recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock" xlink:label="NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock" xlink:to="NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock_lbl" xml:lang="en-US">Summary information about warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future minimum payments under non-cancelable leases for operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" xlink:label="NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" xlink:to="NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of additional information related to leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Concentration of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WorkingCapitalDeficit" xlink:label="NXL_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_WorkingCapitalDeficit" xlink:to="NXL_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xml:lang="en-US">Schedule of Investments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AmortizedCost" xlink:label="NXL_AmortizedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_AmortizedCost" xlink:to="NXL_AmortizedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_AmortizedCost_lbl" xml:lang="en-US">Amortized Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGain" xlink:label="NXL_UnrealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_UnrealizedGain" xlink:to="NXL_UnrealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_UnrealizedGain_lbl" xml:lang="en-US">Unrealized Gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_2_lbl" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Writeoff accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued &#8211; other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued settlement liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccruedResearchAndDevelopmentExpense" xlink:label="NXL_AccruedResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_AccruedResearchAndDevelopmentExpense" xlink:to="NXL_AccruedResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Accrued research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl" xml:lang="en-US">&#160;Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RelatedPartyContribution" xlink:label="NXL_RelatedPartyContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_RelatedPartyContribution" xlink:to="NXL_RelatedPartyContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_RelatedPartyContribution_lbl" xml:lang="en-US">Related party contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RemainingSharesIssuedDescription" xlink:label="NXL_RemainingSharesIssuedDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_RemainingSharesIssuedDescription" xlink:to="NXL_RemainingSharesIssuedDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_RemainingSharesIssuedDescription_lbl" xml:lang="en-US">Remaining shares issued, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_RevenuesFromRelatedParties" xlink:to="NXL_RevenuesFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NXL_RevenuesFromRelatedParties_2_lbl" xml:lang="en-US">Revenue from Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Monthly payment</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ConsultingExpenses" xlink:label="NXL_ConsultingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_ConsultingExpenses" xlink:to="NXL_ConsultingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_ConsultingExpenses_lbl" xml:lang="en-US">Consulting expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherBorrowings" xlink:label="us-gaap_OtherBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherBorrowings" xlink:to="us-gaap_OtherBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherBorrowings_lbl" xml:lang="en-US">Balance owed for accrued,unpaid services and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OwedBalancePaymentDescription" xlink:label="NXL_OwedBalancePaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_OwedBalancePaymentDescription" xlink:to="NXL_OwedBalancePaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_OwedBalancePaymentDescription_lbl" xml:lang="en-US">Owed balance payment, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Consideration paid</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoansFromRelatedParty" xlink:label="NXL_LoansFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_LoansFromRelatedParty" xlink:to="NXL_LoansFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_LoansFromRelatedParty_lbl" xml:lang="en-US">Loans from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_InterestPayableCurrents" xlink:label="NXL_InterestPayableCurrents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_InterestPayableCurrents" xlink:to="NXL_InterestPayableCurrents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_InterestPayableCurrents_lbl" xml:lang="en-US">[custom:InterestPayableCurrents-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingAmount" xlink:label="NXL_OutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_OutstandingAmount" xlink:to="NXL_OutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_OutstandingAmount_lbl" xml:lang="en-US">Outstanding amount</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingInterest" xlink:label="NXL_OutstandingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_OutstandingInterest" xlink:to="NXL_OutstandingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_OutstandingInterest_lbl" xml:lang="en-US">Outstanding interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of Warrants Outstanding at beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Warrants Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Warrants Expired or cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled" xlink:label="NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled" xlink:to="NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired or cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Number of Warrants Outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_4_lbl" xml:lang="en-US">Outstanding Number of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ExercisableNumberOfWarrants" xlink:label="NXL_ExercisableNumberOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_ExercisableNumberOfWarrants" xlink:to="NXL_ExercisableNumberOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_ExercisableNumberOfWarrants_lbl" xml:lang="en-US">Exercisable Number of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xml:lang="en-US">Number of common stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued for services rendered, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xml:lang="en-US">Stock compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccruedAmount" xlink:label="NXL_AccruedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_AccruedAmount" xlink:to="NXL_AccruedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_AccruedAmount_lbl" xml:lang="en-US">Accrued amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease cost ROU assets</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_TotalLeaseAssets" xlink:label="NXL_TotalLeaseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_TotalLeaseAssets" xlink:to="NXL_TotalLeaseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_TotalLeaseAssets_lbl" xml:lang="en-US">Total lease assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liabilities, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Remainder of 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Amount representing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of net future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LeaseLiability" xlink:label="NXL_LeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_LeaseLiability" xlink:to="NXL_LeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_LeaseLiability_lbl" xml:lang="en-US">[custom:LeaseLiability-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WeightedAverageIncrementalBorrowingRate" xlink:label="NXL_WeightedAverageIncrementalBorrowingRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_WeightedAverageIncrementalBorrowingRate" xlink:to="NXL_WeightedAverageIncrementalBorrowingRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_WeightedAverageIncrementalBorrowingRate_lbl" xml:lang="en-US">[custom:WeightedAverageIncrementalBorrowingRate]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Revenue, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_3_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:to="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment_2_lbl" xml:lang="en-US">Payment for Acquisition, Trading Security, Held-for-Investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PurchaseOfPatents" xlink:to="NXL_PurchaseOfPatents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_PurchaseOfPatents_2_lbl" xml:lang="en-US">PurchaseOfPatents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NXL_PaymentsOnLoanPayableShareholder" xlink:to="NXL_PaymentsOnLoanPayableShareholder_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NXL_PaymentsOnLoanPayableShareholder_2_lbl" xml:lang="en-US">PaymentsOnLoanPayableShareholder</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessor, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_2_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedUtilitiesCurrent_2_lbl" xml:lang="en-US">Accrued Utilities, Current</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nxl-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nexalin.com/role/Cover" xlink:href="nxl-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nxl-20230331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="nxl-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="nxl-20230331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusiness" xlink:href="nxl-20230331.xsd#NatureOfOrganizationAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Liquidity" xlink:href="nxl-20230331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpenses" xlink:href="nxl-20230331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:href="nxl-20230331.xsd#Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LoansPayable" xlink:href="nxl-20230331.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficit" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CommitmentsAndContingencies" xlink:href="nxl-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Leases" xlink:href="nxl-20230331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRisk" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SubsequentEvents" xlink:href="nxl-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpensesTables" xlink:href="nxl-20230331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitTables" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesTables" xlink:href="nxl-20230331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskTables" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" xlink:href="nxl-20230331.xsd#NatureOfOrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LiquidityDetailsNarrative" xlink:href="nxl-20230331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:href="nxl-20230331.xsd#SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/AccruedExpensesDetails" xlink:href="nxl-20230331.xsd#AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:href="nxl-20230331.xsd#Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LoansPayableDetailsNarrative" xlink:href="nxl-20230331.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails1" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="nxl-20230331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nxl-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails" xlink:href="nxl-20230331.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails1" xlink:href="nxl-20230331.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails2" xlink:href="nxl-20230331.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetails3" xlink:href="nxl-20230331.xsd#LeasesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/LeasesDetailsNarrative" xlink:href="nxl-20230331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" xlink:href="nxl-20230331.xsd#ConcentrationOfCreditRiskDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CommonStockParValue0.001PerShareMember" xlink:label="loc_NXLCommonStockParValue0.001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NXLCommonStockParValue0.001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WarrantsExercisableForOneShareOfCommonStockMember" xlink:label="loc_NXLWarrantsExercisableForOneShareOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NXLWarrantsExercisableForOneShareOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PatentNetOfAmortization" xlink:label="loc_NXLPatentNetOfAmortization" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_NXLPatentNetOfAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoanPayableOfficer" xlink:label="loc_NXLLoanPayableOfficer" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_NXLLoanPayableOfficer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccountsPayableRelatedParty" xlink:label="loc_NXLAccountsPayableRelatedParty" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_NXLAccountsPayableRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_GainOnSaleOfShorttermInvestments" xlink:label="loc_NXLGainOnSaleOfShorttermInvestments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_NXLGainOnSaleOfShorttermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGainFromShorttermInvestments" xlink:label="loc_NXLUnrealizedGainFromShorttermInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_NXLUnrealizedGainFromShorttermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" xlink:label="loc_NXLNetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_NXLNetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WeightedAverageSharesOutstanding" xlink:label="loc_NXLWeightedAverageSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_NXLWeightedAverageSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RevenuesFromRelatedParties" xlink:label="loc_NXLRevenuesFromRelatedParties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_NXLRevenuesFromRelatedParties" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaapAcquisitionCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAcquisitionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_GainOnSaleOfShorttermInvestments" xlink:label="loc_NXLGainOnSaleOfShorttermInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NXLGainOnSaleOfShorttermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfShortTermInvestments" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:label="loc_us-gaapPaymentsToAcquireTradingSecuritiesHeldforinvestment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireTradingSecuritiesHeldforinvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PurchaseOfPatents" xlink:label="loc_NXLPurchaseOfPatents" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_NXLPurchaseOfPatents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PaymentsOnLoanPayableShareholder" xlink:label="loc_NXLPaymentsOnLoanPayableShareholder" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NXLPaymentsOnLoanPayableShareholder" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PaymentsOnNotesPayableOfficer" xlink:label="loc_NXLPaymentsOnNotesPayableOfficer" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NXLPaymentsOnNotesPayableOfficer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGainOnShorttermInvestments" xlink:label="loc_NXLUnrealizedGainOnShorttermInvestments" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NXLUnrealizedGainOnShorttermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RouAssetAndLeaseLiabilityRecorded" xlink:label="loc_NXLRouAssetAndLeaseLiabilityRecorded" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NXLRouAssetAndLeaseLiabilityRecorded" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/NatureOfOrganizationAndBusiness" xlink:title="00000008 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Liquidity" xlink:title="00000009 - Disclosure - LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" xlink:title="00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" xlink:title="00000012 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LoansPayable" xlink:title="00000013 - Disclosure - LOANS PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficit" xlink:title="00000014 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Leases" xlink:title="00000016 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRisk" xlink:title="00000017 - Disclosure - CONCENTRATION OF CREDIT RISK">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ShortTermInvestmentsPolicyTextBlock" xlink:label="loc_NXLShortTermInvestmentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NXLShortTermInvestmentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PatentsPolicyTextBlock" xlink:label="loc_NXLPatentsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NXLPatentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WarrantAccountingPolicyTextBlock" xlink:label="loc_NXLWarrantAccountingPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NXLWarrantAccountingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="loc_us-gaapLessorLeasesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLessorLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpensesTables" xlink:title="00000021 - Disclosure - ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitTables" xlink:title="00000022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock" xlink:label="loc_NXLSummaryInformationAboutWarrantsToPurchaseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_NXLSummaryInformationAboutWarrantsToPurchaseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" xlink:label="loc_NXLScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_NXLScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskTables" xlink:title="00000024 - Disclosure - CONCENTRATION OF CREDIT RISK (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LiquidityDetailsNarrative" xlink:title="00000026 - Disclosure - LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WorkingCapitalDeficit" xlink:label="loc_NXLWorkingCapitalDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_NXLWorkingCapitalDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DeviceSalesMember" xlink:label="loc_NXLDeviceSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NXLDeviceSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LicensingFeeMember" xlink:label="loc_NXLLicensingFeeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NXLLicensingFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OtherMember" xlink:label="loc_NXLOtherMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NXLOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" xlink:title="00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaapScheduleOfInvestmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfInvestmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapScheduleOfInvestmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapShortTermInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AmortizedCost" xlink:label="loc_NXLAmortizedCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_NXLAmortizedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_UnrealizedGain" xlink:label="loc_NXLUnrealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_NXLUnrealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/AccruedExpensesDetails" xlink:title="00000032 - Disclosure - ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccruedResearchAndDevelopmentExpense" xlink:label="loc_NXLAccruedResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_NXLAccruedResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="loc_us-gaapAccruedUtilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedUtilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_PotentialJointVentureMember" xlink:label="loc_NXLPotentialJointVentureMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_NXLPotentialJointVentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_USAsianConsultingGroupLLCMember" xlink:label="loc_NXLUSAsianConsultingGroupLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_NXLUSAsianConsultingGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ConsultingAgreementMember" xlink:label="loc_NXLConsultingAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NXLConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_MrOsserMember" xlink:label="loc_NXLMrOsserMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NXLMrOsserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoansPayableOfficerMember" xlink:label="loc_NXLLoansPayableOfficerMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NXLLoansPayableOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RelatedPartyContribution" xlink:label="loc_NXLRelatedPartyContribution" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLRelatedPartyContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RemainingSharesIssuedDescription" xlink:label="loc_NXLRemainingSharesIssuedDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLRemainingSharesIssuedDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_RevenuesFromRelatedParties" xlink:label="loc_NXLRevenuesFromRelatedParties" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLRevenuesFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ConsultingExpenses" xlink:label="loc_NXLConsultingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLConsultingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherBorrowings" xlink:label="loc_us-gaapOtherBorrowings" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OwedBalancePaymentDescription" xlink:label="loc_NXLOwedBalancePaymentDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLOwedBalancePaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LoansFromRelatedParty" xlink:label="loc_NXLLoansFromRelatedParty" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLLoansFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_InterestPayableCurrents" xlink:label="loc_NXLInterestPayableCurrents" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLInterestPayableCurrents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingAmount" xlink:label="loc_NXLOutstandingAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLOutstandingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingInterest" xlink:label="loc_NXLOutstandingInterest" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NXLOutstandingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LoansPayableDetailsNarrative" xlink:title="00000034 - Disclosure - LOANS PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LegacyVenturesInternationalIncMember" xlink:label="loc_NXLLegacyVenturesInternationalIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NXLLegacyVenturesInternationalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OutstandingAmount" xlink:label="loc_NXLOutstandingAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NXLOutstandingAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetails" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled" xlink:label="loc_NXLWeightedAverageExercisePriceWarrantsExpiredOrCancelled" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_NXLWeightedAverageExercisePriceWarrantsExpiredOrCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetails1" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_Range1Member" xlink:label="loc_NXLRange1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_NXLRange1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_Range2Member" xlink:label="loc_NXLRange2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_NXLRange2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ExercisableNumberOfWarrants" xlink:label="loc_NXLExercisableNumberOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_NXLExercisableNumberOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AnInvestorMember" xlink:label="loc_NXLAnInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_NXLAnInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_VariousConsultantsMember" xlink:label="loc_NXLVariousConsultantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_NXLVariousConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_AccruedAmount" xlink:label="loc_NXLAccruedAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_NXLAccruedAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails" xlink:title="00000039 - Disclosure - LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_TotalLeaseAssets" xlink:label="loc_NXLTotalLeaseAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_NXLTotalLeaseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails1" xlink:title="00000040 - Disclosure - LEASES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails2" xlink:title="00000041 - Disclosure - LEASES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetails3" xlink:title="00000042 - Disclosure - LEASES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/LeasesDetailsNarrative" xlink:title="00000043 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_DisclosureLeasesAbstract" xlink:label="loc_NXLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_LeaseLiability" xlink:label="loc_NXLLeaseLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_NXLLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_WeightedAverageIncrementalBorrowingRate" xlink:label="loc_NXLWeightedAverageIncrementalBorrowingRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NXLDisclosureLeasesAbstract" xlink:to="loc_NXLWeightedAverageIncrementalBorrowingRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" xlink:title="00000044 - Disclosure - CONCENTRATION OF CREDIT RISK (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerAMember" xlink:label="loc_NXLCustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerBMember" xlink:label="loc_NXLCustomerBMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerCMember" xlink:label="loc_NXLCustomerCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerDMember" xlink:label="loc_NXLCustomerDMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerEMember" xlink:label="loc_NXLCustomerEMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_CustomerFMember" xlink:label="loc_NXLCustomerFMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLCustomerFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" xlink:title="00000045 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_SixCustomerMember" xlink:label="loc_NXLSixCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLSixCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_OneCustomerMember" xlink:label="loc_NXLOneCustomerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLOneCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_ThreeCustomerMember" xlink:label="loc_NXLThreeCustomerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLThreeCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nxl-20230331.xsd#NXL_FourCustomerMember" xlink:label="loc_NXLFourCustomerMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NXLFourCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>nxl-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOaGBmbPtxZ976ekhsmR7bZnqLyYl4CJtnSGJO5KWESAG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:NXL="http://nexalin.com/20230331" elementFormDefault="qualified" targetNamespace="http://nexalin.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nexalin.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss">
	  <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical">
	  <link:definition>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusiness" id="NatureOfOrganizationAndBusiness">
	  <link:definition>00000008 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000009 - Disclosure - LIQUIDITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards">
	  <link:definition>00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000011 - Disclosure - ACCRUED EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions" id="Non-consolidatedJointVentureAndRelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LoansPayable" id="LoansPayable">
	  <link:definition>00000013 - Disclosure - LOANS PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
	  <link:definition>00000014 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/Leases" id="Leases">
	  <link:definition>00000016 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/ConcentrationOfCreditRisk" id="ConcentrationOfCreditRisk">
	  <link:definition>00000017 - Disclosure - CONCENTRATION OF CREDIT RISK</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies">
	  <link:definition>00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables">
	  <link:definition>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000021 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
	  <link:definition>00000022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000023 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskTables" id="ConcentrationOfCreditRiskTables">
	  <link:definition>00000024 - Disclosure - CONCENTRATION OF CREDIT RISK (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative" id="NatureOfOrganizationAndBusinessDetailsNarrative">
	  <link:definition>00000025 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000026 - Disclosure - LIQUIDITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails">
	  <link:definition>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1">
	  <link:definition>00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2">
	  <link:definition>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3">
	  <link:definition>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative">
	  <link:definition>00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
	  <link:definition>00000032 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative" id="Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000033 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LoansPayableDetailsNarrative" id="LoansPayableDetailsNarrative">
	  <link:definition>00000034 - Disclosure - LOANS PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails" id="StockholdersEquityDeficitDetails">
	  <link:definition>00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetails1" id="StockholdersEquityDeficitDetails1">
	  <link:definition>00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
	  <link:definition>00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Deficit) (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LeasesDetails" id="LeasesDetails">
	  <link:definition>00000039 - Disclosure - LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LeasesDetails1" id="LeasesDetails1">
	  <link:definition>00000040 - Disclosure - LEASES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LeasesDetails2" id="LeasesDetails2">
	  <link:definition>00000041 - Disclosure - LEASES (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LeasesDetails3" id="LeasesDetails3">
	  <link:definition>00000042 - Disclosure - LEASES (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000043 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetails" id="ConcentrationOfCreditRiskDetails">
	  <link:definition>00000044 - Disclosure - CONCENTRATION OF CREDIT RISK (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative" id="ConcentrationOfCreditRiskDetailsNarrative">
	  <link:definition>00000045 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="nxl-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nxl-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nxl-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nxl-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="NXL_CommonStockParValue0.001PerShareMember" name="CommonStockParValue0.001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_WarrantsExercisableForOneShareOfCommonStockMember" name="WarrantsExercisableForOneShareOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_DeviceSalesMember" name="DeviceSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_LicensingFeeMember" name="LicensingFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_OtherMember" name="OtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_PotentialJointVentureMember" name="PotentialJointVentureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_USAsianConsultingGroupLLCMember" name="USAsianConsultingGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_MrOsserMember" name="MrOsserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_LoansPayableOfficerMember" name="LoansPayableOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_LegacyVenturesInternationalIncMember" name="LegacyVenturesInternationalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_AnInvestorMember" name="AnInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_VariousConsultantsMember" name="VariousConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_Range1Member" name="Range1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_Range2Member" name="Range2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_SixCustomerMember" name="SixCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_OneCustomerMember" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_ThreeCustomerMember" name="ThreeCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_FourCustomerMember" name="FourCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_CustomerEMember" name="CustomerEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_CustomerFMember" name="CustomerFMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_PatentNetOfAmortization" name="PatentNetOfAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_LoanPayableOfficer" name="LoanPayableOfficer" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_AccountsPayableRelatedParty" name="AccountsPayableRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_GainOnSaleOfShorttermInvestments" name="GainOnSaleOfShorttermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_UnrealizedGainFromShorttermInvestments" name="UnrealizedGainFromShorttermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" name="NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_WeightedAverageSharesOutstanding" name="WeightedAverageSharesOutstanding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_RevenuesFromRelatedParties" name="RevenuesFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_PurchaseOfPatents" name="PurchaseOfPatents" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_PaymentsOnLoanPayableShareholder" name="PaymentsOnLoanPayableShareholder" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_PaymentsOnNotesPayableOfficer" name="PaymentsOnNotesPayableOfficer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_UnrealizedGainOnShorttermInvestments" name="UnrealizedGainOnShorttermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_RouAssetAndLeaseLiabilityRecorded" name="RouAssetAndLeaseLiabilityRecorded" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_ShortTermInvestmentsPolicyTextBlock" name="ShortTermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_PatentsPolicyTextBlock" name="PatentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_WarrantAccountingPolicyTextBlock" name="WarrantAccountingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock" name="SummaryInformationAboutWarrantsToPurchaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" name="ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_AmortizedCost" name="AmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_UnrealizedGain" name="UnrealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_AccruedResearchAndDevelopmentExpense" name="AccruedResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_RelatedPartyContribution" name="RelatedPartyContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_RemainingSharesIssuedDescription" name="RemainingSharesIssuedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_ConsultingExpenses" name="ConsultingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_OwedBalancePaymentDescription" name="OwedBalancePaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_LoansFromRelatedParty" name="LoansFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_InterestPayableCurrents" name="InterestPayableCurrents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_OutstandingAmount" name="OutstandingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_OutstandingInterest" name="OutstandingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled" name="WeightedAverageExercisePriceWarrantsExpiredOrCancelled" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_ExercisableNumberOfWarrants" name="ExercisableNumberOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_AccruedAmount" name="AccruedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_TotalLeaseAssets" name="TotalLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_LeaseLiability" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NXL_WeightedAverageIncrementalBorrowingRate" name="WeightedAverageIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260354976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEXALIN TECHNOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001527352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-5566468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1776 Yorktown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">260-0222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,286,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NXL_CommonStockParValue0.001PerShareMember', window );">Common stock, par value $0.001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NXL_WarrantsExercisableForOneShareOfCommonStockMember', window );">Warrants, exercisable for one share of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants,
    exercisable for one share of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NXLIW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NXL_CommonStockParValue0.001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NXL_CommonStockParValue0.001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NXL_WarrantsExercisableForOneShareOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NXL_WarrantsExercisableForOneShareOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259834144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 174,961<span></span>
</td>
<td class="nump">$ 162,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">5,297,658<span></span>
</td>
<td class="nump">6,831,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,550<span></span>
</td>
<td class="nump">4,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">158,270<span></span>
</td>
<td class="nump">154,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">241,330<span></span>
</td>
<td class="nump">272,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,875,769<span></span>
</td>
<td class="nump">7,425,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU Asset</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">6,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net of accumulated depreciation of $2,315 and $2,181, respectively</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_PatentNetOfAmortization', window );">Patent, net of amortization</a></td>
<td class="nump">49,536<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">5,930,473<span></span>
</td>
<td class="nump">7,432,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable (Includes related party of $10,000 and $260,000, respectively)</a></td>
<td class="nump">54,758<span></span>
</td>
<td class="nump">658,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">597,660<span></span>
</td>
<td class="nump">539,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">43,026<span></span>
</td>
<td class="nump">50,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_LoanPayableOfficer', window );">Loan payable - officer</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,195,444<span></span>
</td>
<td class="nump">1,948,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,463<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,195,444<span></span>
</td>
<td class="nump">1,953,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 7,286,562 shares issued and outstanding at March 31, 2023 and December 31, 2022,&#160;&#160;respectively</a></td>
<td class="nump">7,287<span></span>
</td>
<td class="nump">7,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">41,069<span></span>
</td>
<td class="nump">36,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">77,824,427<span></span>
</td>
<td class="nump">77,824,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,137,754)<span></span>
</td>
<td class="num">(72,389,340)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">4,735,029<span></span>
</td>
<td class="nump">5,478,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">$ 5,930,473<span></span>
</td>
<td class="nump">$ 7,432,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_LoanPayableOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_LoanPayableOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_PatentNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_PatentNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260346144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,315<span></span>
</td>
<td class="nump">$ 2,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_AccountsPayableRelatedParty', window );">Accounts payable related party</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,286,562<span></span>
</td>
<td class="nump">7,286,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,286,562<span></span>
</td>
<td class="nump">7,286,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_AccountsPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_AccountsPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260446656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, net (Includes related party of $0 and $300,499 for the three months ended March 31, 2023 and March 31, 2022, respectively)</a></td>
<td class="nump">$ 30,560<span></span>
</td>
<td class="nump">$ 323,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">46,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">23,450<span></span>
</td>
<td class="nump">277,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">158,600<span></span>
</td>
<td class="nump">295,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">299,323<span></span>
</td>
<td class="nump">138,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">344,953<span></span>
</td>
<td class="nump">218,374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">802,876<span></span>
</td>
<td class="nump">652,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(779,426)<span></span>
</td>
<td class="num">(375,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest income (expense), net</a></td>
<td class="num">(8,837)<span></span>
</td>
<td class="num">(18,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_GainOnSaleOfShorttermInvestments', window );">Gain on sale of short-term investments</a></td>
<td class="nump">38,772<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">31,012<span></span>
</td>
<td class="num">(18,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(748,414)<span></span>
</td>
<td class="num">(393,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_UnrealizedGainFromShorttermInvestments', window );">Unrealized gain from short-term investments</a></td>
<td class="nump">41,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (707,345)<span></span>
</td>
<td class="num">$ (393,249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted', window );">Net loss per share attributable to common stockholders - Basic and Diluted</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_WeightedAverageSharesOutstanding', window );">Weighted Average Shares Outstanding - Basic and Diluted</a></td>
<td class="nump">7,286,562<span></span>
</td>
<td class="nump">4,888,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_GainOnSaleOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_GainOnSaleOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_UnrealizedGainFromShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_UnrealizedGainFromShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_WeightedAverageSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_WeightedAverageSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264839856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_RevenuesFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_RevenuesFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_RevenuesFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260574816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 40,880<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 69,004,703<span></span>
</td>
<td class="num">$ (70,691,524)<span></span>
</td>
<td class="num">$ (1,681,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">4,879,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued for cash</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,099<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for cash, shares</a></td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock compensation</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97,476<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock compensation, shares</a></td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(393,249)<span></span>
</td>
<td class="num">(393,249)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 40,905<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,107,278<span></span>
</td>
<td class="num">(71,084,773)<span></span>
</td>
<td class="num">(1,972,590)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">4,905,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 7,287<span></span>
</td>
<td class="nump">36,313<span></span>
</td>
<td class="nump">77,824,427<span></span>
</td>
<td class="num">(72,389,340)<span></span>
</td>
<td class="nump">5,478,687<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">7,286,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,756<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(748,414)<span></span>
</td>
<td class="num">(748,414)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 7,287<span></span>
</td>
<td class="nump">$ 41,069<span></span>
</td>
<td class="nump">$ 77,824,427<span></span>
</td>
<td class="num">$ (73,137,754)<span></span>
</td>
<td class="nump">$ 4,735,029<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">7,286,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259073168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (748,414)<span></span>
</td>
<td class="num">$ (393,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">97,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Amortization</a></td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_GainOnSaleOfShorttermInvestments', window );">Gain on sale of short-term investments</a></td>
<td class="num">(38,772)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="num">(53,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid assets</a></td>
<td class="nump">30,952<span></span>
</td>
<td class="num">(1,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,900)<span></span>
</td>
<td class="num">(47,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable - related party</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(353,609)<span></span>
</td>
<td class="nump">179,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">57,838<span></span>
</td>
<td class="num">(26,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(12,234)<span></span>
</td>
<td class="num">(11,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,314,649)<span></span>
</td>
<td class="num">(203,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Sale of short-term investments</a></td>
<td class="nump">11,599,356<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment', window );">Purchase of short-term investments</a></td>
<td class="num">(10,022,293)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_PurchaseOfPatents', window );">Purchase of patents</a></td>
<td class="num">(50,196)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">1,526,867<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock for cash, net of financing fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_PaymentsOnLoanPayableShareholder', window );">Payments on loan payable - shareholder</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_PaymentsOnNotesPayableOfficer', window );">Payments on notes payable - officer</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">12,218<span></span>
</td>
<td class="num">(203,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">162,743<span></span>
</td>
<td class="nump">661,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">174,961<span></span>
</td>
<td class="nump">458,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_UnrealizedGainOnShorttermInvestments', window );">Unrealized gain on short-term investments</a></td>
<td class="nump">41,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_RouAssetAndLeaseLiabilityRecorded', window );">ROU asset and lease liability recorded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_GainOnSaleOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_GainOnSaleOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_PaymentsOnLoanPayableShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_PaymentsOnLoanPayableShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_PaymentsOnNotesPayableOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_PaymentsOnNotesPayableOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_PurchaseOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_PurchaseOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_RouAssetAndLeaseLiabilityRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_RouAssetAndLeaseLiabilityRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_UnrealizedGainOnShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_UnrealizedGainOnShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264521808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF THE ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF THE ORGANIZATION AND BUSINESS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--NatureOfOperations_zDAdXvSwT9ul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; <span id="xdx_82D_zyeb6O7vrhU9">NATURE OF THE ORGANIZATION AND BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nexalin
Technology, Inc. (&#8220;NV Nexalin&#8221;) was formed on October&#160;19, 2010 as a Nevada corporation. The Company&#8217;s principal
offices are located at 1776 Yorktown, Suite 550, Houston, Texas 77056.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;6, 2019, Neuro-Health International, Inc. (&#8220;Neuro-Health&#8221;), a Nevada corporation, a wholly owned subsidiary
of NV Nexalin, was formed. Neuro-Health had no activity from December&#160;6, 2019 (Inception) through March&#160;31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November&#160;22, 2021, NV Nexalin entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Nexalin Technology,
Inc., a Delaware corporation (&#8220;Nexalin&#8221;, or the &#8220;Company&#8221;). Pursuant to the Merger Agreement, NV Nexalin merged
with and into Nexalin with all shareholders of NV Nexalin receiving one common share of Nexalin in exchange for twenty shares of NV Nexalin
held at the time of the Merger Agreement. NV Nexalin treated the transaction as a corporate reorganization with the historical consolidated
financial statements of NV Nexalin becoming the historical consolidated financial statements of Nexalin. Nexalin had nominal assets and
liabilities and did not conduct any operations prior to the reorganization other than its incorporation. NV Nexalin has retroactively
applied the 20-for-1 exchange, effective on November&#160;22, 2021, to share and per share amounts on the unaudited condensed consolidated
financial statements for the three months ended March&#160;31, 2023 and 2022. NV Nexalin&#8217;s authorized shares of common stock were
not affected as a result of the Merger Agreement. As a result of the Merger Agreement, NV Nexalin was dissolved, and Neuro-Health became
a subsidiary of Nexalin. The Company completed its initial public offering on September&#160;16, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial public offering consisted of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zo5FUboLWCk7" title="Shares issued during the period">2,315,000</span> units consisting of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued during the period">2,315,000</span> shares of Common Stock and <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU1seVF8r347" title="Shares issued during the period">2,315,000</span> accompanying warrants
to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220920_pdd" title="Warrant to purchase">2,315,000</span> shares of common stock. Each share of common stock was sold together with one Warrant, each to purchase one
share of common stock with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220920_pdd" title="Exercise price">4.15</span> per share at a combined offering price of $4.15, for gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220901__20220920_pp0p0" title="Proceeds from issuance of equity">9,607,250</span>,
before deducting underwriting discounts and offering expenses. In addition, the underwriters purchased <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zOvzs5cvnJlb" title="Shares issued during the period">347,250</span> warrants for net proceeds
of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pp0p0" title="Proceeds from issuance of warrants">3,473</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares and warrants began trading on the Nasdaq Capital Market tier of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) on September&#160;16,
2022, under the symbols &#8220;NXL&#8221; and &#8220;NXLIW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this report, the terms &#8220;Nexalin,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and the &#8220;Company&#8221; refer
to Nexalin Technology, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic.
We developed an easy-to-administer medical device &#8212; referred to as Generation 1 or Gen-1 &#8212; that utilizes bioelectronic medical
technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy
stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) as a Class II device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we continue providing services to medical professionals to support patients&#8217; use of the Gen-1 devices which were in operation
prior to December&#160;2019, we are not making new sales or new marketing efforts of Gen-1 devices. We continue to derive revenue
from devices which we sold or leased prior to the FDA&#8217;s December&#160;2019 reclassification announcements. This revenue
consists of monthly licensing fees and payments for the sale of electrodes. We have suspended marketing efforts for new sales of
devices related to the Gen-1 device for treatment of anxiety and insomnia in the United States until the Nexalin regulatory team
makes a decision on amending our existing 510(k) application at 4 milliamps. A new pre-sub document in preparation of a new 510(k)
for our Gen-3 Halo headset at 15 milliamps was filed with the FDA in January of 2023. Formal comments to our pre-sub document filing
were received in March of 2023. A formal meeting to address FDA comments is scheduled for May of 2023.&#160;&#160;</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have designed and developed a new advanced wave form technology to be emitted at 15 milliamps through new and improved medical devices
referred to as Generation 2 or Gen-2 and Generation 3 or Gen-3. Gen-2 is a clinical use device with a modern enclosure to emit the new
15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual
clinic setting similar to existing Tele-health platforms. Preliminary data provided by the University of California San Diego supports
the safety of utilizing our 15 milliamp waveform technology, however the determination of safety and efficacy of medical devices in the
United States is subject to clearance by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are currently designing clinical trial strategies for the use of Gen-3 for the treatment of substance use disorders including opiate,
cocaine, and alcohol abuse. Recently the Gen-2 device was tested in pilot trials in China for the treatment of Alzheimer&#8217;s disease,
and dementia. Continued pilot testing for Alzheimer&#8217;s and dementia, cognition and memory, and neurotransmitter changes is planned
in China in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Emerging
Growth Company</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and approval of any golden parachute payments not previously approved. Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither
an emerging growth company, nor an emerging growth company which has opted out of using the extended transition period, difficult or
impossible because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
continues to evaluate the impact of the economy and the capital markets and has concluded that, while it is reasonably possible that
events could have negative effects on the Company&#8217;s financial position and results of its operations, the specific impacts are
not readily determinable as of the date of these consolidated financial statements. The unaudited condensed consolidated financial statements
do not include any adjustments that might result from the outcome of uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may
also have a direct impact on the Company&#8217;s operating results and financial position in the future. The ultimate duration and magnitude
of the impact and the efficacy of government interventions on the economy has and may continue to indirectly impact the Company because
of its current dependence upon its distributor relationship with Wider Come Limited. Wider Come Limited acts as a distributor for the
Company&#8217;s devices in China and Asia. Because of significant restrictions imposed by the Chinese government during the COVID-19
pandemic through calendar year 2022 and into 2023, Wider&#8217;s ability to market and sell the Company&#8217;s devices has been negatively
impacted, resulting in decreased revenue to the Company. Patients and salespeople have been restricted in their movements resulting in
a significant slowdown in the medical and other sectors. Significant efforts and funds expended by our Chinese distributor has led to
regulatory approval in China in both depression and insomnia thus far which has allowed for sales of our devices in China in 2022, and
into 2023. The extent of future impact is dependent on future developments, including future activities by the Chinese government and
other possible events which are highly uncertain and not in the Company&#8217;s control, including new information which may emerge concerning
the spread and severity of COVID-19, or any of its variants, and actions taken to address its impact, among others. The repercussions
of this health crisis could have a material adverse effect on the Company&#8217;s business, financial condition, liquidity and operating
results.</span></p>









<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264480464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z31oT8cXpmc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; <span id="xdx_824_z9mHyOKMXo7a">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern,
which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At March&#160;31, 2023,
we had a significant accumulated deficit of approximately $73.1<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230331_zr0dGuvM81Sg" style="display: none" title="Accumulated deficit">73,137,754</span> million. For the three months ended March&#160;31, 2023, we had a loss
from operations of approximately $779<span id="xdx_90E_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_c20230101__20230331_zHXNgDOU5SS1" style="display: none" title="Loss from operation">779,426</span> thousand and negative cash flows used in operations of approximately $1.3<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20230101__20230331_zwAry1sZw8We" style="display: none" title="Cash flows from operations">1,314,649</span> million. While we had
a working capital surplus as of March&#160;31, 2023 of approximately $<span id="xdx_90D_ecustom--WorkingCapitalDeficit_iI_pn3n3_dm_c20230331_z4EDNLOKO0Ci" title="Working capital deficit">4.7</span> million, our operating activities consume most of our cash
resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur operating losses as we execute our development plans, as well as undertaking other potential strategic and
business development initiatives through 2023 and through the twelve months from the date of this report. In addition, we have had and
expect to have negative cash flows from operations, at least into the near future. We have previously funded these losses primarily through
the sale of equity and issuance of convertible notes. The accompanying unaudited consolidated financial statements do not include any
adjustments that might be necessary should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue as a going concern will be dependent upon our ability to execute on our business plan, including the ability to generate
revenue from the proposed joint venture and obtain U.S. approval for the sale of our devices in the United States, and, if necessary,
our ability to raise additional capital. Although no assurances can be given as to our ability to deliver on our revenue plans or that
unforeseen expenses may arise, management has evaluated the significance of the conditions as of March&#160;31, 2023 and has concluded
that due to the receipt of the net proceeds from the completion of the Initial Public Offering, we have sufficient cash and short-term
investments on hand to satisfy its anticipated cash requirements for the next twelve months from the issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264424304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zVTZsUtZX1hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8212; <span id="xdx_82F_zJdfPqCglvkb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ziwgyhRgJr29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zCEbVvtgn9z9">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial information has been prepared in accordance with Generally Accepted Accounting
Principles (&#8220;GAAP&#8221;) for interim financial information. In the opinion of management, such financial information includes
all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company&#8217;s
financial position and the operating results and cash flows. Operating results for the three months ended March&#160;31, 2023 and 2022
are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant
to the rules of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). These unaudited condensed consolidated financial
statements and related notes should be read in conjunction with the Company&#8217;s audited consolidated financial statements for the
year ended December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_ztxBpm3wVJH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zoJyURshDri3">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Nexalin and its wholly owned subsidiary Neuro-Health. Intercompany accounts
and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zVMkEAgoER8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zu2QFZ1AvS8b">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at
the date of the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zP3wCBc1Jfw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zmmdLmF1qRMb">Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company
determines if the contract is within the scope of ASC Topic 606 and then evaluates the contract using the following five steps: (1) identify
the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.
These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements
are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its
acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer
of the Company&#8217;s electrodes will pay a royalty to the Company for a three-year period beginning January&#160;1, 2022. The amount
of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Streams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives revenues from its license agreements by charging a monthly licensing fee for the duration of the agreement. The Company
derives revenues from equipment by selling additional individual electrodes to customers for use with the Nexalin Device. The Company
receives revenue from the sale in China of its Devices to its acting distributor and from the sale of products relating to the use of
those Devices. The Company derives revenue as a royalty fee from the China-based manufacturer for electrodes ordered in connection with
the Company&#8217;s China sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied as long as the
licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time
in which the invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that the Company&#8217;s equipment and Device revenue has one performance obligation. That performance obligation is satisfied
when the equipment and Devices are shipped. The Company recognizes revenue at a point in time in which the electrodes and Devices are
shipped to the customer. The Company does not offer a warranty on the electrodes and Devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of
individual treatments on patients by customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that royalty revenue has one performance obligation. The performance obligation is satisfied at the time the Electrode manufacturer
invoices the acting distributor for the sale to the acting distributor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify; border-collapse: collapse">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
Financing Component &#8212; the Company does not adjust the promised amount of consideration for the effects of a significant financing
component since the Company expects, at contract inception, that the period between when the Company transfers a promised goods or services
to the customer and when the customer pays for that service will be one year or less.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
    Performance Obligations &#8212; all performance obligations related to contracts with a duration of less than one year, the Company
    has elected to apply the optional exemption provided in ASC Topic 606 and therefore, is not required to disclose the aggregate amount
    of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting
    period.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
    and Handling Activities &#8212; the Company elected to account for shipping and handling activities as a fulfilment cost rather than
    as a separate performance obligation.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to Invoice &#8212; the Company has a right to consideration from a customer in an amount that corresponds directly with the value
    to the customer of the Company&#8217;s performance completed to date the Company may recognize revenue in the amount to which the
    entity has a right to invoice.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregated
Revenues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Revenue Streams</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
consists of the following by service offering:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zKXKMNzW1PKb" style="display: none">Schedule of disaggregation of revenue</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Device Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total">264,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Licensing Fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total">23,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total">20,143</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total">6,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">290</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">30,679</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">30,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">323,322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Geographic Locations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">U.S. Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total">30,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total">22,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">China Sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">300,499</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">30,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">323,322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zhxXaSYjMQDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contract
Modifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no contract modifications during the three months ended March&#160;31, 2023 and 2022. Contract modifications are not routine in
the performance of the Company&#8217;s contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives payment for equipment and devices in advance of shipping. The Company recognizes the revenue as being earned upon shipment.
<span id="xdx_906_eus-gaap--DeferredRevenue_iI_pdp0_do_c20230331_za0NdTo1G8y1" title="Deferred revenue"><span id="xdx_902_eus-gaap--DeferredRevenue_iI_pp0p0_do_c20221231_zuh5FH9Q2wq2" title="Deferred revenue">No</span></span> deferred revenue was recognized as of March&#160;31, 2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmOBQHnAe6B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zUHANBYlCnsg">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through,
as well as maintaining cash balances, with major financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--ShortTermInvestmentsPolicyTextBlock_zWieSHVRS2m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zVP5jxNasouc">Short-Term
Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance
sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value
is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or
liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in accumulated other comprehensive
income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income
(expense), net. For declines in the fair values of equity securities that are considered other-than-temporary, impairment losses are
charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments,
including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments on March&#160;31,
2023 and December&#160;31, 2022, respectively.</span></p>









<p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zT4W6RK5rK4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zN12aHCf3Uf5">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivables are reported at their outstanding unpaid principal balances, net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#8217;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. Payments are generally due within 30 days of invoice. The Company writes off accounts receivable against
the allowance for doubtful accounts when a balance is determined to be uncollectible. During the three months ended March&#160;31, 2023
and 2022, the Company did <span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pp0p0_do_c20230101__20230331_z1pga6fdJSQe" title="Writeoff accounts receivable"><span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pdp0_do_c20220101__20220331_zqKYSXNGmcK7" title="Writeoff accounts receivable">no</span></span>t write off accounts receivable. The Company did <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20230331_zljQzIUit65g" title="Allowance for doubtful accounts"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20221231_zSaymtCYV9og" title="Allowance for doubtful accounts">no</span></span>t record an allowance for doubtful accounts on March&#160;31,
2023 and December&#160;31, 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zy8yXrzUygx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zAajoedepadc">Inventory</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods and components stated at the lower of cost or net realizable value with cost determined on a first-in first-out
basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete, slow-moving, quantities
in excess of demand, or otherwise non-saleable items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zasktAHwlD87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zdEHP5BzTYGa">Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
is recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally
five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance
and repairs are charged to expense as incurred. The Company capitalizes costs attributable to the betterment of property and equipment
when such betterment enhances the functionality of the asset or extends the useful life of the asset. Should an asset be disposed of
before the end of its useful life, the cost and accumulated depreciation at that date is removed from the consolidated balance sheets,
with the resulting gain or loss, if any, reflected in operations in that period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--PatentsPolicyTextBlock_zOzG5NGCjWui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zkG0LVSPscje">Patents</span></i>&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was
$<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20230101__20230331_znJU6uuKZbtf" title="Amortization expense">660</span> and $<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20220101__20220331_z9xTxJ8RBtp4" title="Amortization expense">0</span> for the three months ended March&#160;31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zN3dnVivAMF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zXYsMlXZIYKa">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets
and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax
bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are
expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. At March&#160;31, 2023 and December&#160;31, 2022, the Company had a full valuation allowance applied
against its net tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcXCxj3XCBul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span><span id="xdx_86D_zguvg96Hkg0d">Fair
Value Measurements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, <i>Fair Value Measurements and Disclosures</i>, fair value is the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about
risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or
generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>









<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1: Quoted prices are available in active markets for identical assets or liabilities as of
                                            the reporting date. Active markets are those in which transactions for the asset or liability
                                            occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2: Pricing inputs are other than quoted prices in active markets included in Level 1, which
                                            are either directly or indirectly observable as of the reported date. Level 2 includes those
                                            financial instruments that are valued using models or other valuation methodologies. These
                                            models are primarily industry-standard models that consider various assumptions, including
                                            quoted forward prices for commodities, time value, volatility factors and current market
                                            and contractual prices for the underlying instruments, as well as other relevant economic
                                            measures. Substantially all of these assumptions are observable in the marketplace throughout
                                            the full term of the instrument, can be derived from observable data or are supported by
                                            observable levels at which transactions are executed in the marketplace.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3: Pricing inputs include significant inputs that are generally less observable from objective
                                            sources. These inputs may be used with internally developed methodologies that result in
                                            management&#8217;s best estimate of fair value. The significant unobservable inputs used
                                            in the fair value measurement for nonrecurring fair value measurements of long-lived assets
                                            include pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRVlNQryVQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zV52sLvBiGKd">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, short-term investments, accounts receivable, inventory, prepaids, accounts payable and accrued expenses, and
other current liabilities approximate their fair values based on the short-term maturity of these instruments. The carrying amount of
the loans payable approximates the estimated fair value for this financial instrument as management believes that such debt and interest
payable on the note approximates the Company&#8217;s incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the amortized cost, unrealized gains and the fair value at March&#160;31, 2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zs3t7FXsNSp9" style="display: none">Schedule of amortized cost, unrealized gains</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gain</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" style="width: 9%; text-align: right" title="Amortized Cost">5,256,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Unrealized Gain">41,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Fair Value">5,297,658</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" style="text-align: right" title="Amortized Cost">5,256,589</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" style="text-align: right" title="Unrealized Gain">41,069</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" style="text-align: right" title="Fair Value">5,297,658</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" style="text-align: right" title="Amortized Cost">6,794,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" style="text-align: right" title="Unrealized Gain">36,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" style="text-align: right" title="Fair Value">6,831,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" style="text-align: right" title="Amortized Cost">6,794,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" style="text-align: right" title="Unrealized Gain">36,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" style="text-align: right" title="Fair Value">6,831,192</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zgTFJ0y0id8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the carrying value and fair value of the Company&#8217;s financial assets measured at fair value as of March&#160;31,
2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B3_zCQv7SG86EE6" style="display: none">Schedule of fair value, assets measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets">5,297,658</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets">5,297,658</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets">6,831,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets">6,831,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zHJhhT0qg8Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>







<p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zWmitsjX5Ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zL6qrgolIYrg">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
The dilutive effect, if any, of warrants is calculated using the treasury stock method. These shares were included in the basic and diluted
net loss per common share on the unaudited condensed consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including
these potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than
the most recent fair value of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B1_zLU5zHzGbeWe" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/>
March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left">Warrants</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total">2,662,250</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total">21,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zcswmzwYtBwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlC9wDc6glwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zFnBIzw03kOf">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 718, <i>Compensation &#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;), which requires the
measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in
the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASU 2018-07 Compensation &#8212; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the
Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation
methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_ecustom--WarrantAccountingPolicyTextBlock_z3UGM7qS0ERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zwUktMJPX3o7">Warrant
Accounting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued private and public warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815-40,
Derivatives and Hedging: Contracts in Entity&#8217;s Own Equity (&#8220;ASC 815-40&#8221;). The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is assessed as part of this evaluation. During the
reporting periods the Public Warrants were outstanding, they were precluded from liability classification, being equity-classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zxeAWPBgERL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zm3EYQPjFwl2">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
research and development costs are charged to operations as incurred. For the three months ended March&#160;31, 2023 and 2022, the Company
recorded $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development costs">65,833</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development costs">11,565</span>, respectively, in selling, general and administrative expenses on the unaudited condensed consolidated statements
of operations.</span></p>









<p id="xdx_84E_eus-gaap--LessorLeasesPolicyTextBlock_ziXIOmBL8Lmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zM5Iphrt0J28">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease is defined as an agreement that conveys the right to control the use of identified property, plant or equipment (right of use asset
or &#8220;ROU asset&#8221;) for a period of time in exchange for consideration. The Company accounts for its leases in accordance with
ASC 842, Leases, which requires that an ROU asset identified in a lease to be recorded as a noncurrent asset with a related liability.
The Company does not record ROU assets for those agreements of a twelve-month duration or less. The Company recognized a ROU asset and
corresponding lease liability on its balance sheets related to its office lease agreement. See Note 9, Leases, for further discussion,
including the impact on the Company&#8217;s unaudited condensed consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets include any initial direct costs and prepaid lease payments and exclude any lease incentives. Lease expense for minimum lease
payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate the lease
if it is reasonably certain that the Company will exercise that option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zk24gkl5K1N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zPZI23trzxol">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February&#160;2020, the FASB issued ASU 2020-02,
Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting
Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments are in effect
for the Company for interim and annual periods in fiscal years beginning after December&#160;15, 2022. The adoption on January 1, 2023
modified the way the Company analyzes financial instruments, but it did not have a&#160;material impact on our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264413712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zgs8QBaY3Q63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8212; <span id="xdx_823_zO5DBgQn13o8">ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consist of the following amounts:</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zWGpl1Uc50x2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B2_zB0TmldCVjSd" style="display: none">Schedule of accrued expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230331_zwdMPITlfCCi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20221231_zQdRn0BzFWSc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAUCzJ3A_zw7745EclQu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued interest</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">134,501</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111,501</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_zrDMDyBIp372" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued &#8211; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,321</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SettlementLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_z9P6h78x3sld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued settlement liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">336,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">336,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpense_iI_pp0p0_maAUCzJ3A_znBHmHpZLGF6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accrued research and development expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0p0_mtAUCzJ3A_zML3qxSxolBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">597,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">539,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264389488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPzBYTBKyOu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8212; <span id="xdx_824_zDOIujGOFkS4">NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Joint Venture</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;21, 2018, the Company entered into the first of a series of agreements providing for the establishment of a joint venture
(&#8220;JV&#8221;) agreement (the &#8220;JV Agreement&#8221;) with Wider Come Limited, a China company (&#8220;Wider&#8221;) for the
purpose of marketing, sale and distribution of the Company&#8217;s proprietary devices for the treatment of (i) anxiety, depression and
insomnia (&#8220;ADI&#8221;) and (ii) Alzheimer&#8217;s and dementia (&#8220;AD&#8221;) in the applicable territories. Wider has an experienced
medical technology team in China and when formed, the JV will design and implement a comprehensive business model and distribution plan
for our devices in China, Hong Kong, Macau and Taiwan. The JV will be formed following the completion of certain funding, clinical study,
and publication milestones, which Wider has agreed to undertake but not yet completed, as well as resolution of potential regulatory
concerns in China. Following its formation, the JV will design and implement a comprehensive business model and distribution plan for
our devices in China, Hong Kong, Macau and Taiwan.</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
originally contemplated, each of the parties to the JV would hold a <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20180921__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PotentialJointVentureMember_z1Q4coRZBaC1" title="Ownership percentage">50</span>% interest in the equity, profits and losses, shareholder voting,
management control and rights to use production capacity of the facility. The Company will provide an Asian territory exclusive distribution
license for ADI treatment to the JV and Wider. As originally contemplated the JV, if completed, will be controlled by an equally represented
Board of Directors in which neither entity has sole decision-making ability over day-to-day or significant operational decisions. The
parties may determine to alter the equity interest or board composition of the Joint Venture or other economic terms as they move closer
to its implementation. As of March&#160;31, 2023, the JV has not been established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&#160;22, 2019, the Company entered into a supplementary agreement to the JV Agreement (the &#8220;Supplementary Agreement&#8221;).
At the time of the May&#160;2019 Supplementary Agreement, the parties desired to expand the scope of the JV to include and address the
pain management opportunities for our devices and technology. Pursuant to the Supplementary Agreement, Wider was to fund the JV within
thirty days of execution of the JV Agreement with $600,000 in cash to be used for clinical trials and other activities related to pain
management utilization of our devices and technology in China. Within thirty days of the funding, the Company was to issue 5% of the
Company in common stock to Wider&#8217;s shareholders. As of the date of this report the JV has yet to be formally established and therefore
the $600,000 has not been funded. Further, the parties have determined not to proceed with the pain management scope of the JV and have
decided to terminate the May&#160;2019 Supplementary Agreement. The parties may elect to proceed with a similar arrangement in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&#160;6, 2020, the Company entered into a three-year service agreement with Wider, pursuant to which Wider agreed to perform clinical
trials associated with the possible formation of the future JV. In consideration, the Company and certain designated Wider shareholders
entered into stock issuance agreements for the issuance of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200401__20200406_pdd" title="Issuance of common stock">450,000</span> shares of the Company&#8217;s common stock, and simultaneously with
the execution of this service agreement, Wider contributed $<span id="xdx_901_ecustom--RelatedPartyContribution_c20180921_pp0p0" title="Related party contribution">200,000</span> to the Company. During the year ended December&#160;31, 2020, the
Company issued <span id="xdx_903_eus-gaap--SharesIssued_c20201231_pdd" title="Shares issued">150,000</span> shares to affiliates of Wider in satisfaction of the obligation. The fair value of the 150,000 shares issued (less
the contributed $200,000 in cash) resulted in a charge to stock-based compensation of $<span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200101__20201231_pp0p0" title="Stock-based compensation">550,000</span> and was recorded in selling, general and
administrative expenses on the statement of operations. <span id="xdx_900_ecustom--RemainingSharesIssuedDescription_c20200401__20200406" title="Remaining shares issued, description">The remaining 300,000 shares will be issued in accordance with the following
schedule upon Wider&#8217;s successful completion of the following milestones (i) 50% upon successful completion of the fourth of four
clinical trials pursuant to the terms and conditions of the Service Agreements and (ii) 50% upon all four trials being submitted for
publication in international medical journals satisfactory to the Company.</span> As of March&#160;31, 2023, these milestones have not been
met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March&#160;2022, we entered into a second supplement
to the JV Agreement with Wider, whereby the parties confirmed that the JV had not yet been established and is subject to further review
and analysis of regulatory issues in China and the United States, trade and political issues between the two countries and potential changes
in the use and market for the Company&#8217;s products and technology. Pursuant to the second supplement, the parties agreed to use their
commercial efforts to complete documentation by September&#160;30, 2022. Wider has continued its work with respect to undertaking and
establishing clinical trials. In light of general economic conditions in China and the United States and the continued impact of regulatory
issues in China and the United States and trade and political issues between the two counties, the parties determined to further extend
the time frame to complete establishment of the JV to September 30, 2023 and entered into a supplement 3 to the JV Agreement to memorialize
such extension. The parties intend to continue to work together to complete the establishment prior to such extended time, however, the
ramifications of the continued COVID pandemic, especially in China, and the Chinese government&#8217;s regulatory approach to the pandemic
have adversely affected Wider&#8217;s ability to distribute our current products. As a result, the JV may be further delayed or we and
Wider may determine to re-structure the business terms (which changes may include timing and the scope of the intended operations and
trial studies) of the proposed JV.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2023 and 2022, the Company recorded $<span id="xdx_90D_ecustom--RevenuesFromRelatedParties_pp0p0_c20230101__20230331_znUdncemGc02" title="Revenue from Related Parties">0</span> and $<span id="xdx_90C_ecustom--RevenuesFromRelatedParties_pp0p0_c20220101__20220331_zHdiFFtKRW0e" title="Revenue from Related Parties">300,499</span> in revenue, respectively, from Wider on the
unaudited condensed consolidated statements of operations.</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Asian Consulting Group, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&#160;9, 2018, the Company entered into a five-year consulting agreement with U.S. Asian Consulting Group, LLC (&#8220;U.S. Asian&#8221;).
The two members of U.S. Asian are shareholders in the Company and include Marilyn Elson who is the Chief Financial Officer of the Company.
Pursuant to the consulting agreement, U.S. Asian will provide consulting services to the Company with regard to, among other things,
corporate development and financing arrangements. The Company is to pay U.S. Asian $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pp0p0" title="Monthly payment">10,000</span> per month for services rendered and, on October&#160;24,
2018, the Company issued <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pdd" title="Issuance of common stock">249,750</span> shares of the Company&#8217;s common stock to U.S. Asian. The Company recorded consulting expenses related
to the consulting agreement of $<span id="xdx_908_ecustom--ConsultingExpenses_c20230101__20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_pp0p0" title="Consulting expenses">30,000</span> for each of the three months ended March&#160;31, 2023&#160;&#160; and 2022 on the Company&#8217;s
unaudited consolidated statements of operations. At December&#160;31, 2022, U.S. Asian was owed $<span id="xdx_90D_eus-gaap--OtherBorrowings_c20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pp0p0" title="Balance owed for accrued,unpaid services and expenses">260,000</span> for accrued and unpaid services.
<span id="xdx_90A_ecustom--OwedBalancePaymentDescription_c20230101__20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember" title="Owed balance payment, description">A payment of $250,000 was made to U.S. Asian on March&#160;17, 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;22, 2021, the Company entered into a one-year agreement with Leonard Osser to serve on the Company&#8217;s Board of Advisors.
The agreement may be, but has not yet been, extended for an additional one-year term upon agreement of both parties. As consideration
Mr. Osser was entitled to $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211201__20211222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserMember_pp0p0" title="Consideration paid">80,000</span> in shares of the Company&#8217;s common stock which was waived by Mr. Osser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;11, 2022, the Company entered into an employment agreement with Marilyn Elson to serve as Chief Financial Officer of the
Company for a three-year term with an option for the Company and Ms. Elson to extend the term for an additional two years. Ms. Elson
is the spouse of Leonard Osser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Payable &#8211; Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November&#160;1, 2021, the Company received $<span id="xdx_908_ecustom--LoansFromRelatedParty_c20211030__20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Loans from related party">200,000</span>
&#160;&#160;as a loan from the Company&#8217;s Chief Executive Officer. The loan had a principal of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Principal amount">200,000</span>,
an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20211030__20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zla7wWBIkbbh" title="Interest rate">9</span>%,
and a maturity date of the earlier of (i) <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20181001__20181025_zfBcOw1kekK6" title="Maturity date">October
31, 2022</span> or (ii) the date of the consummation of the initial public offering. The note was amended as of
January&#160;1, 2023 to extend the due date to March&#160;17, 2023 and to provide that interest payable on the maturity date will be
$<span id="xdx_909_ecustom--InterestPayableCurrents_iI_c20230317_z311nlY3MCGh">39,000</span>
less any interest payments previously made. Total interest expense on this note was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LoansPayableOfficerMember_pp0p0" title="Interest expense">18,000</span>
and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0p0_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--LoansPayableOfficerMember_z0bjApEueQeg" title="Interest expense">4,500</span> for the three months ended March&#160;31, 2023 and 2022, respectively. The December&#160;31, 2022 outstanding principal
balance of $<span id="xdx_902_ecustom--OutstandingAmount_iI_c20230517_zDX6M7Uz9KX3" title="Outstanding amount">200,000</span>
was satisfied by a payment on March&#160;17, 2023. The March&#160;31, 2023 outstanding interest balance of $<span id="xdx_908_ecustom--OutstandingInterest_iI_c20230426_zkq6qHtkM1O7" title="Outstanding interest">34,500</span>
was satisfied by a payment on April&#160;26, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principle executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056. Under ASC 842 &#8220;<i>Leases</i>&#8221;, we
have two separate sub-leases (through IIcom Strategic Inc. controlled and owned by our Chief Executive Officer) totalling approximately
4,000 square feet of office space under operating leases. Management and supporting staff are hosted at this location. Our lease payments
for fiscal year 2022 were $54,000. Our lease costs for each of the three months ended March&#160;31, 2023 and 2022 were $13,500.&#160;&#160;
The sub-leases are due to expire in 2024. Pursuant to the sublease, we pay the third-party landlord (not the sub landlord) all direct
and indirect rent costs under the primary lease directly for the leased premises. No additional payments are made to the Chief Executive
Officer or the entity controlled by him.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681262233136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LOANS PAYABLE</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zNfHcaYfEQr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8212; <span id="xdx_829_zAcXptiFc996">LOANS PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legacy
Ventures International, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;11, 2017, the Company issued a promissory note (the &#8220;Promissory Note&#8221;) in favor of Legacy Ventures International,
Inc. (&#8220;Legacy&#8221;) as part of a commercial transaction with Legacy that was never consummated. The Promissory Note was issued
in the original principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zQcurheG7qok">500,000</span>, with interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20170901__20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zhpJoN3DCkTg" title="Interest rate">4</span>% per annum and a maturity date of <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20170901__20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zDJ6PhAf4JE5" title="Maturity date">December 31, 2017</span>. As of March&#160;31,
2023, this promissory note is in default. The Company recorded $<span id="xdx_90E_eus-gaap--InterestExpense_pp0p0_c20230101__20230331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zeDNuTBRbupc" title="Interest expense">5,000</span> and $<span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20220331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_z2l8b1vGMNXk" title="Interest expense">5,000</span> of interest expense for the three months ended March&#160;31,
2023 and 2022, respectively. The amount outstanding at March&#160;31, 2023 and December&#160;31, 2022 was $<span id="xdx_903_ecustom--OutstandingAmount_iI_c20230331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zpXMLg3FuMl5" title="Outstanding amount"><span id="xdx_90C_ecustom--OutstandingAmount_iI_c20221231__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zzLGXLlzWaUl" title="Outstanding amount">500,000</span></span>.</span></p>









<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264418192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (Deficit)</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_za5wyz67nUJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8212; <span style="text-transform: uppercase"><span id="xdx_82F_zN6WaLyl8tIe">STOCKHOLDERS&#8217; EQUITY (Deficit)</span></span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2022, the Company issued <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zPpxRjgBfSF7" title="Number of common stock issued">850</span> shares of common stock to an investor for cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zNqSfPY2dc32" title="Proceeds from issuance of common stock">5,100</span>
with a fair value of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zHjt86ROyPEd" title="Share Price">6.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2022, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_pdd" title="Stock issued for services rendered, shares">24,390</span> shares of common stock to a consultant for services rendered in
lieu of cash for an aggregate compensation charge of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_pp0p0" title="Stock Issued During Period, Value, Issued for Services">150,000</span>, of which $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_zzt3jlE8TMp2" title="Share based compensation">37,500</span> was expensed during the three months ended March&#160;31,
2022, in the unaudited condensed consolidated statement of operations. In addition, $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20220331_zWRAV4w6tRwf" title="Stock compensation expenses">60,000</span> was expensed as stock compensation related
to shares to be issued to advisors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March&#160;31, 2023, the Company issued no shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of warrants to purchase shares of the Company&#8217;s common stock are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbEInnHdAiy2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BF_zm5mnQQWXNkc" style="display: none">Schedule of warrants</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of<br/>
warrants</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">Outstanding December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331_zBVoI2Rc0AZb" style="width: 9%; text-align: right" title="Number of Warrants Outstanding at beginning">2,662,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331_z3YUardUvLFg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at beginning">4.15</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331_pdd" style="text-align: right" title="Warrants Issued"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Issued"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_pdd" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpiredOrCancelled_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Expired or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0700">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331_zPtNq21ceaol" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding at end">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331_zLMbz8dfVqFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at end">4.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_zOsuExpRFWYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants to purchase shares of the Company&#8217;s common stock outstanding and exercisable
at March&#160;31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--SummaryInformationAboutWarrantsToPurchaseTableTextBlock_zfJ930USVG78" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_z9B5eNsqGR3l" style="display: none">Summary information about warrants to purchase</span></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Outstanding<br/> Number of<br/> Warrants</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Remaining Life<br/>
    In Years</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Exercise Price</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Exercisable<br/> Number of<br/> Warrants</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price">4.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Outstanding Number of Warrants">2,315,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_zgBMUlIwzbI4" title="Weighted Average Remaining Life In Years">2.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Weighted Average Exercise Price">4.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Exercisable Number of Warrants">2,135,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">4.15</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding Number of Warrants">347,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_zLtUlvkJYGzd" title="Weighted Average Remaining Life In Years">2.5</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price">4.15</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercisable Number of Warrants">347,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding Number of Warrants">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331_zN6b0O8QSvLh" title="Weighted Average Remaining Life In Years">2.75</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price">4.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable Number of Warrants">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A4_zKBDginqzdva" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation expense attributed to the issuance of the warrants, if required to be recognized on the nature of the transaction, was recognized
as they vested/earned. These warrants are exercisable up to three years from the date of grant. All are currently exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264451904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies (Note 8)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zQzMjcwCWYh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8212; <span id="xdx_82B_zNOWUm4a744c">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
Claims</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material pending legal proceedings in which the Company or any of its subsidiaries is a party or in which any director, officer
or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of its voting securities, or security holder
is a party adverse to us or has a material interest adverse to the Company other than the following:</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sarah
Veltz v. Nexalin Technology, Inc. et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plaintiff,
Sarah Veltz, filed a lawsuit in this matter on January&#160;20, 2021 in Orange County Superior Court (Case No. 30-2021-01180164-CU-WT-CJC)
(the &#8220;Complaint&#8221;) naming the Company and others as defendants. In her Complaint, Plaintiff contends that she was employed
by defendants, including Nexalin, and has not been paid all wages, including overtime wages and other benefits allegedly due her. Plaintiff
also contends that, during her employment, she was subjected to sexual harassment by the Company&#8217;s then Chief Executive Officer.
Plaintiff seeks both compensatory and punitive damages. On March&#160;12, 2021, the Company filed its answer to the Complaint. Although
the parties are seeking mediation, the court has set a trial in this matter for March&#160;18, 2024. Management&#8217;s intent
is to contest the allegations vigorously and, as of the date of this report, is unable to provide an evaluation of the potential outcome
of the litigation within the probable or remote range or to provide an estimate of the amount of or a range of potential loss that might
be incurred by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Development Department</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently engaged in settlement discussions with the Employment Development Department (EDD) of the state of California. This
matter involves issues related to our previous management&#8217;s classification of certain work provided to or on behalf of the Company&#8217;s
business as contract labor instead of employee labor. The total amount involved is approximately $300,000. Management has petitioned
for reassessment and believes the hired workers at issue were indeed actual contractors and not employees. We have no business in California
other than one part time and one full time worker residing in California. An initial hearing before an EDD magistrate was held on April&#160;15,
2022. A second hearing was held in June of 2022. We are now in negotiations with the EDD for a final settlement. The Company believes
its potential exposure to be approximately $<span id="xdx_900_ecustom--AccruedAmount_iI_c20221231_zXpYMzZtR1z1" title="Accrued amount"><span id="xdx_90B_ecustom--AccruedAmount_iI_c20230331_zKLlCUnvmuw" title="Accrued amount">300,000</span></span> and, as such, has accrued this amount on the consolidated balance sheets as of March&#160;31,
2023 and December&#160;31, 2022 and believes it has adequately accrued for this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Demand
Letter from The University of Arizona</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;8, 2022, the Company received a demand letter from the University of Arizona seeking payment of $111,094 purportedly due
on an Investigator Initiated Cooperative Study Agreement, dated as of September&#160;25, 2017 (the &#8220;2017 Study&#8221;). The Company
believes that the 2017 Study was not completed and no payment was due. In fact, for a number of months prior to receipt of the demand
letter, the Company had had discussions with the person at the University of Arizona who was to conduct the 2017 Study concerning updating
the 2017 Study and completing an updated study and related work. After receipt of the demand letter, the Company has had discussions
with the University of Arizona concerning resuming an updated study and receipt of credit for some or all the monies claimed to be due
for the 2017 Study. Such discussions are ongoing, and no resolution has been reached but the Company hopes to achieve a consensual resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681262234368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zB8hJXem1pZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8212; <span id="xdx_826_zovszaVFmax1">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the adoption of ASC 842, operating lease agreements are required to be recognized on the balance sheet as ROU assets and corresponding
lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;1, 2022, the Company exercised its right to lease an additional 400 square feet of office space and an increase of monthly
rent of $500. In accordance with ASC 842 management accounted for this as a separate lease and, as a result, recorded an ROU asset and
lease liability of $<span id="xdx_90A_ecustom--LeaseLiability_iI_c20220102_zY4DHYGVYSf8">11,359</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at January&#160;1, 2022. The weighted average incremental borrowing rate applied was <span id="xdx_90A_ecustom--WeightedAverageIncrementalBorrowingRate_dp_c20230101__20230331_zYkRs2FjZjVb">9</span>%.</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
leases are included in the consolidated balance sheets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zm9yV6pGBAd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B0_z9y3yuQHCM2d">Schedule of Operating leases</span></span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Lease assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1pt">Operating lease cost ROU assets</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 37%; text-align: center; padding-bottom: 1pt">Assets</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20230331_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets">4,800</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_c20221231_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets">6,171</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--TotalLeaseAssets_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets">4,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--TotalLeaseAssets_c20221231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets">6,171</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: center">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20230331_pp0p0" style="text-align: right" title="Operating lease liabilities, current">43,026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20221231_pp0p0" style="text-align: right" title="Operating lease liabilities, current">50,797</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current">4,463</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">43,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">55,260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A8_zmgagEbqQoA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease costs, which are included in income from operations in our unaudited condensed consolidated statements of operations,
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z93w3u9sqdvb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BF_zCaqrjlnfcHd">Schedule
    of lease cost</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Leases costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Operating lease costs</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230331_zD8L1pqUktEe" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs">13,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20220331_zxPemt28nPq5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs">13,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LeaseCost_pp0p0_c20230101__20230331_zNFzN48KmJ83" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs">13,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LeaseCost_pp0p0_c20220101__20220331_znFZj38zqeoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs">13,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A2_zfyOFcOdsCMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancellable leases for operating leases for the remaining terms of the leases following the three months ended
March&#160;31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMJce7mbudu2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_z6rabcvfOcI1" style="display: none">Future minimum payments under non-cancelable leases for operating leases</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230331_zXpNELAJW1Ma" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating<br/>
Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 88%">Remainder of 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,304</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,496</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zV2GRPFLZ74g" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,774</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zYjMRwbd27h4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information related to leases is presented as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_zvGp0GjQqYHc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span><span id="xdx_8BC_zFles555rNB5" style="display: none">Schedule of additional information related to leases</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted average remaining lease term</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zSXvjrdi0fnd" title="Weighted average remaining lease term">0.75</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zTzb0dW7T2dj" title="Weighted average remaining lease term">1.00</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230331_zi8EARkc03Z1" title="Weighted average discount rate">9.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_znIbbghubL9b" title="Weighted average discount rate">9.9</span></td><td style="text-align: left">%</td></tr>
  </table>




<p id="xdx_8AE_zd03Tzay9aYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264418192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATION OF CREDIT RISK<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATION OF CREDIT RISK</a></td>
<td class="text"><p id="xdx_802_eus-gaap--ConcentrationRiskDisclosureTextBlock_zUMVSatOzCke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8212; <span id="xdx_821_zoMDeMDoQQVd">CONCENTRATION OF CREDIT RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
customers accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--SixCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znnltBfHkO7e" title="Revenue, percentage">94</span>% of revenues for the three months ended March&#160;31, 2023, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z7Fi5DMylUp7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONCENTRATION OF CREDIT RISK (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B0_z81OUXVNplM2" style="display: none">Concentration of credit risk</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbEAUv4QHoSj" title="Revenue, percentage">25</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBxqhhryJecb" title="Revenue, percentage">17</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvOq3rqOShIe" title="Revenue, percentage">16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhV5UiU86HZ7" title="Revenue, percentage">14</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer E</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmI8tzKCedea" title="Revenue, percentage">12</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmZx8itKW0Rc" title="Revenue, percentage">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
customer, a related party, accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZhKOwdmzyv3" title="Revenue, percentage">93</span>% of revenue for the three months ended March&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
customers accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEuAhvsn5QQ9" title="Revenue, percentage">91</span>% of accounts receivable at March&#160;31, 2023, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXvItKA0wnG7" title="Revenue, percentage">32</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZikiWyMYAX7" title="Revenue, percentage">28</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5fHJCTVXRa" title="Revenue, percentage">31</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlT5Oj9Wdfae" title="Revenue, percentage">84</span>% of accounts receivable at December&#160;31, 2022, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>
Year Ended<br/>
December&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2T22LTDqV84" title="Revenue, percentage">29</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOLbwMDeRZp8" title="Revenue, percentage">20</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdW8hhsp8T08" title="Revenue, percentage">20</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zunwLJIAVGQl" title="Revenue, percentage">15</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A2_zuiN6gqlmNq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264535152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zWgm55rIv9v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8212; <span id="xdx_82D_zwtfW1TTljb2">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated subsequent events and transactions that occurred after the balance sheet date, up to the date that the unaudited financial
statements were issued. Based upon this review management did not identify any subsequent events that would have required adjustment
or disclosure in the unaudited consolidated condensed financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259165872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ziwgyhRgJr29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zCEbVvtgn9z9">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial information has been prepared in accordance with Generally Accepted Accounting
Principles (&#8220;GAAP&#8221;) for interim financial information. In the opinion of management, such financial information includes
all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company&#8217;s
financial position and the operating results and cash flows. Operating results for the three months ended March&#160;31, 2023 and 2022
are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant
to the rules of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). These unaudited condensed consolidated financial
statements and related notes should be read in conjunction with the Company&#8217;s audited consolidated financial statements for the
year ended December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_ztxBpm3wVJH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zoJyURshDri3">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Nexalin and its wholly owned subsidiary Neuro-Health. Intercompany accounts
and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zVMkEAgoER8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zu2QFZ1AvS8b">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at
the date of the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zP3wCBc1Jfw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zmmdLmF1qRMb">Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company
determines if the contract is within the scope of ASC Topic 606 and then evaluates the contract using the following five steps: (1) identify
the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.
These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements
are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its
acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer
of the Company&#8217;s electrodes will pay a royalty to the Company for a three-year period beginning January&#160;1, 2022. The amount
of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Streams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives revenues from its license agreements by charging a monthly licensing fee for the duration of the agreement. The Company
derives revenues from equipment by selling additional individual electrodes to customers for use with the Nexalin Device. The Company
receives revenue from the sale in China of its Devices to its acting distributor and from the sale of products relating to the use of
those Devices. The Company derives revenue as a royalty fee from the China-based manufacturer for electrodes ordered in connection with
the Company&#8217;s China sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied as long as the
licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time
in which the invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that the Company&#8217;s equipment and Device revenue has one performance obligation. That performance obligation is satisfied
when the equipment and Devices are shipped. The Company recognizes revenue at a point in time in which the electrodes and Devices are
shipped to the customer. The Company does not offer a warranty on the electrodes and Devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of
individual treatments on patients by customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
identified that royalty revenue has one performance obligation. The performance obligation is satisfied at the time the Electrode manufacturer
invoices the acting distributor for the sale to the acting distributor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify; border-collapse: collapse">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
Financing Component &#8212; the Company does not adjust the promised amount of consideration for the effects of a significant financing
component since the Company expects, at contract inception, that the period between when the Company transfers a promised goods or services
to the customer and when the customer pays for that service will be one year or less.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
    Performance Obligations &#8212; all performance obligations related to contracts with a duration of less than one year, the Company
    has elected to apply the optional exemption provided in ASC Topic 606 and therefore, is not required to disclose the aggregate amount
    of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting
    period.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
    and Handling Activities &#8212; the Company elected to account for shipping and handling activities as a fulfilment cost rather than
    as a separate performance obligation.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to Invoice &#8212; the Company has a right to consideration from a customer in an amount that corresponds directly with the value
    to the customer of the Company&#8217;s performance completed to date the Company may recognize revenue in the amount to which the
    entity has a right to invoice.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregated
Revenues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Revenue Streams</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
consists of the following by service offering:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zKXKMNzW1PKb" style="display: none">Schedule of disaggregation of revenue</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Device Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total">264,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Licensing Fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total">23,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total">20,143</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total">6,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">290</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">30,679</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">30,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">323,322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Geographic Locations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">U.S. Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total">30,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total">22,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">China Sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">300,499</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">30,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">323,322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zhxXaSYjMQDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contract
Modifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no contract modifications during the three months ended March&#160;31, 2023 and 2022. Contract modifications are not routine in
the performance of the Company&#8217;s contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives payment for equipment and devices in advance of shipping. The Company recognizes the revenue as being earned upon shipment.
<span id="xdx_906_eus-gaap--DeferredRevenue_iI_pdp0_do_c20230331_za0NdTo1G8y1" title="Deferred revenue"><span id="xdx_902_eus-gaap--DeferredRevenue_iI_pp0p0_do_c20221231_zuh5FH9Q2wq2" title="Deferred revenue">No</span></span> deferred revenue was recognized as of March&#160;31, 2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmOBQHnAe6B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zUHANBYlCnsg">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through,
as well as maintaining cash balances, with major financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p id="xdx_841_ecustom--ShortTermInvestmentsPolicyTextBlock_zWieSHVRS2m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zVP5jxNasouc">Short-Term
Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance
sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value
is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or
liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in accumulated other comprehensive
income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income
(expense), net. For declines in the fair values of equity securities that are considered other-than-temporary, impairment losses are
charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments,
including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments on March&#160;31,
2023 and December&#160;31, 2022, respectively.</span></p>









<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zT4W6RK5rK4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zN12aHCf3Uf5">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivables are reported at their outstanding unpaid principal balances, net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#8217;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. Payments are generally due within 30 days of invoice. The Company writes off accounts receivable against
the allowance for doubtful accounts when a balance is determined to be uncollectible. During the three months ended March&#160;31, 2023
and 2022, the Company did <span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pp0p0_do_c20230101__20230331_z1pga6fdJSQe" title="Writeoff accounts receivable"><span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pdp0_do_c20220101__20220331_zqKYSXNGmcK7" title="Writeoff accounts receivable">no</span></span>t write off accounts receivable. The Company did <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20230331_zljQzIUit65g" title="Allowance for doubtful accounts"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20221231_zSaymtCYV9og" title="Allowance for doubtful accounts">no</span></span>t record an allowance for doubtful accounts on March&#160;31,
2023 and December&#160;31, 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zy8yXrzUygx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zAajoedepadc">Inventory</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods and components stated at the lower of cost or net realizable value with cost determined on a first-in first-out
basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete, slow-moving, quantities
in excess of demand, or otherwise non-saleable items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zasktAHwlD87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zdEHP5BzTYGa">Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
is recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally
five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance
and repairs are charged to expense as incurred. The Company capitalizes costs attributable to the betterment of property and equipment
when such betterment enhances the functionality of the asset or extends the useful life of the asset. Should an asset be disposed of
before the end of its useful life, the cost and accumulated depreciation at that date is removed from the consolidated balance sheets,
with the resulting gain or loss, if any, reflected in operations in that period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_PatentsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p id="xdx_844_ecustom--PatentsPolicyTextBlock_zOzG5NGCjWui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zkG0LVSPscje">Patents</span></i>&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was
$<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20230101__20230331_znJU6uuKZbtf" title="Amortization expense">660</span> and $<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20220101__20220331_z9xTxJ8RBtp4" title="Amortization expense">0</span> for the three months ended March&#160;31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zN3dnVivAMF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zXYsMlXZIYKa">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets
and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax
bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are
expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. At March&#160;31, 2023 and December&#160;31, 2022, the Company had a full valuation allowance applied
against its net tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcXCxj3XCBul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span><span id="xdx_86D_zguvg96Hkg0d">Fair
Value Measurements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, <i>Fair Value Measurements and Disclosures</i>, fair value is the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about
risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or
generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>









<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1: Quoted prices are available in active markets for identical assets or liabilities as of
                                            the reporting date. Active markets are those in which transactions for the asset or liability
                                            occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2: Pricing inputs are other than quoted prices in active markets included in Level 1, which
                                            are either directly or indirectly observable as of the reported date. Level 2 includes those
                                            financial instruments that are valued using models or other valuation methodologies. These
                                            models are primarily industry-standard models that consider various assumptions, including
                                            quoted forward prices for commodities, time value, volatility factors and current market
                                            and contractual prices for the underlying instruments, as well as other relevant economic
                                            measures. Substantially all of these assumptions are observable in the marketplace throughout
                                            the full term of the instrument, can be derived from observable data or are supported by
                                            observable levels at which transactions are executed in the marketplace.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3: Pricing inputs include significant inputs that are generally less observable from objective
                                            sources. These inputs may be used with internally developed methodologies that result in
                                            management&#8217;s best estimate of fair value. The significant unobservable inputs used
                                            in the fair value measurement for nonrecurring fair value measurements of long-lived assets
                                            include pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRVlNQryVQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zV52sLvBiGKd">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, short-term investments, accounts receivable, inventory, prepaids, accounts payable and accrued expenses, and
other current liabilities approximate their fair values based on the short-term maturity of these instruments. The carrying amount of
the loans payable approximates the estimated fair value for this financial instrument as management believes that such debt and interest
payable on the note approximates the Company&#8217;s incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the amortized cost, unrealized gains and the fair value at March&#160;31, 2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zs3t7FXsNSp9" style="display: none">Schedule of amortized cost, unrealized gains</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gain</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" style="width: 9%; text-align: right" title="Amortized Cost">5,256,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Unrealized Gain">41,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Fair Value">5,297,658</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" style="text-align: right" title="Amortized Cost">5,256,589</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" style="text-align: right" title="Unrealized Gain">41,069</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" style="text-align: right" title="Fair Value">5,297,658</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" style="text-align: right" title="Amortized Cost">6,794,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" style="text-align: right" title="Unrealized Gain">36,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" style="text-align: right" title="Fair Value">6,831,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" style="text-align: right" title="Amortized Cost">6,794,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" style="text-align: right" title="Unrealized Gain">36,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" style="text-align: right" title="Fair Value">6,831,192</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zgTFJ0y0id8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the carrying value and fair value of the Company&#8217;s financial assets measured at fair value as of March&#160;31,
2023 and December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B3_zCQv7SG86EE6" style="display: none">Schedule of fair value, assets measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets">5,297,658</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets">5,297,658</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets">6,831,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets">6,831,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zHJhhT0qg8Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>







<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zWmitsjX5Ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zL6qrgolIYrg">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
The dilutive effect, if any, of warrants is calculated using the treasury stock method. These shares were included in the basic and diluted
net loss per common share on the unaudited condensed consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including
these potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than
the most recent fair value of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B1_zLU5zHzGbeWe" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/>
March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left">Warrants</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total">2,662,250</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total">21,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zcswmzwYtBwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlC9wDc6glwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zFnBIzw03kOf">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 718, <i>Compensation &#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;), which requires the
measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in
the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASU 2018-07 Compensation &#8212; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the
Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation
methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_WarrantAccountingPolicyTextBlock', window );">Warrant Accounting</a></td>
<td class="text"><p id="xdx_84D_ecustom--WarrantAccountingPolicyTextBlock_z3UGM7qS0ERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zwUktMJPX3o7">Warrant
Accounting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued private and public warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815-40,
Derivatives and Hedging: Contracts in Entity&#8217;s Own Equity (&#8220;ASC 815-40&#8221;). The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is assessed as part of this evaluation. During the
reporting periods the Public Warrants were outstanding, they were precluded from liability classification, being equity-classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zxeAWPBgERL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zm3EYQPjFwl2">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
research and development costs are charged to operations as incurred. For the three months ended March&#160;31, 2023 and 2022, the Company
recorded $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development costs">65,833</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development costs">11,565</span>, respectively, in selling, general and administrative expenses on the unaudited condensed consolidated statements
of operations.</span></p>









<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--LessorLeasesPolicyTextBlock_ziXIOmBL8Lmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zM5Iphrt0J28">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease is defined as an agreement that conveys the right to control the use of identified property, plant or equipment (right of use asset
or &#8220;ROU asset&#8221;) for a period of time in exchange for consideration. The Company accounts for its leases in accordance with
ASC 842, Leases, which requires that an ROU asset identified in a lease to be recorded as a noncurrent asset with a related liability.
The Company does not record ROU assets for those agreements of a twelve-month duration or less. The Company recognized a ROU asset and
corresponding lease liability on its balance sheets related to its office lease agreement. See Note 9, Leases, for further discussion,
including the impact on the Company&#8217;s unaudited condensed consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets include any initial direct costs and prepaid lease payments and exclude any lease incentives. Lease expense for minimum lease
payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate the lease
if it is reasonably certain that the Company will exercise that option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zk24gkl5K1N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zPZI23trzxol">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February&#160;2020, the FASB issued ASU 2020-02,
Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting
Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments are in effect
for the Company for interim and annual periods in fiscal years beginning after December&#160;15, 2022. The adoption on January 1, 2023
modified the way the Company analyzes financial instruments, but it did not have a&#160;material impact on our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_PatentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_PatentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_WarrantAccountingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_WarrantAccountingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259659040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zKXKMNzW1PKb" style="display: none">Schedule of disaggregation of revenue</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Device Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total">264,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Licensing Fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total">23,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total">20,143</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total">6,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">290</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">30,679</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">30,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">323,322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major
Geographic Locations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">U.S. Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total">30,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total">22,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">China Sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">300,499</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">30,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">323,322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of amortized cost, unrealized gains</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zs3t7FXsNSp9" style="display: none">Schedule of amortized cost, unrealized gains</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gain</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" style="width: 9%; text-align: right" title="Amortized Cost">5,256,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Unrealized Gain">41,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Fair Value">5,297,658</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" style="text-align: right" title="Amortized Cost">5,256,589</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" style="text-align: right" title="Unrealized Gain">41,069</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" style="text-align: right" title="Fair Value">5,297,658</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" style="text-align: right" title="Amortized Cost">6,794,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" style="text-align: right" title="Unrealized Gain">36,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" style="text-align: right" title="Fair Value">6,831,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" style="text-align: right" title="Amortized Cost">6,794,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" style="text-align: right" title="Unrealized Gain">36,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" style="text-align: right" title="Fair Value">6,831,192</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value, assets measured on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B3_zCQv7SG86EE6" style="display: none">Schedule of fair value, assets measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets">5,297,658</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets">5,297,658</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">U.S. Treasury Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets">6,831,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets">6,831,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B1_zLU5zHzGbeWe" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/>
March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left">Warrants</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total">2,662,250</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total">21,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264443520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zWGpl1Uc50x2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B2_zB0TmldCVjSd" style="display: none">Schedule of accrued expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230331_zwdMPITlfCCi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20221231_zQdRn0BzFWSc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAUCzJ3A_zw7745EclQu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued interest</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">134,501</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111,501</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_zrDMDyBIp372" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued &#8211; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,321</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SettlementLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_z9P6h78x3sld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued settlement liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">336,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">336,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpense_iI_pp0p0_maAUCzJ3A_znBHmHpZLGF6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accrued research and development expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0p0_mtAUCzJ3A_zML3qxSxolBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">597,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">539,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260501328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbEInnHdAiy2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BF_zm5mnQQWXNkc" style="display: none">Schedule of warrants</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of<br/>
warrants</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">Outstanding December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331_zBVoI2Rc0AZb" style="width: 9%; text-align: right" title="Number of Warrants Outstanding at beginning">2,662,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331_z3YUardUvLFg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at beginning">4.15</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331_pdd" style="text-align: right" title="Warrants Issued"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Issued"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_pdd" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpiredOrCancelled_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Expired or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0700">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331_zPtNq21ceaol" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding at end">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331_zLMbz8dfVqFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at end">4.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock', window );">Summary information about warrants to purchase</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--SummaryInformationAboutWarrantsToPurchaseTableTextBlock_zfJ930USVG78" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_z9B5eNsqGR3l" style="display: none">Summary information about warrants to purchase</span></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Outstanding<br/> Number of<br/> Warrants</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Remaining Life<br/>
    In Years</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Exercise Price</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Exercisable<br/> Number of<br/> Warrants</b></td><td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price">4.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Outstanding Number of Warrants">2,315,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_zgBMUlIwzbI4" title="Weighted Average Remaining Life In Years">2.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Weighted Average Exercise Price">4.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Exercisable Number of Warrants">2,135,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">4.15</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding Number of Warrants">347,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_zLtUlvkJYGzd" title="Weighted Average Remaining Life In Years">2.5</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price">4.15</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercisable Number of Warrants">347,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding Number of Warrants">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331_zN6b0O8QSvLh" title="Weighted Average Remaining Life In Years">2.75</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price">4.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable Number of Warrants">2,662,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681263742480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zm9yV6pGBAd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B0_z9y3yuQHCM2d">Schedule of Operating leases</span></span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Lease assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1pt">Operating lease cost ROU assets</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 37%; text-align: center; padding-bottom: 1pt">Assets</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20230331_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets">4,800</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_c20221231_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets">6,171</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--TotalLeaseAssets_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets">4,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--TotalLeaseAssets_c20221231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets">6,171</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: center">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20230331_pp0p0" style="text-align: right" title="Operating lease liabilities, current">43,026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20221231_pp0p0" style="text-align: right" title="Operating lease liabilities, current">50,797</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current">4,463</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">43,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">55,260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z93w3u9sqdvb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BF_zCaqrjlnfcHd">Schedule
    of lease cost</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Leases costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Operating lease costs</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230331_zD8L1pqUktEe" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs">13,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20220331_zxPemt28nPq5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs">13,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LeaseCost_pp0p0_c20230101__20230331_zNFzN48KmJ83" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs">13,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LeaseCost_pp0p0_c20220101__20220331_znFZj38zqeoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs">13,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future minimum payments under non-cancelable leases for operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMJce7mbudu2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_z6rabcvfOcI1" style="display: none">Future minimum payments under non-cancelable leases for operating leases</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230331_zXpNELAJW1Ma" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating<br/>
Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 88%">Remainder of 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,304</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,496</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zV2GRPFLZ74g" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,774</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock', window );">Schedule of additional information related to leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_zvGp0GjQqYHc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span><span id="xdx_8BC_zFles555rNB5" style="display: none">Schedule of additional information related to leases</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted average remaining lease term</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zSXvjrdi0fnd" title="Weighted average remaining lease term">0.75</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zTzb0dW7T2dj" title="Weighted average remaining lease term">1.00</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230331_zi8EARkc03Z1" title="Weighted average discount rate">9.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_znIbbghubL9b" title="Weighted average discount rate">9.9</span></td><td style="text-align: left">%</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264438800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATION OF CREDIT RISK (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Concentration of credit risk</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z7Fi5DMylUp7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONCENTRATION OF CREDIT RISK (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B0_z81OUXVNplM2" style="display: none">Concentration of credit risk</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbEAUv4QHoSj" title="Revenue, percentage">25</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBxqhhryJecb" title="Revenue, percentage">17</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvOq3rqOShIe" title="Revenue, percentage">16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhV5UiU86HZ7" title="Revenue, percentage">14</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer E</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmI8tzKCedea" title="Revenue, percentage">12</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmZx8itKW0Rc" title="Revenue, percentage">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
customer, a related party, accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZhKOwdmzyv3" title="Revenue, percentage">93</span>% of revenue for the three months ended March&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
customers accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEuAhvsn5QQ9" title="Revenue, percentage">91</span>% of accounts receivable at March&#160;31, 2023, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March&#160;31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXvItKA0wnG7" title="Revenue, percentage">32</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZikiWyMYAX7" title="Revenue, percentage">28</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5fHJCTVXRa" title="Revenue, percentage">31</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlT5Oj9Wdfae" title="Revenue, percentage">84</span>% of accounts receivable at December&#160;31, 2022, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>
Year Ended<br/>
December&#160;31,<br/>
2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Customer A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2T22LTDqV84" title="Revenue, percentage">29</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOLbwMDeRZp8" title="Revenue, percentage">20</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdW8hhsp8T08" title="Revenue, percentage">20</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zunwLJIAVGQl" title="Revenue, percentage">15</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260443808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Sep. 20, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued during the period</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315,000<span></span>
</td>
<td class="nump">2,662,250<span></span>
</td>
<td class="nump">2,662,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,607,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259155792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 73,137,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,389,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operation</a></td>
<td class="nump">779,426<span></span>
</td>
<td class="nump">$ 375,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operations</a></td>
<td class="nump">1,314,649<span></span>
</td>
<td class="nump">$ 203,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259632176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 30,560<span></span>
</td>
<td class="nump">$ 323,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">30,560<span></span>
</td>
<td class="nump">22,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=NXL_DeviceSalesMember', window );">Device Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">264,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=NXL_LicensingFeeMember', window );">Licensing Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">23,870<span></span>
</td>
<td class="nump">20,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=NXL_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 30,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=NXL_DeviceSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=NXL_DeviceSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=NXL_LicensingFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=NXL_LicensingFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=NXL_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=NXL_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259479600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_AmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 5,256,589<span></span>
</td>
<td class="nump">$ 6,794,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_UnrealizedGain', window );">Unrealized Gain</a></td>
<td class="nump">41,069<span></span>
</td>
<td class="nump">36,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">5,297,658<span></span>
</td>
<td class="nump">6,831,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_AmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">5,256,589<span></span>
</td>
<td class="nump">6,794,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_UnrealizedGain', window );">Unrealized Gain</a></td>
<td class="nump">41,069<span></span>
</td>
<td class="nump">36,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 5,297,658<span></span>
</td>
<td class="nump">$ 6,831,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_AmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_AmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_UnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_UnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260249456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 5,297,658<span></span>
</td>
<td class="nump">$ 6,831,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">5,297,658<span></span>
</td>
<td class="nump">6,831,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259952352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,662,250<span></span>
</td>
<td class="nump">21,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,662,250<span></span>
</td>
<td class="nump">21,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681258990784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Writeoff accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 65,833<span></span>
</td>
<td class="nump">$ 11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681250830816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 134,501<span></span>
</td>
<td class="nump">$ 111,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued &#8211; other</a></td>
<td class="nump">37,159<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Accrued settlement liabilities</a></td>
<td class="nump">336,000<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_AccruedResearchAndDevelopmentExpense', window );">Accrued research and development expense</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedUtilitiesCurrent', window );">&#160;Total</a></td>
<td class="nump">$ 597,660<span></span>
</td>
<td class="nump">$ 539,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedUtilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedUtilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681251136016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2021</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>May 09, 2018</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Oct. 25, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 17, 2023</div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Sep. 21, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_RelatedPartyContribution', window );">Related party contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_RemainingSharesIssuedDescription', window );">Remaining shares issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The remaining 300,000 shares will be issued in accordance with the following
schedule upon Wider&#8217;s successful completion of the following milestones (i) 50% upon successful completion of the fourth of four
clinical trials pursuant to the terms and conditions of the Service Agreements and (ii) 50% upon all four trials being submitted for
publication in international medical journals satisfactory to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_RevenuesFromRelatedParties', window );">Revenue from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">300,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_InterestPayableCurrents', window );">[custom:InterestPayableCurrents-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_OutstandingAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_OutstandingInterest', window );">Outstanding interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NXL_LoansPayableOfficerMember', window );">Loans Payable Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_LoansFromRelatedParty', window );">Loans from related party</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NXL_MrOsserMember', window );">Mr Osser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=NXL_USAsianConsultingGroupLLCMember', window );">U S Asian Consulting Group L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherBorrowings', window );">Balance owed for accrued,unpaid services and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_OwedBalancePaymentDescription', window );">Owed balance payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A payment of $250,000 was made to U.S. Asian on March&#160;17, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=NXL_USAsianConsultingGroupLLCMember', window );">U S Asian Consulting Group L L C [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_ConsultingExpenses', window );">Consulting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=NXL_PotentialJointVentureMember', window );">Potential Joint Venture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_ConsultingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_ConsultingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_InterestPayableCurrents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_InterestPayableCurrents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_LoansFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_LoansFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_OutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_OutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_OutstandingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_OutstandingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_OwedBalancePaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_OwedBalancePaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_RelatedPartyContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_RelatedPartyContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_RemainingSharesIssuedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_RemainingSharesIssuedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_RevenuesFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_RevenuesFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NXL_LoansPayableOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NXL_LoansPayableOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NXL_MrOsserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NXL_MrOsserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=NXL_USAsianConsultingGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=NXL_USAsianConsultingGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NXL_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NXL_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=NXL_PotentialJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=NXL_PotentialJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259071312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 11, 2017</div></th>
<th class="th"><div>Oct. 25, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,837<span></span>
</td>
<td class="nump">$ 18,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_OutstandingAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NXL_LegacyVenturesInternationalIncMember', window );">Legacy Ventures International Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_OutstandingAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_OutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_OutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NXL_LegacyVenturesInternationalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NXL_LegacyVenturesInternationalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259480208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding at beginning | shares</a></td>
<td class="nump">2,662,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Warrants Outstanding at beginning | $ / shares</a></td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants Issued | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Warrants Issued | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Warrants Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants Expired or cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled', window );">Weighted Average Exercise Price, Warrants Expired or cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding at end | shares</a></td>
<td class="nump">2,662,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Warrants Outstanding at end | $ / shares</a></td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259619360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">2,662,250<span></span>
</td>
<td class="nump">2,662,250<span></span>
</td>
<td class="nump">2,315,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life In Years</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_ExercisableNumberOfWarrants', window );">Exercisable Number of Warrants</a></td>
<td class="nump">2,662,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=NXL_Range1Member', window );">Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">2,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life In Years</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_ExercisableNumberOfWarrants', window );">Exercisable Number of Warrants</a></td>
<td class="nump">2,135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=NXL_Range2Member', window );">Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">347,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life In Years</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_ExercisableNumberOfWarrants', window );">Exercisable Number of Warrants</a></td>
<td class="nump">347,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_ExercisableNumberOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_ExercisableNumberOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=NXL_Range1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=NXL_Range1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=NXL_Range2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=NXL_Range2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681251069920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Deficit) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock issued</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=NXL_AnInvestorMember', window );">An Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=NXL_VariousConsultantsMember', window );">Various Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services rendered, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=NXL_AnInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=NXL_AnInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=NXL_VariousConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=NXL_VariousConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260521056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies (Note 8)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_AccruedAmount', window );">Accrued amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_AccruedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_AccruedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264902784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease cost ROU assets</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 6,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_TotalLeaseAssets', window );">Total lease assets</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">6,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">43,026<span></span>
</td>
<td class="nump">50,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 43,026<span></span>
</td>
<td class="nump">$ 55,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_TotalLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_TotalLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259808624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259130384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Remainder of 2023</a></td>
<td class="nump">$ 40,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">44,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amount representing interest</a></td>
<td class="nump">1,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net future minimum lease payments</a></td>
<td class="nump">$ 43,026<span></span>
</td>
<td class="nump">$ 55,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264394640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details 3)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681264509168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_LeaseLiability', window );">[custom:LeaseLiability-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NXL_WeightedAverageIncrementalBorrowingRate', window );">[custom:WeightedAverageIncrementalBorrowingRate]</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NXL_WeightedAverageIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NXL_WeightedAverageIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NXL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681259885072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATION OF CREDIT RISK (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerAMember', window );">Customer A [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerAMember', window );">Customer A [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerBMember', window );">Customer B [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerBMember', window );">Customer B [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerCMember', window );">Customer C [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerCMember', window );">Customer C [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerDMember', window );">Customer D [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerDMember', window );">Customer D [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerEMember', window );">Customer E [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_CustomerFMember', window );">Customer F [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_CustomerFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_CustomerFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139681260382160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATION OF CREDIT RISK (Details Narrative) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_SixCustomerMember', window );">Six Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_OneCustomerMember', window );">One Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_ThreeCustomerMember', window );">Three Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NXL_FourCustomerMember', window );">Four Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_SixCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_SixCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_ThreeCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_ThreeCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NXL_FourCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NXL_FourCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>nexalintechno_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NXL="http://nexalin.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nxl-20230331.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NXL:CommonStockParValue0.001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NXL:WarrantsExercisableForOneShareOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-20_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2022-09-20</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-20_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_DeviceSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:DeviceSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_DeviceSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:DeviceSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_LicensingFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:LicensingFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LicensingFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:LicensingFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">NXL:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-21_custom_PotentialJointVentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">NXL:PotentialJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-21</instant>
        </period>
    </context>
    <context id="From2020-04-012020-04-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2018-09-21</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2018-05-012018-05-09_custom_USAsianConsultingGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-09</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NXL:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_USAsianConsultingGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:USAsianConsultingGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-22_custom_MrOsserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NXL:MrOsserMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="From2021-10-302021-11-02_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-30</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-02_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="From2018-10-012018-10-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_LoansPayableOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NXL:LoansPayableOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LoansPayableOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NXL:LoansPayableOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2023-05-17</instant>
        </period>
    </context>
    <context id="AsOf2023-04-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2023-04-26</instant>
        </period>
    </context>
    <context id="AsOf2017-09-11_custom_LegacyVenturesInternationalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-11</instant>
        </period>
    </context>
    <context id="From2017-09-012017-09-11_custom_LegacyVenturesInternationalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-11</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_LegacyVenturesInternationalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LegacyVenturesInternationalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_LegacyVenturesInternationalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LegacyVenturesInternationalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NXL:LegacyVenturesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_AnInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:AnInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_AnInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:AnInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_VariousConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">NXL:VariousConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">NXL:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_SixCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:SixCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OneCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ThreeCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:ThreeCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FourCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerDMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerEMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerFMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527352</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NXL:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-03-31">0001527352</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <NXL:PatentNetOfAmortization
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:LoanPayableOfficer
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:GainOnSaleOfShorttermInvestments
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:UnrealizedGainFromShorttermInvestments
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:GainOnSaleOfShorttermInvestments
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireTradingSecuritiesHeldforinvestment
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:PurchaseOfPatents
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:PaymentsOnLoanPayableShareholder
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:PaymentsOnNotesPayableOfficer
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:UnrealizedGainOnShorttermInvestments
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <NXL:RouAssetAndLeaseLiabilityRecorded
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_custom_DeviceSalesMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_country_CN"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0690"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0692"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0694"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0696"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0698"
      unitRef="Shares"
      xsi:nil="true"/>
    <NXL:WeightedAverageExercisePriceWarrantsExpiredOrCancelled
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0700"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-03-31">001-41507</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-03-31">NEXALIN TECHNOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-03-31">27-5566468</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-03-31">1776 Yorktown</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-03-31">Suite 550</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-03-31">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-03-31">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-03-31">77056</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-03-31">(832)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-03-31">260-0222</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember">Common     stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember">NXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember">Warrants,     exercisable for one share of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember">NXLIW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-012023-03-31_custom_WarrantsExercisableForOneShareOfCommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-03-31">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-05-08" decimals="INF" unitRef="Shares">7286562</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">174961</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">162743</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5297658</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6831192</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">3550</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4875</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">158270</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">154370</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">241330</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">272282</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5875769</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7425462</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4800</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6171</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2315</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2181</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">368</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">503</us-gaap:PropertyPlantAndEquipmentNet>
    <NXL:PatentNetOfAmortization contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">49536</NXL:PatentNetOfAmortization>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5930473</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7432136</us-gaap:Assets>
    <NXL:AccountsPayableRelatedParty contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10000</NXL:AccountsPayableRelatedParty>
    <NXL:AccountsPayableRelatedParty contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">260000</NXL:AccountsPayableRelatedParty>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">54758</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">658367</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">597660</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">539822</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">43026</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">50797</us-gaap:OperatingLeaseLiabilityCurrent>
    <NXL:LoanPayableOfficer contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">200000</NXL:LoanPayableOfficer>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">500000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">500000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1195444</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1948986</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4463</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1195444</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1953449</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">7286562</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">7286562</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">7286562</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">7286562</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">7287</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7287</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">41069</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">36313</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">77824427</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">77824427</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-73137754</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-72389340</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4735029</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5478687</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5930473</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7432136</us-gaap:LiabilitiesAndStockholdersEquity>
    <NXL:RevenuesFromRelatedParties
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</NXL:RevenuesFromRelatedParties>
    <NXL:RevenuesFromRelatedParties
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">300499</NXL:RevenuesFromRelatedParties>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">30560</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">323322</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">7110</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">46015</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">23450</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">277307</us-gaap:GrossProfit>
    <us-gaap:ProfessionalFees
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">158600</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">295456</us-gaap:ProfessionalFees>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">299323</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">138594</us-gaap:LaborAndRelatedExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">344953</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">218374</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">802876</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">652424</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-779426</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-375117</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">8837</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">18132</us-gaap:InterestExpense>
    <NXL:GainOnSaleOfShorttermInvestments
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">38772</NXL:GainOnSaleOfShorttermInvestments>
    <us-gaap:OtherIncome
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1077</us-gaap:OtherIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">31012</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-18132</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-748414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-393249</us-gaap:NetIncomeLoss>
    <NXL:UnrealizedGainFromShorttermInvestments
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">41069</NXL:UnrealizedGainFromShorttermInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-707345</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-393249</us-gaap:ComprehensiveIncomeNetOfTax>
    <NXL:NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.10</NXL:NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted>
    <NXL:NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.08</NXL:NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted>
    <NXL:WeightedAverageSharesOutstanding
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">7286562</NXL:WeightedAverageSharesOutstanding>
    <NXL:WeightedAverageSharesOutstanding
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">4888080</NXL:WeightedAverageSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4879923</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">40880</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">69004703</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-70691524</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1681941</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">850</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5099</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">5100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24390</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">24</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">97476</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">97500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-393249</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-393249</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4905163</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">40905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">69107278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-71084773</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-1972590</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7286562</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">36313</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">77824427</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-72389340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5478687</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">4756</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">4756</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-748414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-748414</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7286562</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">41069</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">77824427</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-73137754</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4735029</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-748414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-393249</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">97500</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">134</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">134</us-gaap:Depreciation>
    <us-gaap:AcquisitionCosts
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">660</us-gaap:AcquisitionCosts>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1371</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1254</us-gaap:OtherNoncashExpense>
    <NXL:GainOnSaleOfShorttermInvestments
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">38772</NXL:GainOnSaleOfShorttermInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1325</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">53540</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-30952</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1671</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">3900</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">47323</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-250000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-353609</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">179386</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">57838</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-26675</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">52000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-12234</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-11087</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1314649</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-203271</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">11599356</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireTradingSecuritiesHeldforinvestment
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">10022293</us-gaap:PaymentsToAcquireTradingSecuritiesHeldforinvestment>
    <NXL:PurchaseOfPatents
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">50196</NXL:PurchaseOfPatents>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1526867</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">5100</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <NXL:PaymentsOnLoanPayableShareholder
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">5000</NXL:PaymentsOnLoanPayableShareholder>
    <NXL:PaymentsOnNotesPayableOfficer
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-200000</NXL:PaymentsOnNotesPayableOfficer>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">100</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">12218</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-203171</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">162743</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">661778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">174961</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">458607</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <NXL:UnrealizedGainOnShorttermInvestments
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">41069</NXL:UnrealizedGainOnShorttermInvestments>
    <NXL:RouAssetAndLeaseLiabilityRecorded
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">11359</NXL:RouAssetAndLeaseLiabilityRecorded>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_801_eus-gaap--NatureOfOperations_zDAdXvSwT9ul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2014; &lt;span id="xdx_82D_zyeb6O7vrhU9"&gt;NATURE OF THE ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nexalin
Technology, Inc. (&#x201c;NV Nexalin&#x201d;) was formed on October&#160;19, 2010 as a Nevada corporation. The Company&#x2019;s principal
offices are located at 1776 Yorktown, Suite 550, Houston, Texas 77056.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September&#160;6, 2019, Neuro-Health International, Inc. (&#x201c;Neuro-Health&#x201d;), a Nevada corporation, a wholly owned subsidiary
of NV Nexalin, was formed. Neuro-Health had no activity from December&#160;6, 2019 (Inception) through March&#160;31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November&#160;22, 2021, NV Nexalin entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with Nexalin Technology,
Inc., a Delaware corporation (&#x201c;Nexalin&#x201d;, or the &#x201c;Company&#x201d;). Pursuant to the Merger Agreement, NV Nexalin merged
with and into Nexalin with all shareholders of NV Nexalin receiving one common share of Nexalin in exchange for twenty shares of NV Nexalin
held at the time of the Merger Agreement. NV Nexalin treated the transaction as a corporate reorganization with the historical consolidated
financial statements of NV Nexalin becoming the historical consolidated financial statements of Nexalin. Nexalin had nominal assets and
liabilities and did not conduct any operations prior to the reorganization other than its incorporation. NV Nexalin has retroactively
applied the 20-for-1 exchange, effective on November&#160;22, 2021, to share and per share amounts on the unaudited condensed consolidated
financial statements for the three months ended March&#160;31, 2023 and 2022. NV Nexalin&#x2019;s authorized shares of common stock were
not affected as a result of the Merger Agreement. As a result of the Merger Agreement, NV Nexalin was dissolved, and Neuro-Health became
a subsidiary of Nexalin. The Company completed its initial public offering on September&#160;16, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial public offering consisted of &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zo5FUboLWCk7" title="Shares issued during the period"&gt;2,315,000&lt;/span&gt; units consisting of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued during the period"&gt;2,315,000&lt;/span&gt; shares of Common Stock and &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU1seVF8r347" title="Shares issued during the period"&gt;2,315,000&lt;/span&gt; accompanying warrants
to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220920_pdd" title="Warrant to purchase"&gt;2,315,000&lt;/span&gt; shares of common stock. Each share of common stock was sold together with one Warrant, each to purchase one
share of common stock with an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220920_pdd" title="Exercise price"&gt;4.15&lt;/span&gt; per share at a combined offering price of $4.15, for gross proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220901__20220920_pp0p0" title="Proceeds from issuance of equity"&gt;9,607,250&lt;/span&gt;,
before deducting underwriting discounts and offering expenses. In addition, the underwriters purchased &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zOvzs5cvnJlb" title="Shares issued during the period"&gt;347,250&lt;/span&gt; warrants for net proceeds
of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220901__20220920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pp0p0" title="Proceeds from issuance of warrants"&gt;3,473&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
shares and warrants began trading on the Nasdaq Capital Market tier of the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) on September&#160;16,
2022, under the symbols &#x201c;NXL&#x201d; and &#x201c;NXLIW&#x201d;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Throughout
this report, the terms &#x201c;Nexalin,&#x201d; &#x201c;our,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and the &#x201c;Company&#x201d; refer
to Nexalin Technology, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Overview&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic.
We developed an easy-to-administer medical device &#x2014; referred to as Generation 1 or Gen-1 &#x2014; that utilizes bioelectronic medical
technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy
stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration
(&#x201c;FDA&#x201d;) as a Class II device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
we continue providing services to medical professionals to support patients&#x2019; use of the Gen-1 devices which were in operation
prior to December&#160;2019, we are not making new sales or new marketing efforts of Gen-1 devices. We continue to derive revenue
from devices which we sold or leased prior to the FDA&#x2019;s December&#160;2019 reclassification announcements. This revenue
consists of monthly licensing fees and payments for the sale of electrodes. We have suspended marketing efforts for new sales of
devices related to the Gen-1 device for treatment of anxiety and insomnia in the United States until the Nexalin regulatory team
makes a decision on amending our existing 510(k) application at 4 milliamps. A new pre-sub document in preparation of a new 510(k)
for our Gen-3 Halo headset at 15 milliamps was filed with the FDA in January of 2023. Formal comments to our pre-sub document filing
were received in March of 2023. A formal meeting to address FDA comments is scheduled for May of 2023.&#160;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have designed and developed a new advanced wave form technology to be emitted at 15 milliamps through new and improved medical devices
referred to as Generation 2 or Gen-2 and Generation 3 or Gen-3. Gen-2 is a clinical use device with a modern enclosure to emit the new
15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual
clinic setting similar to existing Tele-health platforms. Preliminary data provided by the University of California San Diego supports
the safety of utilizing our 15 milliamp waveform technology, however the determination of safety and efficacy of medical devices in the
United States is subject to clearance by the FDA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
we are currently designing clinical trial strategies for the use of Gen-3 for the treatment of substance use disorders including opiate,
cocaine, and alcohol abuse. Recently the Gen-2 device was tested in pilot trials in China for the treatment of Alzheimer&#x2019;s disease,
and dementia. Continued pilot testing for Alzheimer&#x2019;s and dementia, cognition and memory, and neurotransmitter changes is planned
in China in 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Emerging
Growth Company&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and approval of any golden parachute payments not previously approved. Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither
an emerging growth company, nor an emerging growth company which has opted out of using the extended transition period, difficult or
impossible because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
continues to evaluate the impact of the economy and the capital markets and has concluded that, while it is reasonably possible that
events could have negative effects on the Company&#x2019;s financial position and results of its operations, the specific impacts are
not readily determinable as of the date of these consolidated financial statements. The unaudited condensed consolidated financial statements
do not include any adjustments that might result from the outcome of uncertainties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may
also have a direct impact on the Company&#x2019;s operating results and financial position in the future. The ultimate duration and magnitude
of the impact and the efficacy of government interventions on the economy has and may continue to indirectly impact the Company because
of its current dependence upon its distributor relationship with Wider Come Limited. Wider Come Limited acts as a distributor for the
Company&#x2019;s devices in China and Asia. Because of significant restrictions imposed by the Chinese government during the COVID-19
pandemic through calendar year 2022 and into 2023, Wider&#x2019;s ability to market and sell the Company&#x2019;s devices has been negatively
impacted, resulting in decreased revenue to the Company. Patients and salespeople have been restricted in their movements resulting in
a significant slowdown in the medical and other sectors. Significant efforts and funds expended by our Chinese distributor has led to
regulatory approval in China in both depression and insomnia thus far which has allowed for sales of our devices in China in 2022, and
into 2023. The extent of future impact is dependent on future developments, including future activities by the Chinese government and
other possible events which are highly uncertain and not in the Company&#x2019;s control, including new information which may emerge concerning
the spread and severity of COVID-19, or any of its variants, and actions taken to address its impact, among others. The repercussions
of this health crisis could have a material adverse effect on the Company&#x2019;s business, financial condition, liquidity and operating
results.&lt;/span&gt;&lt;/p&gt;









</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-09-012022-09-20_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">2315000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-09-012022-09-20_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2315000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-09-012022-09-20_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2315000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-20" decimals="INF" unitRef="Shares">2315000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-09-20"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-09-012022-09-20"
      decimals="0"
      unitRef="USD">9607250</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-09-012022-09-20_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      unitRef="Shares">347250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-09-012022-09-20_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      unitRef="USD">3473</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z31oT8cXpmc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2014; &lt;span id="xdx_824_z9mHyOKMXo7a"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern,
which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At March&#160;31, 2023,
we had a significant accumulated deficit of approximately $73.1&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230331_zr0dGuvM81Sg" style="display: none" title="Accumulated deficit"&gt;73,137,754&lt;/span&gt; million. For the three months ended March&#160;31, 2023, we had a loss
from operations of approximately $779&lt;span id="xdx_90E_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_c20230101__20230331_zHXNgDOU5SS1" style="display: none" title="Loss from operation"&gt;779,426&lt;/span&gt; thousand and negative cash flows used in operations of approximately $1.3&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20230101__20230331_zwAry1sZw8We" style="display: none" title="Cash flows from operations"&gt;1,314,649&lt;/span&gt; million. While we had
a working capital surplus as of March&#160;31, 2023 of approximately $&lt;span id="xdx_90D_ecustom--WorkingCapitalDeficit_iI_pn3n3_dm_c20230331_z4EDNLOKO0Ci" title="Working capital deficit"&gt;4.7&lt;/span&gt; million, our operating activities consume most of our cash
resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
expect to continue to incur operating losses as we execute our development plans, as well as undertaking other potential strategic and
business development initiatives through 2023 and through the twelve months from the date of this report. In addition, we have had and
expect to have negative cash flows from operations, at least into the near future. We have previously funded these losses primarily through
the sale of equity and issuance of convertible notes. The accompanying unaudited consolidated financial statements do not include any
adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
ability to continue as a going concern will be dependent upon our ability to execute on our business plan, including the ability to generate
revenue from the proposed joint venture and obtain U.S. approval for the sale of our devices in the United States, and, if necessary,
our ability to raise additional capital. Although no assurances can be given as to our ability to deliver on our revenue plans or that
unforeseen expenses may arise, management has evaluated the significance of the conditions as of March&#160;31, 2023 and has concluded
that due to the receipt of the net proceeds from the completion of the Initial Public Offering, we have sufficient cash and short-term
investments on hand to satisfy its anticipated cash requirements for the next twelve months from the issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-73137754</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-779426</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1314649</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <NXL:WorkingCapitalDeficit contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">4700000</NXL:WorkingCapitalDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zVTZsUtZX1hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2014; &lt;span id="xdx_82F_zJdfPqCglvkb"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ziwgyhRgJr29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zCEbVvtgn9z9"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial information has been prepared in accordance with Generally Accepted Accounting
Principles (&#x201c;GAAP&#x201d;) for interim financial information. In the opinion of management, such financial information includes
all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company&#x2019;s
financial position and the operating results and cash flows. Operating results for the three months ended March&#160;31, 2023 and 2022
are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant
to the rules of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). These unaudited condensed consolidated financial
statements and related notes should be read in conjunction with the Company&#x2019;s audited consolidated financial statements for the
year ended December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_ztxBpm3wVJH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zoJyURshDri3"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Nexalin and its wholly owned subsidiary Neuro-Health. Intercompany accounts
and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zVMkEAgoER8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zu2QFZ1AvS8b"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at
the date of the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zP3wCBc1Jfw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zmmdLmF1qRMb"&gt;Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company
determines if the contract is within the scope of ASC Topic 606 and then evaluates the contract using the following five steps: (1) identify
the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.
These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements
are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its
acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer
of the Company&#x2019;s electrodes will pay a royalty to the Company for a three-year period beginning January&#160;1, 2022. The amount
of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Revenue
Streams&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company derives revenues from its license agreements by charging a monthly licensing fee for the duration of the agreement. The Company
derives revenues from equipment by selling additional individual electrodes to customers for use with the Nexalin Device. The Company
receives revenue from the sale in China of its Devices to its acting distributor and from the sale of products relating to the use of
those Devices. The Company derives revenue as a royalty fee from the China-based manufacturer for electrodes ordered in connection with
the Company&#x2019;s China sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Performance
Obligations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied as long as the
licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time
in which the invoice is sent to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that the Company&#x2019;s equipment and Device revenue has one performance obligation. That performance obligation is satisfied
when the equipment and Devices are shipped. The Company recognizes revenue at a point in time in which the electrodes and Devices are
shipped to the customer. The Company does not offer a warranty on the electrodes and Devices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of
individual treatments on patients by customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that royalty revenue has one performance obligation. The performance obligation is satisfied at the time the Electrode manufacturer
invoices the acting distributor for the sale to the acting distributor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Practical
Expedients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of ASC 606, the Company has adopted several practical expedients including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify; border-collapse: collapse"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
Financing Component &#x2014; the Company does not adjust the promised amount of consideration for the effects of a significant financing
component since the Company expects, at contract inception, that the period between when the Company transfers a promised goods or services
to the customer and when the customer pays for that service will be one year or less.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unsatisfied
    Performance Obligations &#x2014; all performance obligations related to contracts with a duration of less than one year, the Company
    has elected to apply the optional exemption provided in ASC Topic 606 and therefore, is not required to disclose the aggregate amount
    of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting
    period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping
    and Handling Activities &#x2014; the Company elected to account for shipping and handling activities as a fulfilment cost rather than
    as a separate performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
    to Invoice &#x2014; the Company has a right to consideration from a customer in an amount that corresponds directly with the value
    to the customer of the Company&#x2019;s performance completed to date the Company may recognize revenue in the amount to which the
    entity has a right to invoice.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Disaggregated
Revenues&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Major
Revenue Streams&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
consists of the following by service offering:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BB_zKXKMNzW1PKb" style="display: none"&gt;Schedule of disaggregation of revenue&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Device Sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0438"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;264,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Licensing Fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total"&gt;23,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total"&gt;20,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total"&gt;6,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;30,679&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;323,322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Major
Geographic Locations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;U.S. Sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;22,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;China Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;300,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;323,322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zhxXaSYjMQDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Contract
Modifications&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no contract modifications during the three months ended March&#160;31, 2023 and 2022. Contract modifications are not routine in
the performance of the Company&#x2019;s contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Deferred
Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives payment for equipment and devices in advance of shipping. The Company recognizes the revenue as being earned upon shipment.
&lt;span id="xdx_906_eus-gaap--DeferredRevenue_iI_pdp0_do_c20230331_za0NdTo1G8y1" title="Deferred revenue"&gt;&lt;span id="xdx_902_eus-gaap--DeferredRevenue_iI_pp0p0_do_c20221231_zuh5FH9Q2wq2" title="Deferred revenue"&gt;No&lt;/span&gt;&lt;/span&gt; deferred revenue was recognized as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmOBQHnAe6B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zUHANBYlCnsg"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through,
as well as maintaining cash balances, with major financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ShortTermInvestmentsPolicyTextBlock_zWieSHVRS2m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zVP5jxNasouc"&gt;Short-Term
Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance
sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value
is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or
liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in accumulated other comprehensive
income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income
(expense), net. For declines in the fair values of equity securities that are considered other-than-temporary, impairment losses are
charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments,
including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments on March&#160;31,
2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;









&lt;p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zT4W6RK5rK4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zN12aHCf3Uf5"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivables are reported at their outstanding unpaid principal balances, net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#x2019;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. Payments are generally due within 30 days of invoice. The Company writes off accounts receivable against
the allowance for doubtful accounts when a balance is determined to be uncollectible. During the three months ended March&#160;31, 2023
and 2022, the Company did &lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pp0p0_do_c20230101__20230331_z1pga6fdJSQe" title="Writeoff accounts receivable"&gt;&lt;span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pdp0_do_c20220101__20220331_zqKYSXNGmcK7" title="Writeoff accounts receivable"&gt;no&lt;/span&gt;&lt;/span&gt;t write off accounts receivable. The Company did &lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20230331_zljQzIUit65g" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20221231_zSaymtCYV9og" title="Allowance for doubtful accounts"&gt;no&lt;/span&gt;&lt;/span&gt;t record an allowance for doubtful accounts on March&#160;31,
2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zy8yXrzUygx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zAajoedepadc"&gt;Inventory&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of finished goods and components stated at the lower of cost or net realizable value with cost determined on a first-in first-out
basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete, slow-moving, quantities
in excess of demand, or otherwise non-saleable items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zasktAHwlD87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zdEHP5BzTYGa"&gt;Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
is recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally
five years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maintenance
and repairs are charged to expense as incurred. The Company capitalizes costs attributable to the betterment of property and equipment
when such betterment enhances the functionality of the asset or extends the useful life of the asset. Should an asset be disposed of
before the end of its useful life, the cost and accumulated depreciation at that date is removed from the consolidated balance sheets,
with the resulting gain or loss, if any, reflected in operations in that period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--PatentsPolicyTextBlock_zOzG5NGCjWui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zkG0LVSPscje"&gt;Patents&lt;/span&gt;&lt;/i&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was
$&lt;span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20230101__20230331_znJU6uuKZbtf" title="Amortization expense"&gt;660&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20220101__20220331_z9xTxJ8RBtp4" title="Amortization expense"&gt;0&lt;/span&gt; for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zN3dnVivAMF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zXYsMlXZIYKa"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets
and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax
bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are
expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. At March&#160;31, 2023 and December&#160;31, 2022, the Company had a full valuation allowance applied
against its net tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcXCxj3XCBul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span&gt;&lt;span id="xdx_86D_zguvg96Hkg0d"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
defined in ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, fair value is the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about
risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or
generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.&lt;/span&gt;&lt;/p&gt;









&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1: Quoted prices are available in active markets for identical assets or liabilities as of
                                            the reporting date. Active markets are those in which transactions for the asset or liability
                                            occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2: Pricing inputs are other than quoted prices in active markets included in Level 1, which
                                            are either directly or indirectly observable as of the reported date. Level 2 includes those
                                            financial instruments that are valued using models or other valuation methodologies. These
                                            models are primarily industry-standard models that consider various assumptions, including
                                            quoted forward prices for commodities, time value, volatility factors and current market
                                            and contractual prices for the underlying instruments, as well as other relevant economic
                                            measures. Substantially all of these assumptions are observable in the marketplace throughout
                                            the full term of the instrument, can be derived from observable data or are supported by
                                            observable levels at which transactions are executed in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3: Pricing inputs include significant inputs that are generally less observable from objective
                                            sources. These inputs may be used with internally developed methodologies that result in
                                            management&#x2019;s best estimate of fair value. The significant unobservable inputs used
                                            in the fair value measurement for nonrecurring fair value measurements of long-lived assets
                                            include pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRVlNQryVQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zV52sLvBiGKd"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of cash, short-term investments, accounts receivable, inventory, prepaids, accounts payable and accrued expenses, and
other current liabilities approximate their fair values based on the short-term maturity of these instruments. The carrying amount of
the loans payable approximates the estimated fair value for this financial instrument as management believes that such debt and interest
payable on the note approximates the Company&#x2019;s incremental borrowing rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the amortized cost, unrealized gains and the fair value at March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zs3t7FXsNSp9" style="display: none"&gt;Schedule of amortized cost, unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gain&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" style="width: 9%; text-align: right" title="Amortized Cost"&gt;5,256,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Unrealized Gain"&gt;41,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Fair Value"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" style="text-align: right" title="Amortized Cost"&gt;5,256,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" style="text-align: right" title="Unrealized Gain"&gt;41,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" style="text-align: right" title="Fair Value"&gt;5,297,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" style="text-align: right" title="Amortized Cost"&gt;6,794,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" style="text-align: right" title="Unrealized Gain"&gt;36,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" style="text-align: right" title="Fair Value"&gt;6,831,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" style="text-align: right" title="Amortized Cost"&gt;6,794,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" style="text-align: right" title="Unrealized Gain"&gt;36,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" style="text-align: right" title="Fair Value"&gt;6,831,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zgTFJ0y0id8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides the carrying value and fair value of the Company&#x2019;s financial assets measured at fair value as of March&#160;31,
2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B3_zCQv7SG86EE6" style="display: none"&gt;Schedule of fair value, assets measured on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt"&gt;U.S. Treasury Notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;U.S. Treasury Notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;6,831,192&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;6,831,192&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0548"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zHJhhT0qg8Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zWmitsjX5Ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zL6qrgolIYrg"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
The dilutive effect, if any, of warrants is calculated using the treasury stock method. These shares were included in the basic and diluted
net loss per common share on the unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including
these potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise price could be less than
the most recent fair value of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B1_zLU5zHzGbeWe" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt;
March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total"&gt;2,662,250&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total"&gt;21,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;21,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zcswmzwYtBwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlC9wDc6glwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zFnBIzw03kOf"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 718, &lt;i&gt;Compensation &#x2014; Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;), which requires the
measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in
the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASU 2018-07 Compensation &#x2014; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the
Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation
methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--WarrantAccountingPolicyTextBlock_z3UGM7qS0ERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86F_zwUktMJPX3o7"&gt;Warrant
Accounting&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued private and public warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815-40,
Derivatives and Hedging: Contracts in Entity&#x2019;s Own Equity (&#x201c;ASC 815-40&#x201d;). The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is assessed as part of this evaluation. During the
reporting periods the Public Warrants were outstanding, they were precluded from liability classification, being equity-classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zxeAWPBgERL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zm3EYQPjFwl2"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
research and development costs are charged to operations as incurred. For the three months ended March&#160;31, 2023 and 2022, the Company
recorded $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development costs"&gt;65,833&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development costs"&gt;11,565&lt;/span&gt;, respectively, in selling, general and administrative expenses on the unaudited condensed consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;









&lt;p id="xdx_84E_eus-gaap--LessorLeasesPolicyTextBlock_ziXIOmBL8Lmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zM5Iphrt0J28"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease is defined as an agreement that conveys the right to control the use of identified property, plant or equipment (right of use asset
or &#x201c;ROU asset&#x201d;) for a period of time in exchange for consideration. The Company accounts for its leases in accordance with
ASC 842, Leases, which requires that an ROU asset identified in a lease to be recorded as a noncurrent asset with a related liability.
The Company does not record ROU assets for those agreements of a twelve-month duration or less. The Company recognized a ROU asset and
corresponding lease liability on its balance sheets related to its office lease agreement. See Note 9, Leases, for further discussion,
including the impact on the Company&#x2019;s unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets include any initial direct costs and prepaid lease payments and exclude any lease incentives. Lease expense for minimum lease
payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate the lease
if it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zk24gkl5K1N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zPZI23trzxol"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February&#160;2020, the FASB issued ASU 2020-02,
Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting
Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments are in effect
for the Company for interim and annual periods in fiscal years beginning after December&#160;15, 2022. The adoption on January 1, 2023
modified the way the Company analyzes financial instruments, but it did not have a&#160;material impact on our consolidated financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ziwgyhRgJr29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zCEbVvtgn9z9"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial information has been prepared in accordance with Generally Accepted Accounting
Principles (&#x201c;GAAP&#x201d;) for interim financial information. In the opinion of management, such financial information includes
all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company&#x2019;s
financial position and the operating results and cash flows. Operating results for the three months ended March&#160;31, 2023 and 2022
are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant
to the rules of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). These unaudited condensed consolidated financial
statements and related notes should be read in conjunction with the Company&#x2019;s audited consolidated financial statements for the
year ended December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_ztxBpm3wVJH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zoJyURshDri3"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Nexalin and its wholly owned subsidiary Neuro-Health. Intercompany accounts
and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zVMkEAgoER8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zu2QFZ1AvS8b"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at
the date of the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zP3wCBc1Jfw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zmmdLmF1qRMb"&gt;Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company
determines if the contract is within the scope of ASC Topic 606 and then evaluates the contract using the following five steps: (1) identify
the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.
These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements
are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its
acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer
of the Company&#x2019;s electrodes will pay a royalty to the Company for a three-year period beginning January&#160;1, 2022. The amount
of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Revenue
Streams&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company derives revenues from its license agreements by charging a monthly licensing fee for the duration of the agreement. The Company
derives revenues from equipment by selling additional individual electrodes to customers for use with the Nexalin Device. The Company
receives revenue from the sale in China of its Devices to its acting distributor and from the sale of products relating to the use of
those Devices. The Company derives revenue as a royalty fee from the China-based manufacturer for electrodes ordered in connection with
the Company&#x2019;s China sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Performance
Obligations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied as long as the
licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time
in which the invoice is sent to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that the Company&#x2019;s equipment and Device revenue has one performance obligation. That performance obligation is satisfied
when the equipment and Devices are shipped. The Company recognizes revenue at a point in time in which the electrodes and Devices are
shipped to the customer. The Company does not offer a warranty on the electrodes and Devices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of
individual treatments on patients by customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
identified that royalty revenue has one performance obligation. The performance obligation is satisfied at the time the Electrode manufacturer
invoices the acting distributor for the sale to the acting distributor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Practical
Expedients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of ASC 606, the Company has adopted several practical expedients including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify; border-collapse: collapse"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
Financing Component &#x2014; the Company does not adjust the promised amount of consideration for the effects of a significant financing
component since the Company expects, at contract inception, that the period between when the Company transfers a promised goods or services
to the customer and when the customer pays for that service will be one year or less.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unsatisfied
    Performance Obligations &#x2014; all performance obligations related to contracts with a duration of less than one year, the Company
    has elected to apply the optional exemption provided in ASC Topic 606 and therefore, is not required to disclose the aggregate amount
    of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting
    period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping
    and Handling Activities &#x2014; the Company elected to account for shipping and handling activities as a fulfilment cost rather than
    as a separate performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
    to Invoice &#x2014; the Company has a right to consideration from a customer in an amount that corresponds directly with the value
    to the customer of the Company&#x2019;s performance completed to date the Company may recognize revenue in the amount to which the
    entity has a right to invoice.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Disaggregated
Revenues&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Major
Revenue Streams&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
consists of the following by service offering:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BB_zKXKMNzW1PKb" style="display: none"&gt;Schedule of disaggregation of revenue&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Device Sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0438"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;264,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Licensing Fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total"&gt;23,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total"&gt;20,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total"&gt;6,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;30,679&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;323,322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Major
Geographic Locations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;U.S. Sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;22,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;China Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;300,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;323,322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zhxXaSYjMQDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Contract
Modifications&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no contract modifications during the three months ended March&#160;31, 2023 and 2022. Contract modifications are not routine in
the performance of the Company&#x2019;s contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Deferred
Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives payment for equipment and devices in advance of shipping. The Company recognizes the revenue as being earned upon shipment.
&lt;span id="xdx_906_eus-gaap--DeferredRevenue_iI_pdp0_do_c20230331_za0NdTo1G8y1" title="Deferred revenue"&gt;&lt;span id="xdx_902_eus-gaap--DeferredRevenue_iI_pp0p0_do_c20221231_zuh5FH9Q2wq2" title="Deferred revenue"&gt;No&lt;/span&gt;&lt;/span&gt; deferred revenue was recognized as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGq05k7CjHel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BB_zKXKMNzW1PKb" style="display: none"&gt;Schedule of disaggregation of revenue&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Device Sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0438"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--DeviceSalesMember_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;264,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Licensing Fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total"&gt;23,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--LicensingFeeMember_pp0p0" style="text-align: right" title="Total"&gt;20,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total"&gt;6,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Total"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331__srt--ProductOrServiceAxis__custom--OtherMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;30,679&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;323,322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Major
Geographic Locations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;U.S. Sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 9%; text-align: right" title="Total"&gt;22,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;China Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20220101__20220331__srt--StatementGeographicalAxis__country--CN_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;300,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_pp0p0_c20230101__20230331_zXNvtvo4vZel" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;30,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_pp0p0_c20220101__20220331_z2RKhYCDDjhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;323,322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31_custom_DeviceSalesMember"
      decimals="0"
      unitRef="USD">264500</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_custom_LicensingFeeMember"
      decimals="0"
      unitRef="USD">23870</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31_custom_LicensingFeeMember"
      decimals="0"
      unitRef="USD">20143</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">6400</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">8000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_custom_OtherMember"
      decimals="0"
      unitRef="USD">290</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31_custom_OtherMember"
      decimals="0"
      unitRef="USD">30679</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">30560</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">323322</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_country_US"
      decimals="0"
      unitRef="USD">30560</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31_country_US"
      decimals="0"
      unitRef="USD">22823</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31_country_CN"
      decimals="0"
      unitRef="USD">300499</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">30560</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">323322</us-gaap:Revenues>
    <us-gaap:DeferredRevenue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredRevenue>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmOBQHnAe6B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zUHANBYlCnsg"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through,
as well as maintaining cash balances, with major financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <NXL:ShortTermInvestmentsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_ecustom--ShortTermInvestmentsPolicyTextBlock_zWieSHVRS2m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zVP5jxNasouc"&gt;Short-Term
Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance
sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value
is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or
liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in accumulated other comprehensive
income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income
(expense), net. For declines in the fair values of equity securities that are considered other-than-temporary, impairment losses are
charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments,
including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments on March&#160;31,
2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;









</NXL:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zT4W6RK5rK4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zN12aHCf3Uf5"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivables are reported at their outstanding unpaid principal balances, net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#x2019;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. Payments are generally due within 30 days of invoice. The Company writes off accounts receivable against
the allowance for doubtful accounts when a balance is determined to be uncollectible. During the three months ended March&#160;31, 2023
and 2022, the Company did &lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pp0p0_do_c20230101__20230331_z1pga6fdJSQe" title="Writeoff accounts receivable"&gt;&lt;span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_pdp0_do_c20220101__20220331_zqKYSXNGmcK7" title="Writeoff accounts receivable"&gt;no&lt;/span&gt;&lt;/span&gt;t write off accounts receivable. The Company did &lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20230331_zljQzIUit65g" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_pp0p0_do_c20221231_zSaymtCYV9og" title="Allowance for doubtful accounts"&gt;no&lt;/span&gt;&lt;/span&gt;t record an allowance for doubtful accounts on March&#160;31,
2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zy8yXrzUygx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zAajoedepadc"&gt;Inventory&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of finished goods and components stated at the lower of cost or net realizable value with cost determined on a first-in first-out
basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete, slow-moving, quantities
in excess of demand, or otherwise non-saleable items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zasktAHwlD87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zdEHP5BzTYGa"&gt;Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
is recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally
five years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maintenance
and repairs are charged to expense as incurred. The Company capitalizes costs attributable to the betterment of property and equipment
when such betterment enhances the functionality of the asset or extends the useful life of the asset. Should an asset be disposed of
before the end of its useful life, the cost and accumulated depreciation at that date is removed from the consolidated balance sheets,
with the resulting gain or loss, if any, reflected in operations in that period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <NXL:PatentsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_844_ecustom--PatentsPolicyTextBlock_zOzG5NGCjWui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zkG0LVSPscje"&gt;Patents&lt;/span&gt;&lt;/i&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was
$&lt;span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20230101__20230331_znJU6uuKZbtf" title="Amortization expense"&gt;660&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20220101__20220331_z9xTxJ8RBtp4" title="Amortization expense"&gt;0&lt;/span&gt; for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NXL:PatentsPolicyTextBlock>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">660</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AdjustmentForAmortization>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zN3dnVivAMF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zXYsMlXZIYKa"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets
and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax
bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are
expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. At March&#160;31, 2023 and December&#160;31, 2022, the Company had a full valuation allowance applied
against its net tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcXCxj3XCBul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span&gt;&lt;span id="xdx_86D_zguvg96Hkg0d"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
defined in ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, fair value is the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about
risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or
generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.&lt;/span&gt;&lt;/p&gt;









&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1: Quoted prices are available in active markets for identical assets or liabilities as of
                                            the reporting date. Active markets are those in which transactions for the asset or liability
                                            occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2: Pricing inputs are other than quoted prices in active markets included in Level 1, which
                                            are either directly or indirectly observable as of the reported date. Level 2 includes those
                                            financial instruments that are valued using models or other valuation methodologies. These
                                            models are primarily industry-standard models that consider various assumptions, including
                                            quoted forward prices for commodities, time value, volatility factors and current market
                                            and contractual prices for the underlying instruments, as well as other relevant economic
                                            measures. Substantially all of these assumptions are observable in the marketplace throughout
                                            the full term of the instrument, can be derived from observable data or are supported by
                                            observable levels at which transactions are executed in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-collapse: collapse"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3: Pricing inputs include significant inputs that are generally less observable from objective
                                            sources. These inputs may be used with internally developed methodologies that result in
                                            management&#x2019;s best estimate of fair value. The significant unobservable inputs used
                                            in the fair value measurement for nonrecurring fair value measurements of long-lived assets
                                            include pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRVlNQryVQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zV52sLvBiGKd"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of cash, short-term investments, accounts receivable, inventory, prepaids, accounts payable and accrued expenses, and
other current liabilities approximate their fair values based on the short-term maturity of these instruments. The carrying amount of
the loans payable approximates the estimated fair value for this financial instrument as management believes that such debt and interest
payable on the note approximates the Company&#x2019;s incremental borrowing rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the amortized cost, unrealized gains and the fair value at March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zs3t7FXsNSp9" style="display: none"&gt;Schedule of amortized cost, unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gain&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" style="width: 9%; text-align: right" title="Amortized Cost"&gt;5,256,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Unrealized Gain"&gt;41,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Fair Value"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" style="text-align: right" title="Amortized Cost"&gt;5,256,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" style="text-align: right" title="Unrealized Gain"&gt;41,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" style="text-align: right" title="Fair Value"&gt;5,297,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" style="text-align: right" title="Amortized Cost"&gt;6,794,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" style="text-align: right" title="Unrealized Gain"&gt;36,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" style="text-align: right" title="Fair Value"&gt;6,831,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" style="text-align: right" title="Amortized Cost"&gt;6,794,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" style="text-align: right" title="Unrealized Gain"&gt;36,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" style="text-align: right" title="Fair Value"&gt;6,831,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zgTFJ0y0id8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides the carrying value and fair value of the Company&#x2019;s financial assets measured at fair value as of March&#160;31,
2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B3_zCQv7SG86EE6" style="display: none"&gt;Schedule of fair value, assets measured on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt"&gt;U.S. Treasury Notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;U.S. Treasury Notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;6,831,192&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;6,831,192&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0548"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zHJhhT0qg8Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zKHtzlES9GKe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zs3t7FXsNSp9" style="display: none"&gt;Schedule of amortized cost, unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gain&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AmortizedCost_iI_pp0p0_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zXAEF48LBHT" style="width: 9%; text-align: right" title="Amortized Cost"&gt;5,256,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--UnrealizedGain_c20230101__20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Unrealized Gain"&gt;41,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="width: 9%; text-align: right" title="Fair Value"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--AmortizedCost_iI_pp0p0_c20230331_zcvnnNYkDeEc" style="text-align: right" title="Amortized Cost"&gt;5,256,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--UnrealizedGain_c20230101__20230331_pp0p0" style="text-align: right" title="Unrealized Gain"&gt;41,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20230331_pp0p0" style="text-align: right" title="Fair Value"&gt;5,297,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizedCost_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zF1mdcPrRms1" style="text-align: right" title="Amortized Cost"&gt;6,794,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--UnrealizedGain_pdp0_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zvbwE6uOUIPg" style="text-align: right" title="Unrealized Gain"&gt;36,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zLgxazE5BYg4" style="text-align: right" title="Fair Value"&gt;6,831,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--AmortizedCost_c20221231_pdp0" style="text-align: right" title="Amortized Cost"&gt;6,794,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--UnrealizedGain_pdp0_c20220101__20221231_zPt6qFhqR0Ph" style="text-align: right" title="Unrealized Gain"&gt;36,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zFXeOZExiWP2" style="text-align: right" title="Fair Value"&gt;6,831,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <NXL:AmortizedCost
      contextRef="AsOf2023-03-31_us-gaap_ShortTermInvestmentsMember"
      decimals="0"
      unitRef="USD">5256589</NXL:AmortizedCost>
    <NXL:UnrealizedGain
      contextRef="From2023-01-012023-03-31_us-gaap_ShortTermInvestmentsMember"
      decimals="0"
      unitRef="USD">41069</NXL:UnrealizedGain>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-03-31_us-gaap_ShortTermInvestmentsMember"
      decimals="0"
      unitRef="USD">5297658</us-gaap:AssetsFairValueDisclosure>
    <NXL:AmortizedCost contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5256589</NXL:AmortizedCost>
    <NXL:UnrealizedGain
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">41069</NXL:UnrealizedGain>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5297658</us-gaap:AssetsFairValueDisclosure>
    <NXL:AmortizedCost
      contextRef="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="0"
      unitRef="USD">6794879</NXL:AmortizedCost>
    <NXL:UnrealizedGain
      contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="0"
      unitRef="USD">36313</NXL:UnrealizedGain>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="0"
      unitRef="USD">6831192</us-gaap:AssetsFairValueDisclosure>
    <NXL:AmortizedCost contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6794879</NXL:AmortizedCost>
    <NXL:UnrealizedGain
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">36313</NXL:UnrealizedGain>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6831192</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztuv7wz9QjY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B3_zCQv7SG86EE6" style="display: none"&gt;Schedule of fair value, assets measured on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1pt"&gt;U.S. Treasury Notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230331_zOftKFLovdz5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;5,297,658&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;U.S. Treasury Notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231_zV4AYyN1XZKb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;6,831,192&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzmWI2FpIbw9" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;6,831,192&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb9EQixzqyoa" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0548"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNy97Gfw7Fne" style="border-bottom: Black 1pt solid; text-align: right" title="Financial assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5297658</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">5297658</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6831192</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">6831192</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zWmitsjX5Ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zL6qrgolIYrg"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
The dilutive effect, if any, of warrants is calculated using the treasury stock method. These shares were included in the basic and diluted
net loss per common share on the unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including
these potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise price could be less than
the most recent fair value of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B1_zLU5zHzGbeWe" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt;
March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total"&gt;2,662,250&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total"&gt;21,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;21,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zcswmzwYtBwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zImOw1zS5SX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B1_zLU5zHzGbeWe" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt;
March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1pt; text-align: left"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total"&gt;2,662,250&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total"&gt;21,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zaWikIG45Sdb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zU5iZyIDj9pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;21,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2662250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">21600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">2662250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">21600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlC9wDc6glwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zFnBIzw03kOf"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 718, &lt;i&gt;Compensation &#x2014; Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;), which requires the
measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in
the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASU 2018-07 Compensation &#x2014; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the
Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation
methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <NXL:WarrantAccountingPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84D_ecustom--WarrantAccountingPolicyTextBlock_z3UGM7qS0ERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86F_zwUktMJPX3o7"&gt;Warrant
Accounting&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued private and public warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815-40,
Derivatives and Hedging: Contracts in Entity&#x2019;s Own Equity (&#x201c;ASC 815-40&#x201d;). The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is assessed as part of this evaluation. During the
reporting periods the Public Warrants were outstanding, they were precluded from liability classification, being equity-classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NXL:WarrantAccountingPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zxeAWPBgERL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zm3EYQPjFwl2"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
research and development costs are charged to operations as incurred. For the three months ended March&#160;31, 2023 and 2022, the Company
recorded $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development costs"&gt;65,833&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development costs"&gt;11,565&lt;/span&gt;, respectively, in selling, general and administrative expenses on the unaudited condensed consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;









</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">65833</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">11565</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84E_eus-gaap--LessorLeasesPolicyTextBlock_ziXIOmBL8Lmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zM5Iphrt0J28"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease is defined as an agreement that conveys the right to control the use of identified property, plant or equipment (right of use asset
or &#x201c;ROU asset&#x201d;) for a period of time in exchange for consideration. The Company accounts for its leases in accordance with
ASC 842, Leases, which requires that an ROU asset identified in a lease to be recorded as a noncurrent asset with a related liability.
The Company does not record ROU assets for those agreements of a twelve-month duration or less. The Company recognized a ROU asset and
corresponding lease liability on its balance sheets related to its office lease agreement. See Note 9, Leases, for further discussion,
including the impact on the Company&#x2019;s unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets include any initial direct costs and prepaid lease payments and exclude any lease incentives. Lease expense for minimum lease
payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate the lease
if it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zk24gkl5K1N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zPZI23trzxol"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February&#160;2020, the FASB issued ASU 2020-02,
Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting
Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments are in effect
for the Company for interim and annual periods in fiscal years beginning after December&#160;15, 2022. The adoption on January 1, 2023
modified the way the Company analyzes financial instruments, but it did not have a&#160;material impact on our consolidated financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80A_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zgs8QBaY3Q63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2014; &lt;span id="xdx_823_zO5DBgQn13o8"&gt;ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consist of the following amounts:&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zWGpl1Uc50x2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B2_zB0TmldCVjSd" style="display: none"&gt;Schedule of accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230331_zwdMPITlfCCi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231_zQdRn0BzFWSc" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAUCzJ3A_zw7745EclQu7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;134,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_zrDMDyBIp372" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Accrued &#x2013; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--SettlementLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_z9P6h78x3sld" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Accrued settlement liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpense_iI_pp0p0_maAUCzJ3A_znBHmHpZLGF6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accrued research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0p0_mtAUCzJ3A_zML3qxSxolBe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;597,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;539,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zWGpl1Uc50x2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B2_zB0TmldCVjSd" style="display: none"&gt;Schedule of accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230331_zwdMPITlfCCi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231_zQdRn0BzFWSc" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAUCzJ3A_zw7745EclQu7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;134,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_zrDMDyBIp372" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Accrued &#x2013; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--SettlementLiabilitiesCurrent_iI_pp0p0_maAUCzJ3A_z9P6h78x3sld" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Accrued settlement liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpense_iI_pp0p0_maAUCzJ3A_znBHmHpZLGF6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accrued research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0p0_mtAUCzJ3A_zML3qxSxolBe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;597,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;539,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">134501</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">111501</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">37159</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2321</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">336000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">336000</us-gaap:SettlementLiabilitiesCurrent>
    <NXL:AccruedResearchAndDevelopmentExpense contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">90000</NXL:AccruedResearchAndDevelopmentExpense>
    <NXL:AccruedResearchAndDevelopmentExpense contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">90000</NXL:AccruedResearchAndDevelopmentExpense>
    <us-gaap:AccruedUtilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">597660</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">539822</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPzBYTBKyOu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2014; &lt;span id="xdx_824_zDOIujGOFkS4"&gt;NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Potential
Joint Venture&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December&#160;21, 2018, the Company entered into the first of a series of agreements providing for the establishment of a joint venture
(&#x201c;JV&#x201d;) agreement (the &#x201c;JV Agreement&#x201d;) with Wider Come Limited, a China company (&#x201c;Wider&#x201d;) for the
purpose of marketing, sale and distribution of the Company&#x2019;s proprietary devices for the treatment of (i) anxiety, depression and
insomnia (&#x201c;ADI&#x201d;) and (ii) Alzheimer&#x2019;s and dementia (&#x201c;AD&#x201d;) in the applicable territories. Wider has an experienced
medical technology team in China and when formed, the JV will design and implement a comprehensive business model and distribution plan
for our devices in China, Hong Kong, Macau and Taiwan. The JV will be formed following the completion of certain funding, clinical study,
and publication milestones, which Wider has agreed to undertake but not yet completed, as well as resolution of potential regulatory
concerns in China. Following its formation, the JV will design and implement a comprehensive business model and distribution plan for
our devices in China, Hong Kong, Macau and Taiwan.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
originally contemplated, each of the parties to the JV would hold a &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20180921__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PotentialJointVentureMember_z1Q4coRZBaC1" title="Ownership percentage"&gt;50&lt;/span&gt;% interest in the equity, profits and losses, shareholder voting,
management control and rights to use production capacity of the facility. The Company will provide an Asian territory exclusive distribution
license for ADI treatment to the JV and Wider. As originally contemplated the JV, if completed, will be controlled by an equally represented
Board of Directors in which neither entity has sole decision-making ability over day-to-day or significant operational decisions. The
parties may determine to alter the equity interest or board composition of the Joint Venture or other economic terms as they move closer
to its implementation. As of March&#160;31, 2023, the JV has not been established.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May&#160;22, 2019, the Company entered into a supplementary agreement to the JV Agreement (the &#x201c;Supplementary Agreement&#x201d;).
At the time of the May&#160;2019 Supplementary Agreement, the parties desired to expand the scope of the JV to include and address the
pain management opportunities for our devices and technology. Pursuant to the Supplementary Agreement, Wider was to fund the JV within
thirty days of execution of the JV Agreement with $600,000 in cash to be used for clinical trials and other activities related to pain
management utilization of our devices and technology in China. Within thirty days of the funding, the Company was to issue 5% of the
Company in common stock to Wider&#x2019;s shareholders. As of the date of this report the JV has yet to be formally established and therefore
the $600,000 has not been funded. Further, the parties have determined not to proceed with the pain management scope of the JV and have
decided to terminate the May&#160;2019 Supplementary Agreement. The parties may elect to proceed with a similar arrangement in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April&#160;6, 2020, the Company entered into a three-year service agreement with Wider, pursuant to which Wider agreed to perform clinical
trials associated with the possible formation of the future JV. In consideration, the Company and certain designated Wider shareholders
entered into stock issuance agreements for the issuance of &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200401__20200406_pdd" title="Issuance of common stock"&gt;450,000&lt;/span&gt; shares of the Company&#x2019;s common stock, and simultaneously with
the execution of this service agreement, Wider contributed $&lt;span id="xdx_901_ecustom--RelatedPartyContribution_c20180921_pp0p0" title="Related party contribution"&gt;200,000&lt;/span&gt; to the Company. During the year ended December&#160;31, 2020, the
Company issued &lt;span id="xdx_903_eus-gaap--SharesIssued_c20201231_pdd" title="Shares issued"&gt;150,000&lt;/span&gt; shares to affiliates of Wider in satisfaction of the obligation. The fair value of the 150,000 shares issued (less
the contributed $200,000 in cash) resulted in a charge to stock-based compensation of $&lt;span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200101__20201231_pp0p0" title="Stock-based compensation"&gt;550,000&lt;/span&gt; and was recorded in selling, general and
administrative expenses on the statement of operations. &lt;span id="xdx_900_ecustom--RemainingSharesIssuedDescription_c20200401__20200406" title="Remaining shares issued, description"&gt;The remaining 300,000 shares will be issued in accordance with the following
schedule upon Wider&#x2019;s successful completion of the following milestones (i) 50% upon successful completion of the fourth of four
clinical trials pursuant to the terms and conditions of the Service Agreements and (ii) 50% upon all four trials being submitted for
publication in international medical journals satisfactory to the Company.&lt;/span&gt; As of March&#160;31, 2023, these milestones have not been
met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March&#160;2022, we entered into a second supplement
to the JV Agreement with Wider, whereby the parties confirmed that the JV had not yet been established and is subject to further review
and analysis of regulatory issues in China and the United States, trade and political issues between the two countries and potential changes
in the use and market for the Company&#x2019;s products and technology. Pursuant to the second supplement, the parties agreed to use their
commercial efforts to complete documentation by September&#160;30, 2022. Wider has continued its work with respect to undertaking and
establishing clinical trials. In light of general economic conditions in China and the United States and the continued impact of regulatory
issues in China and the United States and trade and political issues between the two counties, the parties determined to further extend
the time frame to complete establishment of the JV to September 30, 2023 and entered into a supplement 3 to the JV Agreement to memorialize
such extension. The parties intend to continue to work together to complete the establishment prior to such extended time, however, the
ramifications of the continued COVID pandemic, especially in China, and the Chinese government&#x2019;s regulatory approach to the pandemic
have adversely affected Wider&#x2019;s ability to distribute our current products. As a result, the JV may be further delayed or we and
Wider may determine to re-structure the business terms (which changes may include timing and the scope of the intended operations and
trial studies) of the proposed JV.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March&#160;31, 2023 and 2022, the Company recorded $&lt;span id="xdx_90D_ecustom--RevenuesFromRelatedParties_pp0p0_c20230101__20230331_znUdncemGc02" title="Revenue from Related Parties"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--RevenuesFromRelatedParties_pp0p0_c20220101__20220331_zHdiFFtKRW0e" title="Revenue from Related Parties"&gt;300,499&lt;/span&gt; in revenue, respectively, from Wider on the
unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;U.S.
Asian Consulting Group, LLC&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May&#160;9, 2018, the Company entered into a five-year consulting agreement with U.S. Asian Consulting Group, LLC (&#x201c;U.S. Asian&#x201d;).
The two members of U.S. Asian are shareholders in the Company and include Marilyn Elson who is the Chief Financial Officer of the Company.
Pursuant to the consulting agreement, U.S. Asian will provide consulting services to the Company with regard to, among other things,
corporate development and financing arrangements. The Company is to pay U.S. Asian $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pp0p0" title="Monthly payment"&gt;10,000&lt;/span&gt; per month for services rendered and, on October&#160;24,
2018, the Company issued &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pdd" title="Issuance of common stock"&gt;249,750&lt;/span&gt; shares of the Company&#x2019;s common stock to U.S. Asian. The Company recorded consulting expenses related
to the consulting agreement of $&lt;span id="xdx_908_ecustom--ConsultingExpenses_c20230101__20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_pp0p0" title="Consulting expenses"&gt;30,000&lt;/span&gt; for each of the three months ended March&#160;31, 2023&#160;&#160; and 2022 on the Company&#x2019;s
unaudited consolidated statements of operations. At December&#160;31, 2022, U.S. Asian was owed $&lt;span id="xdx_90D_eus-gaap--OtherBorrowings_c20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember_pp0p0" title="Balance owed for accrued,unpaid services and expenses"&gt;260,000&lt;/span&gt; for accrued and unpaid services.
&lt;span id="xdx_90A_ecustom--OwedBalancePaymentDescription_c20230101__20230331__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember" title="Owed balance payment, description"&gt;A payment of $250,000 was made to U.S. Asian on March&#160;17, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December&#160;22, 2021, the Company entered into a one-year agreement with Leonard Osser to serve on the Company&#x2019;s Board of Advisors.
The agreement may be, but has not yet been, extended for an additional one-year term upon agreement of both parties. As consideration
Mr. Osser was entitled to $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211201__20211222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserMember_pp0p0" title="Consideration paid"&gt;80,000&lt;/span&gt; in shares of the Company&#x2019;s common stock which was waived by Mr. Osser.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January&#160;11, 2022, the Company entered into an employment agreement with Marilyn Elson to serve as Chief Financial Officer of the
Company for a three-year term with an option for the Company and Ms. Elson to extend the term for an additional two years. Ms. Elson
is the spouse of Leonard Osser.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loan
Payable &#x2013; Officer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November&#160;1, 2021, the Company received $&lt;span id="xdx_908_ecustom--LoansFromRelatedParty_c20211030__20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Loans from related party"&gt;200,000&lt;/span&gt;
&#160;&#160;as a loan from the Company&#x2019;s Chief Executive Officer. The loan had a principal of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Principal amount"&gt;200,000&lt;/span&gt;,
an interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20211030__20211102__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zla7wWBIkbbh" title="Interest rate"&gt;9&lt;/span&gt;%,
and a maturity date of the earlier of (i) &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20181001__20181025_zfBcOw1kekK6" title="Maturity date"&gt;October
31, 2022&lt;/span&gt; or (ii) the date of the consummation of the initial public offering. The note was amended as of
January&#160;1, 2023 to extend the due date to March&#160;17, 2023 and to provide that interest payable on the maturity date will be
$&lt;span id="xdx_909_ecustom--InterestPayableCurrents_iI_c20230317_z311nlY3MCGh"&gt;39,000&lt;/span&gt;
less any interest payments previously made. Total interest expense on this note was $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LoansPayableOfficerMember_pp0p0" title="Interest expense"&gt;18,000&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0p0_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--LoansPayableOfficerMember_z0bjApEueQeg" title="Interest expense"&gt;4,500&lt;/span&gt; for the three months ended March&#160;31, 2023 and 2022, respectively. The December&#160;31, 2022 outstanding principal
balance of $&lt;span id="xdx_902_ecustom--OutstandingAmount_iI_c20230517_zDX6M7Uz9KX3" title="Outstanding amount"&gt;200,000&lt;/span&gt;
was satisfied by a payment on March&#160;17, 2023. The March&#160;31, 2023 outstanding interest balance of $&lt;span id="xdx_908_ecustom--OutstandingInterest_iI_c20230426_zkq6qHtkM1O7" title="Outstanding interest"&gt;34,500&lt;/span&gt;
was satisfied by a payment on April&#160;26, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
principle executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056. Under ASC 842 &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d;, we
have two separate sub-leases (through IIcom Strategic Inc. controlled and owned by our Chief Executive Officer) totalling approximately
4,000 square feet of office space under operating leases. Management and supporting staff are hosted at this location. Our lease payments
for fiscal year 2022 were $54,000. Our lease costs for each of the three months ended March&#160;31, 2023 and 2022 were $13,500.&#160;&#160;
The sub-leases are due to expire in 2024. Pursuant to the sublease, we pay the third-party landlord (not the sub landlord) all direct
and indirect rent costs under the primary lease directly for the leased premises. No additional payments are made to the Chief Executive
Officer or the entity controlled by him.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2018-09-21_custom_PotentialJointVentureMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-04-012020-04-06"
      decimals="INF"
      unitRef="Shares">450000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <NXL:RelatedPartyContribution contextRef="AsOf2018-09-21" decimals="0" unitRef="USD">200000</NXL:RelatedPartyContribution>
    <us-gaap:SharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">150000</us-gaap:SharesIssued>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">550000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <NXL:RemainingSharesIssuedDescription contextRef="From2020-04-012020-04-06">The remaining 300,000 shares will be issued in accordance with the following
schedule upon Wider&#x2019;s successful completion of the following milestones (i) 50% upon successful completion of the fourth of four
clinical trials pursuant to the terms and conditions of the Service Agreements and (ii) 50% upon all four trials being submitted for
publication in international medical journals satisfactory to the Company.</NXL:RemainingSharesIssuedDescription>
    <NXL:RevenuesFromRelatedParties
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</NXL:RevenuesFromRelatedParties>
    <NXL:RevenuesFromRelatedParties
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">300499</NXL:RevenuesFromRelatedParties>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2018-05-012018-05-09_custom_USAsianConsultingGroupLLCMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2018-05-012018-05-09_custom_USAsianConsultingGroupLLCMember"
      decimals="INF"
      unitRef="Shares">249750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <NXL:ConsultingExpenses
      contextRef="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">30000</NXL:ConsultingExpenses>
    <us-gaap:OtherBorrowings
      contextRef="AsOf2023-03-31_custom_USAsianConsultingGroupLLCMember"
      decimals="0"
      unitRef="USD">260000</us-gaap:OtherBorrowings>
    <NXL:OwedBalancePaymentDescription contextRef="From2023-01-012023-03-31_custom_USAsianConsultingGroupLLCMember">A payment of $250,000 was made to U.S. Asian on March&#160;17, 2023.</NXL:OwedBalancePaymentDescription>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2021-12-012021-12-22_custom_MrOsserMember"
      decimals="0"
      unitRef="USD">80000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <NXL:LoansFromRelatedParty
      contextRef="From2021-10-302021-11-02_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">200000</NXL:LoansFromRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-11-02_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-10-302021-11-02_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-10-012018-10-25">2022-10-31</us-gaap:DebtInstrumentMaturityDate>
    <NXL:InterestPayableCurrents contextRef="AsOf2023-03-17" decimals="0" unitRef="USD">39000</NXL:InterestPayableCurrents>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-03-31_custom_LoansPayableOfficerMember"
      decimals="0"
      unitRef="USD">18000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-01-012022-03-31_custom_LoansPayableOfficerMember"
      decimals="0"
      unitRef="USD">4500</us-gaap:InterestExpenseDebt>
    <NXL:OutstandingAmount contextRef="AsOf2023-05-17" decimals="0" unitRef="USD">200000</NXL:OutstandingAmount>
    <NXL:OutstandingInterest contextRef="AsOf2023-04-26" decimals="0" unitRef="USD">34500</NXL:OutstandingInterest>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zNfHcaYfEQr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2014; &lt;span id="xdx_829_zAcXptiFc996"&gt;LOANS PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legacy
Ventures International, Inc.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September&#160;11, 2017, the Company issued a promissory note (the &#x201c;Promissory Note&#x201d;) in favor of Legacy Ventures International,
Inc. (&#x201c;Legacy&#x201d;) as part of a commercial transaction with Legacy that was never consummated. The Promissory Note was issued
in the original principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zQcurheG7qok"&gt;500,000&lt;/span&gt;, with interest at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20170901__20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zhpJoN3DCkTg" title="Interest rate"&gt;4&lt;/span&gt;% per annum and a maturity date of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20170901__20170911__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zDJ6PhAf4JE5" title="Maturity date"&gt;December 31, 2017&lt;/span&gt;. As of March&#160;31,
2023, this promissory note is in default. The Company recorded $&lt;span id="xdx_90E_eus-gaap--InterestExpense_pp0p0_c20230101__20230331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zeDNuTBRbupc" title="Interest expense"&gt;5,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20220331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_z2l8b1vGMNXk" title="Interest expense"&gt;5,000&lt;/span&gt; of interest expense for the three months ended March&#160;31,
2023 and 2022, respectively. The amount outstanding at March&#160;31, 2023 and December&#160;31, 2022 was $&lt;span id="xdx_903_ecustom--OutstandingAmount_iI_c20230331__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zpXMLg3FuMl5" title="Outstanding amount"&gt;&lt;span id="xdx_90C_ecustom--OutstandingAmount_iI_c20221231__dei--LegalEntityAxis__custom--LegacyVenturesInternationalIncMember_zzLGXLlzWaUl" title="Outstanding amount"&gt;500,000&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;









</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2017-09-11_custom_LegacyVenturesInternationalIncMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2017-09-012017-09-11_custom_LegacyVenturesInternationalIncMember"
      decimals="INF"
      unitRef="Pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2017-09-012017-09-11_custom_LegacyVenturesInternationalIncMember">2017-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-03-31_custom_LegacyVenturesInternationalIncMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-03-31_custom_LegacyVenturesInternationalIncMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:InterestExpense>
    <NXL:OutstandingAmount
      contextRef="AsOf2023-03-31_custom_LegacyVenturesInternationalIncMember"
      decimals="0"
      unitRef="USD">500000</NXL:OutstandingAmount>
    <NXL:OutstandingAmount
      contextRef="AsOf2022-12-31_custom_LegacyVenturesInternationalIncMember"
      decimals="0"
      unitRef="USD">500000</NXL:OutstandingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_za5wyz67nUJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2014; &lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_82F_zN6WaLyl8tIe"&gt;STOCKHOLDERS&#x2019; EQUITY (Deficit)&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Issuance
of Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March&#160;31, 2022, the Company issued &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zPpxRjgBfSF7" title="Number of common stock issued"&gt;850&lt;/span&gt; shares of common stock to an investor for cash proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zNqSfPY2dc32" title="Proceeds from issuance of common stock"&gt;5,100&lt;/span&gt;
with a fair value of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20220331__srt--CounterpartyNameAxis__custom--AnInvestorMember_zHjt86ROyPEd" title="Share Price"&gt;6.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March&#160;31, 2022, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_pdd" title="Stock issued for services rendered, shares"&gt;24,390&lt;/span&gt; shares of common stock to a consultant for services rendered in
lieu of cash for an aggregate compensation charge of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_pp0p0" title="Stock Issued During Period, Value, Issued for Services"&gt;150,000&lt;/span&gt;, of which $&lt;span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--VariousConsultantsMember_zzt3jlE8TMp2" title="Share based compensation"&gt;37,500&lt;/span&gt; was expensed during the three months ended March&#160;31,
2022, in the unaudited condensed consolidated statement of operations. In addition, $&lt;span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20220331_zWRAV4w6tRwf" title="Stock compensation expenses"&gt;60,000&lt;/span&gt; was expensed as stock compensation related
to shares to be issued to advisors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March&#160;31, 2023, the Company issued no shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
issuance of warrants to purchase shares of the Company&#x2019;s common stock are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbEInnHdAiy2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BF_zm5mnQQWXNkc" style="display: none"&gt;Schedule of warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt;
warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331_zBVoI2Rc0AZb" style="width: 9%; text-align: right" title="Number of Warrants Outstanding at beginning"&gt;2,662,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331_z3YUardUvLFg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at beginning"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331_pdd" style="text-align: right" title="Warrants Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_pdd" style="text-align: right" title="Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0694"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Expired or cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired or cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpiredOrCancelled_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Expired or cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331_zPtNq21ceaol" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding at end"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331_zLMbz8dfVqFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at end"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zOsuExpRFWYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about warrants to purchase shares of the Company&#x2019;s common stock outstanding and exercisable
at March&#160;31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--SummaryInformationAboutWarrantsToPurchaseTableTextBlock_zfJ930USVG78" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_z9B5eNsqGR3l" style="display: none"&gt;Summary information about warrants to purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Outstanding&lt;br/&gt; Number of&lt;br/&gt; Warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Remaining Life&lt;br/&gt;
    In Years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Exercisable&lt;br/&gt; Number of&lt;br/&gt; Warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Outstanding Number of Warrants"&gt;2,315,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_zgBMUlIwzbI4" title="Weighted Average Remaining Life In Years"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Weighted Average Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Exercisable Number of Warrants"&gt;2,135,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding Number of Warrants"&gt;347,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_zLtUlvkJYGzd" title="Weighted Average Remaining Life In Years"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercisable Number of Warrants"&gt;347,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding Number of Warrants"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331_zN6b0O8QSvLh" title="Weighted Average Remaining Life In Years"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable Number of Warrants"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zKBDginqzdva" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
compensation expense attributed to the issuance of the warrants, if required to be recognized on the nature of the transaction, was recognized
as they vested/earned. These warrants are exercisable up to three years from the date of grant. All are currently exercisable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-01-012022-03-31_custom_AnInvestorMember"
      decimals="INF"
      unitRef="Shares">850</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-03-31_custom_AnInvestorMember"
      decimals="0"
      unitRef="USD">5100</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="AsOf2022-03-31_custom_AnInvestorMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-03-31_custom_VariousConsultantsMember"
      decimals="INF"
      unitRef="Shares">24390</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-03-31_custom_VariousConsultantsMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_VariousConsultantsMember"
      decimals="0"
      unitRef="USD">37500</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">60000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbEInnHdAiy2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BF_zm5mnQQWXNkc" style="display: none"&gt;Schedule of warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt;
warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331_zBVoI2Rc0AZb" style="width: 9%; text-align: right" title="Number of Warrants Outstanding at beginning"&gt;2,662,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331_z3YUardUvLFg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at beginning"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331_pdd" style="text-align: right" title="Warrants Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_pdd" style="text-align: right" title="Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0694"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230331_pdd" style="text-align: right" title="Weighted Average Exercise Price, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Expired or cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired or cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpiredOrCancelled_c20230101__20230331_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Expired or cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331_zPtNq21ceaol" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding at end"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331_zLMbz8dfVqFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding at end"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2662250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">2662250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NXL:SummaryInformationAboutWarrantsToPurchaseTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--SummaryInformationAboutWarrantsToPurchaseTableTextBlock_zfJ930USVG78" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_z9B5eNsqGR3l" style="display: none"&gt;Summary information about warrants to purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Outstanding&lt;br/&gt; Number of&lt;br/&gt; Warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Remaining Life&lt;br/&gt;
    In Years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Exercisable&lt;br/&gt; Number of&lt;br/&gt; Warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Outstanding Number of Warrants"&gt;2,315,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_zgBMUlIwzbI4" title="Weighted Average Remaining Life In Years"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Weighted Average Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range1Member_pdd" style="width: 17%; text-align: right" title="Exercisable Number of Warrants"&gt;2,135,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding Number of Warrants"&gt;347,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_zLtUlvkJYGzd" title="Weighted Average Remaining Life In Years"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ExercisableNumberOfWarrants_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercisable Number of Warrants"&gt;347,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding Number of Warrants"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331_zN6b0O8QSvLh" title="Weighted Average Remaining Life In Years"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExercisableNumberOfWarrants_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable Number of Warrants"&gt;2,662,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</NXL:SummaryInformationAboutWarrantsToPurchaseTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_custom_Range1Member"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_custom_Range1Member"
      decimals="INF"
      unitRef="Shares">2315000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2023-01-012023-03-31_custom_Range1Member">P2Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_Range1Member"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <NXL:ExercisableNumberOfWarrants
      contextRef="From2023-01-012023-03-31_custom_Range1Member"
      decimals="INF"
      unitRef="Shares">2135000</NXL:ExercisableNumberOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_custom_Range2Member"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_custom_Range2Member"
      decimals="INF"
      unitRef="Shares">347250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2023-01-012023-03-31_custom_Range2Member">P2Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_Range2Member"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <NXL:ExercisableNumberOfWarrants
      contextRef="From2023-01-012023-03-31_custom_Range2Member"
      decimals="INF"
      unitRef="Shares">347250</NXL:ExercisableNumberOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">2662250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2023-01-01to2023-03-31">P2Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <NXL:ExercisableNumberOfWarrants
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">2662250</NXL:ExercisableNumberOfWarrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zQzMjcwCWYh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2014; &lt;span id="xdx_82B_zNOWUm4a744c"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Claims&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no material pending legal proceedings in which the Company or any of its subsidiaries is a party or in which any director, officer
or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of its voting securities, or security holder
is a party adverse to us or has a material interest adverse to the Company other than the following:&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sarah
Veltz v. Nexalin Technology, Inc. et al.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Plaintiff,
Sarah Veltz, filed a lawsuit in this matter on January&#160;20, 2021 in Orange County Superior Court (Case No. 30-2021-01180164-CU-WT-CJC)
(the &#x201c;Complaint&#x201d;) naming the Company and others as defendants. In her Complaint, Plaintiff contends that she was employed
by defendants, including Nexalin, and has not been paid all wages, including overtime wages and other benefits allegedly due her. Plaintiff
also contends that, during her employment, she was subjected to sexual harassment by the Company&#x2019;s then Chief Executive Officer.
Plaintiff seeks both compensatory and punitive damages. On March&#160;12, 2021, the Company filed its answer to the Complaint. Although
the parties are seeking mediation, the court has set a trial in this matter for March&#160;18, 2024. Management&#x2019;s intent
is to contest the allegations vigorously and, as of the date of this report, is unable to provide an evaluation of the potential outcome
of the litigation within the probable or remote range or to provide an estimate of the amount of or a range of potential loss that might
be incurred by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Employment
Development Department&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is currently engaged in settlement discussions with the Employment Development Department (EDD) of the state of California. This
matter involves issues related to our previous management&#x2019;s classification of certain work provided to or on behalf of the Company&#x2019;s
business as contract labor instead of employee labor. The total amount involved is approximately $300,000. Management has petitioned
for reassessment and believes the hired workers at issue were indeed actual contractors and not employees. We have no business in California
other than one part time and one full time worker residing in California. An initial hearing before an EDD magistrate was held on April&#160;15,
2022. A second hearing was held in June of 2022. We are now in negotiations with the EDD for a final settlement. The Company believes
its potential exposure to be approximately $&lt;span id="xdx_900_ecustom--AccruedAmount_iI_c20221231_zXpYMzZtR1z1" title="Accrued amount"&gt;&lt;span id="xdx_90B_ecustom--AccruedAmount_iI_c20230331_zKLlCUnvmuw" title="Accrued amount"&gt;300,000&lt;/span&gt;&lt;/span&gt; and, as such, has accrued this amount on the consolidated balance sheets as of March&#160;31,
2023 and December&#160;31, 2022 and believes it has adequately accrued for this matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Demand
Letter from The University of Arizona&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December&#160;8, 2022, the Company received a demand letter from the University of Arizona seeking payment of $111,094 purportedly due
on an Investigator Initiated Cooperative Study Agreement, dated as of September&#160;25, 2017 (the &#x201c;2017 Study&#x201d;). The Company
believes that the 2017 Study was not completed and no payment was due. In fact, for a number of months prior to receipt of the demand
letter, the Company had had discussions with the person at the University of Arizona who was to conduct the 2017 Study concerning updating
the 2017 Study and completing an updated study and related work. After receipt of the demand letter, the Company has had discussions
with the University of Arizona concerning resuming an updated study and receipt of credit for some or all the monies claimed to be due
for the 2017 Study. Such discussions are ongoing, and no resolution has been reached but the Company hopes to achieve a consensual resolution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <NXL:AccruedAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">300000</NXL:AccruedAmount>
    <NXL:AccruedAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">300000</NXL:AccruedAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zB8hJXem1pZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2014; &lt;span id="xdx_826_zovszaVFmax1"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the adoption of ASC 842, operating lease agreements are required to be recognized on the balance sheet as ROU assets and corresponding
lease liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January&#160;1, 2022, the Company exercised its right to lease an additional 400 square feet of office space and an increase of monthly
rent of $500. In accordance with ASC 842 management accounted for this as a separate lease and, as a result, recorded an ROU asset and
lease liability of $&lt;span id="xdx_90A_ecustom--LeaseLiability_iI_c20220102_zY4DHYGVYSf8"&gt;11,359&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at January&#160;1, 2022. The weighted average incremental borrowing rate applied was &lt;span id="xdx_90A_ecustom--WeightedAverageIncrementalBorrowingRate_dp_c20230101__20230331_zYkRs2FjZjVb"&gt;9&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
leases are included in the consolidated balance sheets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zm9yV6pGBAd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_z9y3yuQHCM2d"&gt;Schedule of Operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Classification&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Lease assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1pt"&gt;Operating lease cost ROU assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 37%; text-align: center; padding-bottom: 1pt"&gt;Assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20230331_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets"&gt;4,800&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_c20221231_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets"&gt;6,171&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--TotalLeaseAssets_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets"&gt;4,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--TotalLeaseAssets_c20221231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets"&gt;6,171&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20230331_pp0p0" style="text-align: right" title="Operating lease liabilities, current"&gt;43,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20221231_pp0p0" style="text-align: right" title="Operating lease liabilities, current"&gt;50,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;43,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;55,260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_zmgagEbqQoA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease costs, which are included in income from operations in our unaudited condensed consolidated statements of operations,
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z93w3u9sqdvb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BF_zCaqrjlnfcHd"&gt;Schedule
    of lease cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Leases costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230331_zD8L1pqUktEe" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs"&gt;13,500&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20220331_zxPemt28nPq5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs"&gt;13,500&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LeaseCost_pp0p0_c20230101__20230331_zNFzN48KmJ83" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs"&gt;13,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LeaseCost_pp0p0_c20220101__20220331_znFZj38zqeoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs"&gt;13,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zfyOFcOdsCMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancellable leases for operating leases for the remaining terms of the leases following the three months ended
March&#160;31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMJce7mbudu2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_z6rabcvfOcI1" style="display: none"&gt;Future minimum payments under non-cancelable leases for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230331_zXpNELAJW1Ma" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Fiscal Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating&lt;br/&gt;
Leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 88%"&gt;Remainder of 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,496&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zV2GRPFLZ74g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,774&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Present value of net future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;43,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zYjMRwbd27h4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional
information related to leases is presented as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_zvGp0GjQqYHc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zFles555rNB5" style="display: none"&gt;Schedule of additional information related to leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zSXvjrdi0fnd" title="Weighted average remaining lease term"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zTzb0dW7T2dj" title="Weighted average remaining lease term"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230331_zi8EARkc03Z1" title="Weighted average discount rate"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_znIbbghubL9b" title="Weighted average discount rate"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AE_zd03Tzay9aYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







</us-gaap:LesseeOperatingLeasesTextBlock>
    <NXL:LeaseLiability contextRef="AsOf2022-01-02" decimals="0" unitRef="USD">11359</NXL:LeaseLiability>
    <NXL:WeightedAverageIncrementalBorrowingRate
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.09</NXL:WeightedAverageIncrementalBorrowingRate>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zm9yV6pGBAd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_z9y3yuQHCM2d"&gt;Schedule of Operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Classification&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Lease assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1pt"&gt;Operating lease cost ROU assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 37%; text-align: center; padding-bottom: 1pt"&gt;Assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20230331_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets"&gt;4,800&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_c20221231_pdp0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease cost ROU assets"&gt;6,171&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--TotalLeaseAssets_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets"&gt;4,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--TotalLeaseAssets_c20221231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets"&gt;6,171&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20230331_pp0p0" style="text-align: right" title="Operating lease liabilities, current"&gt;43,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20221231_pp0p0" style="text-align: right" title="Operating lease liabilities, current"&gt;50,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liabilities, non-current"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;43,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;55,260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4800</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6171</us-gaap:OperatingLeaseRightOfUseAsset>
    <NXL:TotalLeaseAssets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4800</NXL:TotalLeaseAssets>
    <NXL:TotalLeaseAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6171</NXL:TotalLeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">43026</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">50797</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4463</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">43026</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">55260</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z93w3u9sqdvb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BF_zCaqrjlnfcHd"&gt;Schedule
    of lease cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Leases costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230331_zD8L1pqUktEe" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs"&gt;13,500&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20220331_zxPemt28nPq5" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Operating lease costs"&gt;13,500&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LeaseCost_pp0p0_c20230101__20230331_zNFzN48KmJ83" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs"&gt;13,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LeaseCost_pp0p0_c20220101__20220331_znFZj38zqeoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease costs"&gt;13,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">13500</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">13500</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">13500</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">13500</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMJce7mbudu2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_z6rabcvfOcI1" style="display: none"&gt;Future minimum payments under non-cancelable leases for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230331_zXpNELAJW1Ma" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Fiscal Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating&lt;br/&gt;
Leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 88%"&gt;Remainder of 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,496&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zV2GRPFLZ74g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,774&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Present value of net future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;43,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">40304</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4496</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">44800</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1774</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">43026</us-gaap:OperatingLeaseLiability>
    <NXL:ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock_zvGp0GjQqYHc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zFles555rNB5" style="display: none"&gt;Schedule of additional information related to leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zSXvjrdi0fnd" title="Weighted average remaining lease term"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zTzb0dW7T2dj" title="Weighted average remaining lease term"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230331_zi8EARkc03Z1" title="Weighted average discount rate"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_znIbbghubL9b" title="Weighted average discount rate"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</NXL:ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-03-31">P0Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-03-31" decimals="INF" unitRef="Pure">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_802_eus-gaap--ConcentrationRiskDisclosureTextBlock_zUMVSatOzCke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2014; &lt;span id="xdx_821_zoMDeMDoQQVd"&gt;CONCENTRATION OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Six
customers accounted for &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--SixCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znnltBfHkO7e" title="Revenue, percentage"&gt;94&lt;/span&gt;% of revenues for the three months ended March&#160;31, 2023, as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z7Fi5DMylUp7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONCENTRATION OF CREDIT RISK (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B0_z81OUXVNplM2" style="display: none"&gt;Concentration of credit risk&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbEAUv4QHoSj" title="Revenue, percentage"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBxqhhryJecb" title="Revenue, percentage"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvOq3rqOShIe" title="Revenue, percentage"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhV5UiU86HZ7" title="Revenue, percentage"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer E&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmI8tzKCedea" title="Revenue, percentage"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmZx8itKW0Rc" title="Revenue, percentage"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;One
customer, a related party, accounted for &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZhKOwdmzyv3" title="Revenue, percentage"&gt;93&lt;/span&gt;% of revenue for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
customers accounted for &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEuAhvsn5QQ9" title="Revenue, percentage"&gt;91&lt;/span&gt;% of accounts receivable at March&#160;31, 2023, as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXvItKA0wnG7" title="Revenue, percentage"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZikiWyMYAX7" title="Revenue, percentage"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5fHJCTVXRa" title="Revenue, percentage"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Four
customers accounted for &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlT5Oj9Wdfae" title="Revenue, percentage"&gt;84&lt;/span&gt;% of accounts receivable at December&#160;31, 2022, as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;
Year Ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2T22LTDqV84" title="Revenue, percentage"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOLbwMDeRZp8" title="Revenue, percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdW8hhsp8T08" title="Revenue, percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zunwLJIAVGQl" title="Revenue, percentage"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zuiN6gqlmNq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_SixCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="From2023-01-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z7Fi5DMylUp7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONCENTRATION OF CREDIT RISK (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B0_z81OUXVNplM2" style="display: none"&gt;Concentration of credit risk&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbEAUv4QHoSj" title="Revenue, percentage"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBxqhhryJecb" title="Revenue, percentage"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvOq3rqOShIe" title="Revenue, percentage"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhV5UiU86HZ7" title="Revenue, percentage"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer E&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmI8tzKCedea" title="Revenue, percentage"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmZx8itKW0Rc" title="Revenue, percentage"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;One
customer, a related party, accounted for &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZhKOwdmzyv3" title="Revenue, percentage"&gt;93&lt;/span&gt;% of revenue for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
customers accounted for &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEuAhvsn5QQ9" title="Revenue, percentage"&gt;91&lt;/span&gt;% of accounts receivable at March&#160;31, 2023, as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXvItKA0wnG7" title="Revenue, percentage"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZikiWyMYAX7" title="Revenue, percentage"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5fHJCTVXRa" title="Revenue, percentage"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Four
customers accounted for &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlT5Oj9Wdfae" title="Revenue, percentage"&gt;84&lt;/span&gt;% of accounts receivable at December&#160;31, 2022, as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;
Year Ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2T22LTDqV84" title="Revenue, percentage"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOLbwMDeRZp8" title="Revenue, percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdW8hhsp8T08" title="Revenue, percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zunwLJIAVGQl" title="Revenue, percentage"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerDMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerEMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerFMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_custom_OneCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_ThreeCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_FourCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zWgm55rIv9v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2014; &lt;span id="xdx_82D_zwtfW1TTljb2"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluated subsequent events and transactions that occurred after the balance sheet date, up to the date that the unaudited financial
statements were issued. Based upon this review management did not identify any subsequent events that would have required adjustment
or disclosure in the unaudited consolidated condensed financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MA%K4,1R/NZ_\F5@C4_4/1^.4S>-D<4Y-W'OAI3!H%;E[7G-3Z^#EMM7];&)
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MKV'Z@S"_?[LOP>FP^9I8,_:WKROD8!?K46&C(1MC$-<5U)V-RN<Q2J!%$8]
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M>P1-X\R%S$G+<_3R1HI-<13](*04<7&Y9A0<40+P_%% 5U?=J-/M^K\9L_\
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MMTO;&Y8NR[<A+REC:5Q>+BB9TZPPX,]?TY1]W!0O6*IW?(/_ 5!+ P04
M" !0BJI64_Y)8\ &  !\'P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;*U9:W.;.!3]*QKOSDX[4]=(XF&RB6<2I]UV)J^IF^UG!62;+2!7X*3IK]\K
M((!!J(['7VP>TM6Y5[KW'*33)R&_9VO.<_0SB=/L;+3.\\W)9)(%:YZP[+W8
M\!3>+(5,6 ZW<C7)-I*SL.B4Q!-B6>XD85$ZFIT6S^[D[%1L\SA*^9U$V39)
MF'R^X+%X.AOAT<N#+]%JG:L'D]GIAJWX@N?WFSL)=Y/:2A@E/,TBD2+)EV>C
M<WPRIZ[J4+3X-^)/6>L:*5<>A/BN;CZ'9R-+(>(Q#W)E@L'?(Y_S.%:6 ,>/
MRNBH'E-U;%^_6/]8. _./+",ST7\+0KS]=EH.D(A7[)MG'\13Y]XY9"C[ 4B
MSHI?]%2V]=P1"K99+I*J,R!(HK3\9S^K0+0Z@!U]!U)U(-T.]D '6G6@A:,E
MLL*M2Y:SV:D43TBJUF!-712Q*7J#-U&JIG&12W@;0;]\-K^]N?QPL_APB>!J
M<7OU^?+\*]PLOL+?]8>;KPMT^Q'-SQ>?T,>KVV\+].8^9=LPRGGX%HW1_>(2
MO?GS[>DD!RC*X"2HAKTHAR4#PU)T+=)\G:$/:<C#W?X3<*'V@[SX<4&,!J^9
M?(\H?H>(1:@&SWS_[L0 A]9AI84]9RBL+%NC)>1(AI92) C23K(\2E?ENHWR
MB&<GNK"59JG>K,KIDVS# GXV@J3-N'SDH]E??V#7^EOG\Y&,[43 KB-@FZS/
M;J $78DLTSE9]G2+GJK./,[&GCVUL7TZ>6SCU[2C/B6V7[?;@>;4T!SCY)R'
M_T%B02W*,Y0+*$:!2(,HYB@%S#%@5D_5=:!F<9OQ$$7I_E/H'',*CV1L)TYN
M'2?7.(6+7 3?42 2X(R,J:JK<]=H0X\0Z3PM[=BMR?8]Q[+T4^W5+GA&%RXY
MC!I$@^"]WJ"8=E>AN<T.K&D-:VJ$=9X(F4>_!F%->T.ZKM6!91SAP)7AU_A]
M<W*+=%PD1\R!0A'_J58(UWGB:X+GX8XKFD;$&0@QMAIFLXP@_V$J:U.4,4AM
ML439&H(^SKE,()T?>54!M-QE]0"-Z=3S2 >W&<!>:W_7MQ9K8S._K%FZXEFG
M+F49AY+&TA#%$7N(XN$:59D_4I$ZEK7=8) F&,2<34$@MJJ80ZKSZ)$]Q-JE
M6%G978O$Z<YIO]78H8X]4(APHPBPD6YG=Y)O6!16LZ0%2'M#4\MW>JNNWVR,
MW592[0)L"!N;&?LS)$6:"_FLQ69K4L*WND5)U\SVJ))D6G -96,CTS5SO&'/
M:H)!?$H>,]"A\$3F>LQ.'PP!2NFC/H!EC7G<,"PV4VS7+:T;?68<4X>ZEM]U
MH]\0>SZ=N@/!;T@4FUD44,HM1+JJ\_K%VZ=)QYO2:1=CO]F8N*[G#&!L&!6;
M*?62+[F4 %)R6,9;?20/X$RM5L%]@G:(-216<$.KV,RK5P6=OA1O_:+ND^48
M$])3+=IVV)IZ>HRDH55BIM6;?82Q#CG1L"JFV';M[D+6M206)4,UCC2\27[#
MFYWOLE((["'JR5$)\UC6=J/0$"8Q$^;BU8J(:+@3.[Y/';<[=\:A7U]+24.P
MY#<$NY7!6N7/ZSS3L:EE$4)\VG7M@.]IHVL--1,S-;==VP#I#?FB85_'PGYO
MCHRC'>!(0^/$3.-U\=A(\1B%4$ >GK5)J'6OS^?8(>[4];K^'9G/2</GQ'U5
M?5E&*4N#?>K+ 9_1AOIR)&N[46CT C'KA9?Z$H@D41]@Q3["4LABZM\56ROP
MMHG-D@],N'&85_ UT8@3/$37I-$<Q*PY[MASN8L$3L:"I2UQFJV9Y&L1AUQJ
M/3N6$B%])3)V!I4(:90(,2N1MFNIR'E;>(OE,@H&_-*H#B6,>I+;//SK4Y0V
M^H7NJ5_:)>A-)6;>:C-6NU&KU2@:3S4-!Y<>;80,-4J$PHN0![(0C"#""H_4
MEW]QP7]LX3LX'N*)RO;NA@O!7:VN::9D&!Z28;01(-0L0.9#:&%U/?!5E*9J
M A39<1F)4.N#1I&XQ+.[I*UIY[K8\Z8#/K1V^,URP^0#A\=F]'W5@3W;=[L[
M8YIVMC-UK0$53QM%06TC4=4[>"WR!=![\Q4]0$(8#BJ.9&TW&(TJH695<I]"
M'L71+R@!JY=-P[T%).VK$AM;;O>;Q@SA@(+7:!)JWF/X<GM?;CJ5.X.[GYC%
MZ8?LG<%5KAUK;[\RU#[)P9@ZW7.<2>L<,^%R51SO9JC8(BF/ NNG]1'R>7%P
MVGE^@4_FY4%P8Z8\E[YF$LI+!F%8@DGKO0?3(LNCWO(F%YOBM/1!Y+E(BLLU
M9T#CJ@&\7PI@P^I&#5 ?N,_^!U!+ P04    " !0BJI6&$Q<^_@0  "&*@
M&    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*5:6V_;QA)^YZ]8N$#A +(L
MR7;2-A? <9+&16,'<=*<"\[#BER)>T)QV5W2LOKKSS<SNQ2EV$F!\V*+Y.[L
M7+^YD,_6SG\)I3&MNEM5=7A^4+9M\\OQ<<A+L])A[!I3X\G"^95N<>F7QZ'Q
M1A>\:54=SR:3Q\<K;>N#%\_XWGO_XIGKVLK6YKU7H5NMM-^\-)5;/S^8'J0;
M'^RR;.G&\8MGC5Z:&]-^:MY[7!WW5 J[,G6PKE;>+)X?G$]_>7E*ZWG!']:L
MP^"W(DGFSGVAB\OB^<&$&#*5R5NBH/'OUER8JB)"8.//2/.@/Y(V#G\GZF]8
M=L@RU\%<N.JS+=KR^<%/!ZHP"]U5[0>W?FNB/&=$+W=5X+]J'==.#E3>A=:M
MXF9PL+*U_-=W40]_9\,L;I@QWW(0<_E*M_K%,^_6RM-J4*,?+"KO!G.V)J/<
MM!Y/+?:U+Z[./W[Z\%I=OU$?W^+?AU_/KR[_=?[Q\OI*G5^]4B\_W5Q>O;ZY
M>7;<XC#:<IQ'PB^%\.P!PB?JG:O;,JC7=6&*W?W'8++G=)8X?3G[)L%WVH_5
MR72D9I/9R3?HG?22GS"]LP?H7?NEKNU?FIQCI"Y<'5QE"RV^4A?JO3?!U*W<
M< OUQM:ZSJVNU UN&CAF&]2_S^>A]7"M_]RG(6'@Y'X&*-Q^"8W.S?.#AL[R
MM^;@Q8\_3!]/GGY#O-->O--O4?]_#/L=PM<?7V=3]>,//\VFLZ?J;YX#!?O&
M>2@N>VOAU7ZCKLR=!O'LH\G+VE5NN1FIRSH?JT.B/9L\O?HCK>$;TZ>/U%H'
M14AD"@6K7.>MFQNOIC^35TPG"D\U]MSJ0JL\'@CSC=7'TH"#5:/K#3/^Y&E0
MC;>P9Z.KS"T6-C?8ZXVJ7 XF"Z5;-7WRY+'Z)T"E=6NXR$UG6Z/.SB8C]=91
M9.+>1_ 7U),GD[/'8W5=9S>F@6L03X^9)3!V93KOCMX:7;4EY&N-KYDI7>V+
M.UB8!![=*P_=79>NJC8*G('9T,V#+2Q0%;*HK=Y& X6-=SDI=:%J)ZAHVXU:
M>+=2KTR^P[TZ!(<0"6<^4FWI7;<L%0(Q+_M(9+&OW*WLF\WX+IYMF5"&A :7
MMFYQ8*W.E]YP_$B<59KCZYWQ2U X;&&JJ)%XJU^_=0,+"1+Y@?]DI%#2SBM3
MZ369<Z"U@:*'3C52SJO!H0,WH;/&ZGWG0Z?!+;BG=?M<[<BZHH=%Q@R2="QS
M>BAWJTJ%$KS!@(7Q0>U8#(DN-[!(O82#$_NK%3CG];PPKB*MWN6EKI>&S*O:
M-1C9R+H]BEEI*G9GXKU%0J7']\DQ'K+1(L-3&/ FK^N@8Q:E"$M*->#6#6!4
M!*0M)<>XS8&6>8^LT,NB!]&P!=%=!<P-A";YOT%'/4A'B(Q[:N+FH(>E.@2#
M93!+5ED]MY5MK>%K55A:UM(A19>38R*T&B..PU!!2A;[[\GL<(\<"%YL01V8
M,@2>@6 E=.=-ZYU4(M4FTTU3V:CDV>0(ACR:]G8=*;-8&%Y*6'=/B($?<0R2
M ,RFJY7K6!TU$^YJW166E$;"H9R27]^QR2(&!8+>&+625&XHE>_%/Q^.'[.A
MK#W&ZJXM8;^_"*-ZWTQ.W;K\BUH#&C)2O69I"7G)Q; 4==7#KGK^_44[<4DX
M6-@ J6]-,6*F=^ 07J=7)M,#*-WQIT$"(?Z;RA"K8G"X$937=//*YMBT,%["
M5VVSP90!E90$0ME#6\@L<'A*;@LU&YU,ST:3R>0[OT['TS/U\^CQY,EH=C91
M)Z?Q_^CTR8FZ[GP6%4\B Q(1RV!Z;N#!%-A%9)44>*5#H?]4%[JQ+;B#G;^@
M*T",^*3BN.*&+1>?]ZC*SWJ(WA<_(_%'\,;"B&>%S6J.XC7![M4_?H][F=/M
MW<O//5!#C,;$X"%-<CY"IY&UP D\1=C!ZNRVQJ^VI&,R3/3C;=?Y_5MKLW^G
M"Z,A6P_F"6I0C,\&8/]56?.R"RBE0LBN;U'K4</RV62%"78I!6=A()=KX%"U
MN]4<]S6Y: !H=Y6 3>,=X5.@V.]J^V<'3?#F'BMP#<!OR$GG$?1=O71DYF7E
MYK KQ0;^E>+XIK&%6=E\G'TVB04*0B08'39'K3O2!>"3W-)C:\%8C'4HF/H:
MD&6G#$_Y/:A?31V14TTIN>+Z:%LP BE;U;5 W[_@E7/KN$/SKD8D1/I9V^N.
M09=R$3BZLZ;=Q*P:W*JV>L09!Q[ <M:&,@,.+'RW#'1R$S9YR0"M&W@,H@%W
M[9*S@7 EDDCIER,V*"PC0W%;-M3_X<7KFT?])A8%RFL16+>&RBS*LZ?HTRHD
MF%4#R.DXL%F"ON*ALQKI+F"MO$)>L@O* _,-R_%I?#-6;YPK>/4K"*/.HPU$
MK5F*N3>OSON 8]B\(&+J\C*R.%:?2UN9;$V51-W:NJ.3W:WEL*>60^1PO67Q
M= $?Y?J4'X2NH;!2#4ZFS!"A776A+R1V-;DN+=(#P3I5*7T2S?H<VA>94A^#
M-U((I8"5_D)\U0B-H"O#)J2+%2,-/8*;@QG.(CNG0M"!B#@$*$,!Y.'0N)-Q
M=;O/H4(V*.B,"JX.]>]D^:A:SF(['%.%%DV6IVZQ1L;-)7,2+C$8R<$1TIEC
MSJ*P.#"?IAH09V$B,#=ZLYMW27[:$WVQB"*6\#.8!##(J?AKQ2RBRJ+^%ED2
MVJ,B;B5$]VTFA_8NBE/OBS6R)GMGS<4$-\$!((1(EMS0%[!+BA;J\%JC5QF,
M2D+BK-SR*(<TAH,D\R BS1T41!=GT\GA%S@R545)M3OAA+3/PB%XCI"G5>'R
MCEFVA(RFT;[OUC4O%(H9R4<GD= GZJVN'*%?@6J0V[RS0<!ROX20*;:U+#R!
M#OA-UUVL"J3OX:E0Q=4,FPZ:I4.^8@[D(%W&$2'5/?="L8[JR9USG\;X+"8E
M,"T*X$1@%OISX%TTFRNZ*L+=.SW@"CF%G402BRF&J86N6"^ZN$7)1T+24@:N
M7<B=&\:UU @/-93:0*9#_K$B1"%GW$D.(7LX*\Q25I@QA<&3D_0$DL@"RPT'
M-,BT"76BTTHSA:!"J%./F5<N=)Z#GR%9,L(Z&S"_*S>)/8X^P:>P:PG,]?[!
M$+_&?E()@7;N[5R@6L)X(/@N=L+"6MU:WW9(:"( $+=ETP8+EC1C3>_]'Q'J
M1S$I-P@@8@\>_QZ!:ZE_@>NA7M<1OP?9HH9#^4 ]/)S@ C&(G12O-\CAKZQ9
M]A@>,D&6A9&UDH13& [UU*>S=E#$E&X--Q)X*@Q56+;NXRU2C:4(U)'S$7L^
M$3$DV\40<NAN_E\ '2DD!QI[LE(2$,Z/Z"C0P[!F*[3Y,6?D'?R+DZAX.]?0
MR55:+RT-]:E+ZO,2M,;,)8;O^YPA_%$/T#(+[&\V.,^=.GJ[JA/<:BS(C@#O
MN491)PV%KG*'IE[I.;:-U0?$.C.7\';6NR[" 8*W@@.-K9#[F%U6T$4)O=[/
MV'GU5VG0POL^-8$Y2EZC3,*<%EH]IG$FI\(B43?B9$3U:R+#O2, S;*V_1AT
M95: <A&0RU&>!C V>"6=*EL0+EL#;K)> /P01'I-,Q%"P%^]6\.Y4QL%I)+F
M-574)BY42UF8R\)M 1YHWFYK4=M-G.O/#O6C5(G@'@HN[NK/<[0"V %\V"FN
M?NL 8JU&14.]4:K)R141J0WO$S"=SG9F4;]=O[RAAX/)'($?%2T@C!PGX-+J
M)7M7;GRK>4IC5HT,$;@&N=4H,KK4K)"PWOS962_%0\9PPUJ1)#BO&-!DQA#;
M15&+3?5G*I[NUYXU [<=J3E*95I,D"+5P(BOYV; 2D%M##>YFVT6Y"$"O$>W
MY$L2]T/62>ADDM/):6\1[><:&CZZOJO,9JO=R8S:.?0RAH8O(8&W@X1+&;H@
M?RRUYVB#$O..&R+B"J KQUN9N*#"M#!R'G4:"RKO[C:#@8:8:]\:,L[9%8+&
M<G0H\H&KYY;KE RV)138J%O7\CCF 988!AJ":& /%U(;M:0Y'\(<J):7';;W
MQ1YI'CGEECR"^KA&,BE*B\Z3Q4>]1J>3V>'\T>'T41;UFMPQBA2^87Z6=-?
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M.6W0<FOF7H DXP?-(9"+_XB\N2"_,(1%_$[4-N!HDS-@TUIES%]OS\,W@,J
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MLR<3&4UH!K1NM1MOSYNI[G"\F8V1D[5"AC05,!T/%QAY7#-O-B_!UFG&6]F
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MF;XY?C7_\NKK_:OYQ_G+[ 7[PTDWF[QG;P6?W$_?OU16UQSH_5!PU4HX$,#
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MOW+388->POII?W $;[!Q;.#Q1F\Y!A@K>\BQ8#<X;$=%<&9+GL%%C%ENP;Q
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M-S&:<& *+P=]WJPB%?PL?G3>YR+X#-[G;?J3]V=1(,A^2_!W_*(;[#4HQ[_
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MG9L[NI&RZ)"%H<4J[TISH8E7/HSI44%I'&A](83>&R9!^4QU_@)02P,$%
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M+0MD!'IZW"1 ^:.MV)/2+GLD3B2+]ZEZLJ1C:T;\9"%Z#4*R60 WG1S-QF+
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M>9HE!$! ?LZCJ4( /$"-J\EI$;/8 %+@2$\DY"?56.G:-B,:^\,/H-99CU9
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M!V)<D#Q1=WQ]A64\5F#$$VF_L"Y\.WT'HEPJGI9@K2"EK/B3US(/6X!3;P_
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M*C>(]24A_&D@V_GL\\WZ!U!+ P04    " !0BJI6=/_BMW4"  !&!@  &0
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M/+[?'=C7W7!Q*Q< BMRE229[UD*IY;%MRW !*96'? D9OHFY2*G"H9C;<BF
M1D:4)K;3:'AV2EEF];MF;BSZ7;Y2"<M@+(A<I2D5?TX@X9N>U;3N)R9LOE!Z
MPNYWEW0.4U#7R[' D5VZ1"R%3#*>$0%QS_*;QT%'KS<+OC/8R*UGHDEFG-_J
MP3#J60T=$"00*NU \6L- T@2;81A_"X\K7)++=Q^OG<_,^S(,J,2!CRY89%:
M]*R.12*(Z2I1$[[Y"@5/6_N%/)'FDVR*M0V+A"NI>%J(,8*49?DWO2ORL"5
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M2/U?O#X8ZH%DE>FM<R95IS:WN3I+@>L"]7[!F'P>Z';=GL[)7U!+ P04
M" !0BJI6B4B%S^L+  ")D   &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6RUW6UOVL@6!_#W^RE&[-Y5*[4!FT!"-D%*\?-#$B5I5U?5?>&8(?C6V.S8
MA$:Z'_[.&(-Q,$.0_MU=;0/E_&:,.>.Q?9A<+E/V(YM2FI.?LSC)KEK3/)]?
MM-M9.*6S(#M)YS3A?S-)V2S(^4/VW,[FC ;C(F@6M]5.I]^>!5'2&EX6S]VQ
MX66ZR.,HH7>,9(O9+&"O7VB<+J]:2FO]Q'WT/,W%$^WAY3QXI@\T_SJ_8_Q1
M>Z.,HQE-LBA-"*.3J]:U<N%W^R*@>,6WB"ZSK9^)V)2G-/TA'MCCJU9'](C&
M-,P%$? _7NB(QK&0>#_^*='6IDT1N/WS6C>*C><;\Q1D=)3&?T?C?'K5.F^1
M,9T$BSB_3Y<6+3>H)[PPC;/B_V19OK;3(N$BR]-9&<Q[,(N2U9_!S_*-V I0
M3O<$J&6 ^B9@;PO=,J#[MH7NGH#3,N#T;4!O3T"O#.B]-Z!?!O3?!/3W;?19
M&7#VWG?IO PX?QO0WQ,P* ,&[WV7E,YZSW7>VREEL[/?O;>5]>Y6WN[O_2'K
M':X4>[R]^BP6'V0MR(/A)4N7A(G7<T_\4&1#$<\_OU$B$O<A9_QO(QZ7#V]N
M;SZ/;F\>;CU;NW[4->+<VC>/Y)M^\_CU7B?7-QJYU[WB;^ZN[Q__31[OKV\>
MKD>/-@\B'S2:!U&<D9N L4"DX$?RF7Q]T,B'/SY>MG/>0=%,.RP[HZ\ZH^[I
MC$+\-,FG&=&3,1TWQ)OR^.ZA>/M ^ZH$:/-W=O/VJNNW]XLJ%6_2EQ/243\1
MM:,J#1T:R<.OYXR']XOP3D.X)@_W@U?2&8AHY;QI;\BC-1J>$'5_WPUY^&V8
M\_#>WM;-0WWGF]Y5BM:[#>'6^\/5ID_".[:]#&]ZXYW#;[QRMK?O[COVNMK?
M&^Z]8],EK?OR\ <ZYZTK3?NME@+=S0C3+;S>'N^>QD%.Q^0N8/DK>61!D@6K
M@_9WC[^4V#F=9?]IZ.>7E=MM=L6,YB*;!R&]:O$I2T;9"VT-__Q=Z7?^:DHT
M)*8A,1V)&4C,1&(6$K.1F(/$7"3F(3$?A-4&@=/-(' JTX=VEBV")*0DG9 P
MG<UX]O/)3?BC*>VETK%IO\)."TR<Q+P,3WL=_L]E^V4[H9%MZDC,0&(F$K.0
MF(W$'"3F(C$/B?D@K);0O4U"]Z0)O3ZJSXNC>LAGS2QZ6HC#>E-*2ZUC4QJ)
M:4A,1V(&$C.1F(7$;"3F(#$7B7E(S%]A_:V#FMJI'=1J*=W?I'1?FM(/TX"W
M32)^J&X\>?XB#3\VBY&8AL1T)&8@,1.)64C,[N],LY2&:9:#;--%8AX2\T%8
M+8O/-EE\)L]B,:W^+*YEC\5,>T[YZ?:^P[)4.C:AD9B&Q'0D9B Q$XE99SM'
MA?YN"MJ[K^HU92JR9RX2\Y"8#\)JF7J^R=3S U-H<6,M2IY)MGWD_43&- M9
M--^7M5+UV*R5=_%Q2@G;=+/;Z7SBGY1U=Y=1'),G6G:;1.(N7)BR<7&>OXSR
M*<EY^"2-XW3)PW\3-QW'BYB2Q9R?_O\=C2G[\_=S53G[*R/9(@QIEDT6<3%H
MQ;2X0)A.Z@2913'-\C3AK7^(/I)>YU\K[$#X@O'.\$?BI]]"OI%1&,2$G[$$
M<4;F"R:N3>0D3XN7YY3-,A(D8OA,QI&0LC7UP-_.B&_=]3.C=$:3?/7"#]%V
M9P+^MHB6U@T\T6(?+YYF42Y.F28I^VV^>(IY)XIN1N(_WFI2/.0=F]%QT<'_
M<B01@AC!LTD0YBE[77=SQ+<S2%Y/FD9/Y"=$1V(&$C.1F(7$;"3F(#$7B7E(
MS =AM:%XL!F*!P>&XA>:+/A0P=(9V;YA$=&L:0B6:L<.P4A,0V(Z$C.0F#G8
MF<6\F<!8@YTS$G[X.AT,WDR'D+URD)B+Q#PDYH.P6J8JG:I@H2/-53_(%RS*
M7\F89VE3<LKCC\U.J*9!-1VJ&0?>]^)^OK@EON^6N@GMC@75;*CF0#47JGE0
MS4=I]63?JDY2I!^Z[ZLBJ M;3)#YU/\N> V>8CI:,"9FWY\[C84#<O3H$0"I
M:5!-AVH&5#.AF@75;*CF0#47JGFEMCU5Z@YVKO?XJ$;K>:Y6>:[*#RZ+/,OY
MJ;0X4PYFZ2+)&_-:BAR=UTA-@VHZ5#.@F@G5+*AF0S6GU"0WVLJ,1;;J034?
MI=43NRK^4Z1E1;7$CLJ#>&-J(TN=1E!-@VHZ5#.@F@G5+*AF0S4'JKFE5CO(
MBCJS^CCA01OU45H]LZN*/D5>TN>E09*1<D).;B>3**2,?/?I[(FRYFDYM+(/
MJFE038=J!E0SH9H%U6RHYD U%ZIY4,U':?6AH*H%5%851_@2?P5:&0C5-*BF
M0S4#JIE0S8)J-E1SH)H+U3RHYJ.T^I!0U1(J\F+"]04[0G^*$J3F"_70@D*H
MID$U':H94,U4&FKWSG?.<:WR9=M3W-T9K@WMF@/57*CF034?I=6SM:H95.1%
M@Z-I1"=$_TG#A?@2[_MF\]#J0:BF034=JAE0S81J%E2SH9H#U5RHYD$U'Z75
M!X.J+%$Y_U6S>6AI(E33H)H.U0RH9D(U"ZK94,V!:BY4\Z":C]+J0T)5'J?(
MZ^-6U_J*ZCBV_<6_QD%@MS:KZ:;)2-[DT>D-+7R#:@94,Z&:!=5LJ.9 -1>J
M>5#-1VGU-6JJDCI57MIUQZ(DC.9!++GW7A('TUK>U+%I#=5TJ&9 -1.J65#-
MAFH.5'.AF@?5?)163^NJ>$Z5%\]MKL&Q/96R9?Q@*Z<[)YW!VXR&UK]!-1VJ
M&5#-A&H65+.AF@/57*CF034?I=4SNBJ34^5E<CXCMUEVX,*<W#CV+!RJ:5!-
MAVH&5#.AF@75;*CF0#47JGE0S4=I]>RO:NG4[B^Z,*<B"X]&4$V#:CI4,Z":
M"=4LJ&9#-0>JN5#-@VH^2JL/"541GBHOPANE22:^2+_Z)OD\B!H7[I$C1Z<_
MM/ .JNFEMGV5XGSW(H4!;=2$:A94LZ&: ]5<J.9!-1^EU?.ZJJA3Y<OK?24/
MY#J+@H2(#%_$N:B?-UFZF!./_SN2GP! B^J@F@;5=*AF0#43JEE0S89J#E1S
MH9H'U7R45A\5JJ(ZM?^K3@"@I79038-J.E0SH)H)U2RH9D,U!ZJY4,V#:CY*
MJP\)5>6>*J_<.V9A;3EU]"  K=@KM>TJ5/5T<-9[,W/7H:T:4,V$:A94LZ&:
M ]5<J.9!-1^EU=.[JL53Y0OP%;^.)G[E9_:O8KFYQJR&%MU!-:W4MD_'E=W3
M<1W:J '53*AF034;JCE0S85J'E3S45H]J:MJ.E5>3?<EB%>'[.5J-4BQ;B83
M*W\N$G$%CX@6HY"NUI8LOS_3N R=O)VC4Q]:D ?5=*AF0#53;2AX;%AYUX*V
M:D,U!ZJY4,V#:CY*J_\NK*K4KGM@%361\T_E % >U0^N^"LWC\USJ*9!-1VJ
M&5#-/+!GK]>[4YR*_:'V5FLE+X.,S((Q%<OV?CUY."FOZO+3-#]@X735VOJ7
MM34MYFM!-\*&:@Y4<Z&:!]5\E%8?-JI2OJZ\E._=]P/(_[9?L5FG6GJ_0-[V
MT<,+M%P0JNE0S8!J)E2SH)H-U1RHYD(U#ZKY**T^:E3E@EWU%]TOZ$)K"*&:
M!M5TJ&9 -1.J65#-AFH.5'.AF@?5?)16'Q*V?AFOM"!IN#4YD%U9D"M'YS]2
MTZ":#M4,J&:66FU9N88+"]!&;:CF0#47JGE0S4=I]<2N*@&[\DK NS3G\_PH
MB(F31GS"_XT_6C JG_A#ZP*AF@;5=*AF0#43JEE0S89J#E1SH9H'U7R45A\,
MJO+![J]:D*\+K1V$:AI4TZ&: =5,J&9!-1NJ.5#-A6H>5/-16GU(J&H'N_(%
M^6Z7"679-)J3.64AGQP$SXW?"98S1P\ T$I!J*9#-0.JF5#-@FHV5'.@F@O5
M/*CFEUK]V_:]-[^SNYU-*<VU( ^&ES/*GNF(QG%&0K$LA^C)UK.$T8E8NN?B
M6FVU=Y[7E0M#:7C>5"ZLXOEVQ0\OYWPT\ /V'"49B>F$-]4Y.>,#%HN>IYL'
M>3J_:BDM\I3F>3HK?IS28$R9> '_^TG*ST'*!Z*!9<I^%)LS_#]02P,$%
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MN)H)'9_=?9Y_6J"'^=_SF[L0O0N XRQGZ!.F%,LD>8]^1U\7 7KWZ_N)S45
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M.MP 3H'*#N+ZBA#^TI !FHK^[']02P,$%     @ 4(JJ5E5&,V01 P  - L
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MC(?A0T;D$_K5GPK)U?_E=UW4A81?+Z$/T8E(<0@]2YT2 7P)5O#AG=MV/AL
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M/\U<I?4-RBU:K9M&*SB@]0V+"Q3Z9RCP@G" /CY.GT#1T8.7=%>GZJ(%7;3
MZL6'HH'^O7(H1L,+AWEFWUS)"A<P<O3&D""VX.0?WOF)]VDHU'\2>Q$Q["*&
MQ]3S^PH$5H2M$#5A4<&E0@_WCPA+"6HP>R.86$&SQ;=Y=.EYF;O=S]0')7[J
M=Z 77J/.:W34ZW>N,&U]'K;7:$3'[?5!A^W%G;WXKZ:2$CPGE"@"\DQO1"&
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M    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;*U576_:,!3]*U8V3:VTXI
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M82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3
M%+(F*&1-_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"% ,4    " !0BJI6
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( %"*JE:_S*?6[P   "L"   1              "  :\
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M2P$"% ,4    " !0BJI6::_:B/8"  "/"   &               @($8%0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4(JJ5AL 8E23
M!0  CQ0  !@              ("!1!@  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( %"*JE9/ YV3DP(  .0%   8              "
M@0T>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !0BJI6
MDI(;4CX%  #O&P  &               @('6(   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ 4(JJ5E/^26/ !@  ?!\  !@
M     ("!2B8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M %"*JE883%S[^!   (8J   8              " @4 M  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !0BJI6-_+C37D%    #   &
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M970Q,RYX;6Q02P$"% ,4    " !0BJI6))8/&/T#  #C"0  &0
M    @(&:<P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M %"*JE8SE=-3/@@  'H2   9              " @<YW  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ 4(JJ5B7GW$I !0  UPP  !D
M             ("!0X   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !0BJI6R-WEZ\H"  "R!@  &0              @(&ZA0  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %"*JE9Y&?#?P0(
M  X&   9              " @;N(  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ 4(JJ5O#S\^WM'@  V%X  !D              ("!
MLXL  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !0BJI6
M!(X$]QL$   ;"P  &0              @('7J@  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( %"*JE:0L&J5G0(  +0%   9
M      " @2FO  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ 4(JJ5J&F77+G @  %P<  !D              ("!_;$  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !0BJI6Z"?95)D#  !F"@
M&0              @($;M0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( %"*JE9MIY[4L (  % &   9              " @>NX  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 4(JJ5HL@_:R@
M!   FQ\  !D              ("!TKL  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !0BJI6[_D<EAH#  #<"0  &0
M@(&IP   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %"*
MJE9=\@&[ @0  "85   9              " @?K#  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ 4(JJ5D)1U0PZ P  %@L  !D
M         ("!,\@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !0BJI6KL].51H#  #*#0  &0              @(&DRP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %"*JE9T_^*W=0(  $8&
M   9              " @?7.  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ 4(JJ5EOO5$ _ P  F0H  !D              ("!H=$
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !0BJI6EWG%
MDK,"  "I!P  &0              @($7U0  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( %"*JE:)2(7/ZPL  (F0   9
M  " @0'8  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M4(JJ5BOHV3SO P  W1<  !D              ("!(^0  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !0BJI6548S9!$#   T"P  &0
M            @(%)Z   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( %"*JE:3"N_V>@0  ! <   9              " @9'K  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 4(JJ5MN'"^]_!
ME1H  !D              ("!0O   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !0BJI6;0*0"3$"   *!0  &0              @('X
M]   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %"*JE86
MJU>/@ (  *8'   9              " @6#W  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ 4(JJ5M>TPL%) @  % 8  !D
M     ("!%_H  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %"*JE98=E])D ,  / 3   9              "
M@2D) 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 4(JJ
M5I* G8<O P  2A(   T              ( !\ P! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !0BJI6EXJ[',     3 @  "P              @ %*$ $
M7W)E;',O+G)E;'-02P$"% ,4    " !0BJI65VX1AM\#   *'@  #P
M        @ $S$0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 4(JJ5K@V
MQ-RI 0  +AL  !H              ( !/Q4! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 4(JJ5E/9*RFR 0  4QL  !,
M     ( !(!<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@
& QD!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>113</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/NatureOfOrganizationAndBusiness</Role>
      <ShortName>NATURE OF THE ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/Liquidity</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions</Role>
      <ShortName>NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - LOANS PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LoansPayable</Role>
      <ShortName>LOANS PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - STOCKHOLDERS??? EQUITY (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/StockholdersEquityDeficit</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - CONCENTRATION OF CREDIT RISK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/ConcentrationOfCreditRisk</Role>
      <ShortName>CONCENTRATION OF CREDIT RISK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nexalin.com/role/AccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - STOCKHOLDERS??? EQUITY (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nexalin.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nexalin.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - CONCENTRATION OF CREDIT RISK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/ConcentrationOfCreditRiskTables</Role>
      <ShortName>CONCENTRATION OF CREDIT RISK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nexalin.com/role/ConcentrationOfCreditRisk</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative</Role>
      <ShortName>NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/NatureOfOrganizationAndBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/Liquidity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/AccruedExpensesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - LOANS PAYABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LoansPayableDetailsNarrative</Role>
      <ShortName>LOANS PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/LoansPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/StockholdersEquityDeficitDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/StockholdersEquityDeficitDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCKHOLDERS??? EQUITY (Deficit) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Deficit) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/LeasesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - LEASES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LeasesDetails1</Role>
      <ShortName>LEASES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - LEASES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LeasesDetails2</Role>
      <ShortName>LEASES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - LEASES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LeasesDetails3</Role>
      <ShortName>LEASES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/LeasesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/LeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - CONCENTRATION OF CREDIT RISK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/ConcentrationOfCreditRiskDetails</Role>
      <ShortName>CONCENTRATION OF CREDIT RISK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/ConcentrationOfCreditRiskTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nexalintechno_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative</Role>
      <ShortName>CONCENTRATION OF CREDIT RISK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nexalin.com/role/ConcentrationOfCreditRiskTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nexalintechno_10q.htm">nexalintechno_10q.htm</File>
    <File>nexalintechno_ex10-14.htm</File>
    <File>nexalintechno_ex31-1.htm</File>
    <File>nexalintechno_ex31-2.htm</File>
    <File>nexalintechno_ex32-1.htm</File>
    <File>nexalintechno_ex32-2.htm</File>
    <File>nxl-20230331.xsd</File>
    <File>nxl-20230331_cal.xml</File>
    <File>nxl-20230331_def.xml</File>
    <File>nxl-20230331_lab.xml</File>
    <File>nxl-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="355">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nexalintechno_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 355,
    "http://xbrl.sec.gov/dei/2023": 34
   },
   "contextCount": 113,
   "dts": {
    "calculationLink": {
     "local": [
      "nxl-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nxl-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nexalintechno_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nxl-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nxl-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nxl-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 370,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 36,
    "http://nexalin.com/20230331": 11,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 52
   },
   "keyCustom": 36,
   "keyStandard": 180,
   "memberCustom": 25,
   "memberStandard": 18,
   "nsprefix": "NXL",
   "nsuri": "http://nexalin.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://nexalin.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://nexalin.com/role/AccruedExpenses",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions",
     "shortName": "NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - LOANS PAYABLE",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://nexalin.com/role/LoansPayable",
     "shortName": "LOANS PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Deficit)",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://nexalin.com/role/StockholdersEquityDeficit",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://nexalin.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://nexalin.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - CONCENTRATION OF CREDIT RISK",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://nexalin.com/role/ConcentrationOfCreditRisk",
     "shortName": "CONCENTRATION OF CREDIT RISK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://nexalin.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://nexalin.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://nexalin.com/role/AccruedExpensesTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Deficit) (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://nexalin.com/role/StockholdersEquityDeficitTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://nexalin.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - CONCENTRATION OF CREDIT RISK (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://nexalin.com/role/ConcentrationOfCreditRiskTables",
     "shortName": "CONCENTRATION OF CREDIT RISK (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2020-04-012020-04-06",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
     "shortName": "NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2022-09-012022-09-20",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - LIQUIDITY (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://nexalin.com/role/LiquidityDetailsNarrative",
     "shortName": "LIQUIDITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "NXL:WorkingCapitalDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-012023-03-31_country_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:AmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:AmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - ACCRUED EXPENSES (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://nexalin.com/role/AccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2020-04-012020-04-06",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative",
     "shortName": "NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2018-09-21",
      "decimals": "0",
      "lang": null,
      "name": "NXL:RelatedPartyContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2018-10-012018-10-25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - LOANS PAYABLE (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://nexalin.com/role/LoansPayableDetailsNarrative",
     "shortName": "LOANS PAYABLE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2017-09-11_custom_LegacyVenturesInternationalIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://nexalin.com/role/StockholdersEquityDeficitDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://nexalin.com/role/StockholdersEquityDeficitDetails1",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NXL:SummaryInformationAboutWarrantsToPurchaseTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2020-04-012020-04-06",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Deficit) (Details Narrative)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Deficit) (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_AnInvestorMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "NXL:AccruedAmount",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:AccruedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "NXL:AccruedAmount",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:AccruedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - LEASES (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://nexalin.com/role/LeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "NXL:TotalLeaseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - LEASES (Details 1)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://nexalin.com/role/LeasesDetails1",
     "shortName": "LEASES (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - LEASES (Details 2)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://nexalin.com/role/LeasesDetails2",
     "shortName": "LEASES (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NXL:ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - LEASES (Details 3)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://nexalin.com/role/LeasesDetails3",
     "shortName": "LEASES (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NXL:ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2022-01-02",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - LEASES (Details Narrative)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://nexalin.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2022-01-02",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - CONCENTRATION OF CREDIT RISK (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
     "shortName": "CONCENTRATION OF CREDIT RISK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_SixCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative",
     "shortName": "CONCENTRATION OF CREDIT RISK (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_SixCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "NXL:RevenuesFromRelatedParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN (LOSS) (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2022-01-012022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - NATURE OF THE ORGANIZATION AND BUSINESS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://nexalin.com/role/NatureOfOrganizationAndBusiness",
     "shortName": "NATURE OF THE ORGANIZATION AND BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - LIQUIDITY",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://nexalin.com/role/Liquidity",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "nexalintechno_10q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "NXL_AccountsPayableRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedParty",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_AccruedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued amount"
       }
      }
     },
     "localname": "AccruedAmount",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_AccruedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedUtilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development expense"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpense",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_AmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost"
       }
      }
     },
     "localname": "AmortizedCost",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_AnInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "An Investor [Member]"
       }
      }
     },
     "localname": "AnInvestorMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_CommonStockParValue0.001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.001 per share"
       }
      }
     },
     "localname": "CommonStockParValue0.001PerShareMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_ConsultingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting expenses"
       }
      }
     },
     "localname": "ConsultingExpenses",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer D [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_CustomerEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer E [Member]"
       }
      }
     },
     "localname": "CustomerEMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_CustomerFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer F [Member]"
       }
      }
     },
     "localname": "CustomerFMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_DeviceSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Device Sales [Member]"
       }
      }
     },
     "localname": "DeviceSalesMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://nexalin.com/20230331",
     "xbrltype": "stringItemType"
    },
    "NXL_ExercisableNumberOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable Number of Warrants"
       }
      }
     },
     "localname": "ExercisableNumberOfWarrants",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "NXL_FourCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Customer [Member]"
       }
      }
     },
     "localname": "FourCustomerMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_GainOnSaleOfShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of short-term investments",
        "negatedLabel": "Gain on sale of short-term investments"
       }
      }
     },
     "localname": "GainOnSaleOfShorttermInvestments",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_InterestPayableCurrents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InterestPayableCurrents-0]"
       }
      }
     },
     "localname": "InterestPayableCurrents",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_LeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:LeaseLiability-0]"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_LegacyVenturesInternationalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Ventures International Inc [Member]"
       }
      }
     },
     "localname": "LegacyVenturesInternationalIncMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_LicensingFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Fee [Member]"
       }
      }
     },
     "localname": "LicensingFeeMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_LoanPayableOfficer": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan payable - officer"
       }
      }
     },
     "localname": "LoanPayableOfficer",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_LoansFromRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans from related party"
       }
      }
     },
     "localname": "LoansFromRelatedParty",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_LoansPayableOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable Officer [Member]"
       }
      }
     },
     "localname": "LoansPayableOfficerMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_MrOsserMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Osser [Member]"
       }
      }
     },
     "localname": "MrOsserMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders - Basic and Diluted"
       }
      }
     },
     "localname": "NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "NXL_OneCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Customer [Member]"
       }
      }
     },
     "localname": "OneCustomerMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_OutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding amount"
       }
      }
     },
     "localname": "OutstandingAmount",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative",
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_OutstandingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding interest"
       }
      }
     },
     "localname": "OutstandingInterest",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_OwedBalancePaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owed balance payment, description"
       }
      }
     },
     "localname": "OwedBalancePaymentDescription",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "NXL_PatentNetOfAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent, net of amortization"
       }
      }
     },
     "localname": "PatentNetOfAmortization",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_PatentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents"
       }
      }
     },
     "localname": "PatentsPolicyTextBlock",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "NXL_PaymentsOnLoanPayableShareholder": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentsOnLoanPayableShareholder",
        "negatedLabel": "Payments on loan payable - shareholder"
       }
      }
     },
     "localname": "PaymentsOnLoanPayableShareholder",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_PaymentsOnNotesPayableOfficer": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments on notes payable - officer"
       }
      }
     },
     "localname": "PaymentsOnNotesPayableOfficer",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_PotentialJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential Joint Venture [Member]"
       }
      }
     },
     "localname": "PotentialJointVentureMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_PurchaseOfPatents": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseOfPatents",
        "negatedLabel": "Purchase of patents"
       }
      }
     },
     "localname": "PurchaseOfPatents",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_Range1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range 1 [Member]"
       }
      }
     },
     "localname": "Range1Member",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_Range2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range 2 [Member]"
       }
      }
     },
     "localname": "Range2Member",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_RelatedPartyContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party contribution"
       }
      }
     },
     "localname": "RelatedPartyContribution",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_RemainingSharesIssuedDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining shares issued, description"
       }
      }
     },
     "localname": "RemainingSharesIssuedDescription",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "NXL_RevenuesFromRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from related parties",
        "verboseLabel": "Revenue from Related Parties"
       }
      }
     },
     "localname": "RevenuesFromRelatedParties",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLossParenthetical",
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_RouAssetAndLeaseLiabilityRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU asset and lease liability recorded"
       }
      }
     },
     "localname": "RouAssetAndLeaseLiabilityRecorded",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of additional information related to leases"
       }
      }
     },
     "localname": "ScheduleOfAdditionalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "NXL_ShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "NXL_SixCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Customer [Member]"
       }
      }
     },
     "localname": "SixCustomerMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_SummaryInformationAboutWarrantsToPurchaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary information about warrants to purchase"
       }
      }
     },
     "localname": "SummaryInformationAboutWarrantsToPurchaseTableTextBlock",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "NXL_ThreeCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Customer [Member]"
       }
      }
     },
     "localname": "ThreeCustomerMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_TotalLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease assets"
       }
      }
     },
     "localname": "TotalLeaseAssets",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_USAsianConsultingGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S Asian Consulting Group L L C [Member]"
       }
      }
     },
     "localname": "USAsianConsultingGroupLLCMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_UnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain"
       }
      }
     },
     "localname": "UnrealizedGain",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_UnrealizedGainFromShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain from short-term investments"
       }
      }
     },
     "localname": "UnrealizedGainFromShorttermInvestments",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_UnrealizedGainOnShorttermInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on short-term investments"
       }
      }
     },
     "localname": "UnrealizedGainOnShorttermInvestments",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "NXL_VariousConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Various Consultants [Member]"
       }
      }
     },
     "localname": "VariousConsultantsMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_WarrantAccountingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Accounting"
       }
      }
     },
     "localname": "WarrantAccountingPolicyTextBlock",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "NXL_WarrantsExercisableForOneShareOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, exercisable for one share of Common Stock"
       }
      }
     },
     "localname": "WarrantsExercisableForOneShareOfCommonStockMember",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "NXL_WeightedAverageExercisePriceWarrantsExpiredOrCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Warrants Expired or cancelled"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExpiredOrCancelled",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "NXL_WeightedAverageIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:WeightedAverageIncrementalBorrowingRate]"
       }
      }
     },
     "localname": "WeightedAverageIncrementalBorrowingRate",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "NXL_WeightedAverageSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Shares Outstanding - Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageSharesOutstanding",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "NXL_WorkingCapitalDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital deficit"
       }
      }
     },
     "localname": "WorkingCapitalDeficit",
     "nsuri": "http://nexalin.com/20230331",
     "presentation": [
      "http://nexalin.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r606",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r220",
      "r246",
      "r322",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative",
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r197"
     ],
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r192",
      "r577",
      "r648",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r192",
      "r577",
      "r648",
      "r659",
      "r660"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "localname": "PlatformOperatorCryptoAssetTable",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r189",
      "r330",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r557",
      "r575",
      "r583",
      "r619",
      "r644",
      "r645",
      "r648",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r189",
      "r330",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r557",
      "r575",
      "r583",
      "r619",
      "r644",
      "r645",
      "r648",
      "r659"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r220",
      "r246",
      "r322",
      "r563",
      "r564"
     ],
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative",
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r395",
      "r398",
      "r400",
      "r471",
      "r484",
      "r505",
      "r529",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r558",
      "r576",
      "r586",
      "r648",
      "r659"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r395",
      "r398",
      "r400",
      "r471",
      "r484",
      "r505",
      "r529",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r558",
      "r576",
      "r586",
      "r648",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r636",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r582"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable (Includes related party of $10,000 and $260,000, respectively)"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedUtilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://nexalin.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Utilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedUtilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r125",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r68",
      "r130",
      "r349",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r1",
      "r7",
      "r23",
      "r288",
      "r291",
      "r316",
      "r365",
      "r366",
      "r623",
      "r624",
      "r625",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquisitionCosts": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "Amortization"
       }
      }
     },
     "localname": "AcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r63",
      "r582",
      "r662"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r382",
      "r632",
      "r633",
      "r634",
      "r649",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r4",
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Writeoff accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r126",
      "r152",
      "r177",
      "r183",
      "r187",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r283",
      "r285",
      "r297",
      "r347",
      "r421",
      "r582",
      "r594",
      "r646",
      "r647",
      "r656"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r121",
      "r133",
      "r152",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r283",
      "r285",
      "r297",
      "r582",
      "r646",
      "r647",
      "r656"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Fair Value",
        "verboseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r124",
      "r560"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r26",
      "r75",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r75"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r118",
      "r127",
      "r128",
      "r129",
      "r152",
      "r168",
      "r169",
      "r171",
      "r172",
      "r175",
      "r176",
      "r198",
      "r207",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r244",
      "r245",
      "r248",
      "r251",
      "r257",
      "r297",
      "r374",
      "r375",
      "r376",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r409",
      "r430",
      "r454",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r615",
      "r629",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price",
        "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding at end",
        "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding at beginning",
        "verboseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
      "http://nexalin.com/role/StockholdersEquityDeficitDetails",
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrant to purchase",
        "periodEndLabel": "Number of Warrants Outstanding at end",
        "periodStartLabel": "Number of Warrants Outstanding at beginning",
        "verboseLabel": "Outstanding Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
      "http://nexalin.com/role/StockholdersEquityDeficitDetails",
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 8)",
        "verboseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r205",
      "r206",
      "r545",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r632",
      "r633",
      "r649",
      "r661",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r62",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r62",
      "r409",
      "r427",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r62",
      "r348",
      "r582"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 7,286,562 shares issued and outstanding at March 31, 2023 and December 31, 2022,\u00a0\u00a0respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r136",
      "r138",
      "r146",
      "r344",
      "r357"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r31",
      "r33",
      "r49",
      "r50",
      "r192",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r31",
      "r33",
      "r49",
      "r50",
      "r192",
      "r371",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r31",
      "r33",
      "r49",
      "r50",
      "r192",
      "r544",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "CONCENTRATION OF CREDIT RISK"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r31",
      "r33",
      "r49",
      "r50",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Revenue, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r30",
      "r31",
      "r33",
      "r34",
      "r49",
      "r87",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r31",
      "r33",
      "r49",
      "r50",
      "r192",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r71",
      "r152",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r297",
      "r646"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r32",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r150",
      "r216",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "LOANS PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LoansPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r59",
      "r60",
      "r91",
      "r92",
      "r155",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r306",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r51",
      "r53",
      "r217",
      "r306",
      "r571",
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount",
        "verboseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative",
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r19",
      "r51",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative",
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r116",
      "r570",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LoansPayableDetailsNarrative",
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r155",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r306",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r20",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Monthly payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r4",
      "r39"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Schedule of disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Stock-based compensation",
        "verboseLabel": "Stock compensation expenses"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative",
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r119",
      "r140",
      "r141",
      "r142",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r174",
      "r199",
      "r200",
      "r259",
      "r269",
      "r270",
      "r271",
      "r280",
      "r281",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r316",
      "r365",
      "r366",
      "r367",
      "r382",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r48",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of fair value, assets measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r230",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r296",
      "r326",
      "r327",
      "r328",
      "r571",
      "r572",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r230",
      "r260",
      "r265",
      "r296",
      "r326",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r230",
      "r260",
      "r265",
      "r296",
      "r327",
      "r571",
      "r572",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r230",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r296",
      "r328",
      "r571",
      "r572",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r230",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r326",
      "r327",
      "r328",
      "r571",
      "r572",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r6",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r70",
      "r152",
      "r177",
      "r182",
      "r186",
      "r188",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r297",
      "r569",
      "r646"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Accounts payable - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r618",
      "r628"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r52",
      "r98",
      "r143",
      "r180",
      "r305",
      "r439",
      "r592",
      "r663"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest income (expense), net",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss",
      "http://nexalin.com/role/LoansPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r74",
      "r236",
      "r242",
      "r573",
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://nexalin.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedUtilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r132",
      "r561",
      "r582"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r123",
      "r131",
      "r202",
      "r203",
      "r204",
      "r329",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r394",
      "r396",
      "r397",
      "r399",
      "r401",
      "r462",
      "r471",
      "r484",
      "r492",
      "r505",
      "r509",
      "r510",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r394",
      "r396",
      "r397",
      "r399",
      "r401",
      "r462",
      "r471",
      "r484",
      "r492",
      "r505",
      "r509",
      "r510",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r626"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r310",
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Schedule of lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Future minimum payments under non-cancelable leases for operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r152",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r284",
      "r285",
      "r286",
      "r297",
      "r408",
      "r568",
      "r594",
      "r646",
      "r656",
      "r657"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r67",
      "r93",
      "r351",
      "r582",
      "r631",
      "r642",
      "r651"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r122",
      "r152",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r284",
      "r285",
      "r286",
      "r297",
      "r582",
      "r646",
      "r656",
      "r657"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r106",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "NATURE OF THE ORGANIZATION AND BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash flows from operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://nexalin.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r69",
      "r77",
      "r97",
      "r120",
      "r134",
      "r137",
      "r142",
      "r152",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r170",
      "r177",
      "r182",
      "r186",
      "r188",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r295",
      "r297",
      "r355",
      "r429",
      "r452",
      "r453",
      "r569",
      "r592",
      "r646"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r177",
      "r182",
      "r186",
      "r188",
      "r569"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Loss from operation",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss",
      "http://nexalin.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r311",
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total lease liabilities",
        "verboseLabel": "Present value of net future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails",
      "http://nexalin.com/role/LeasesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, current portion",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets",
      "http://nexalin.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, net of current portion",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets",
      "http://nexalin.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "ROU Asset",
        "verboseLabel": "Operating lease cost ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets",
      "http://nexalin.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r313",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r312",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Schedule of Operating leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://nexalin.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedUtilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued \u2013 other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherBorrowings": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.",
        "label": "Balance owed for accrued,unpaid services and expenses"
       }
      }
     },
     "localname": "OtherBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r8",
      "r11",
      "r135",
      "r138",
      "r145",
      "r298",
      "r299",
      "r304",
      "r343",
      "r356",
      "r623",
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r358",
      "r431",
      "r524",
      "r525",
      "r526"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Non-cash lease expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).",
        "label": "Payment for Acquisition, Trading Security, Held-for-Investment",
        "negatedLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireTradingSecuritiesHeldforinvestment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Sale of common stock for cash, net of financing fees",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r2",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from issuance of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r592",
      "r664",
      "r665"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r346",
      "r354",
      "r582"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Equipment, net of accumulated depreciation of $2,315 and $2,181, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r5",
      "r109",
      "r115",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r637",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r266",
      "r320",
      "r321",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r426",
      "r428",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r434",
      "r435",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r266",
      "r320",
      "r321",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r426",
      "r428",
      "r461",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r321",
      "r323",
      "r379",
      "r380",
      "r381",
      "r436",
      "r437",
      "r438",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r57",
      "r273",
      "r658"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r64",
      "r84",
      "r350",
      "r368",
      "r370",
      "r378",
      "r410",
      "r582"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets",
      "http://nexalin.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r119",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r199",
      "r200",
      "r269",
      "r270",
      "r271",
      "r280",
      "r281",
      "r287",
      "r289",
      "r290",
      "r292",
      "r294",
      "r365",
      "r367",
      "r382",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r432",
      "r556",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r144",
      "r152",
      "r178",
      "r179",
      "r181",
      "r184",
      "r185",
      "r189",
      "r190",
      "r192",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r297",
      "r345",
      "r646"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues, net (Includes related party of $0 and $300,499 for the three months ended March 31, 2023 and March 31, 2022, respectively)",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Consideration paid"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Shares issued during the period",
        "terseLabel": "Number of common stock issued",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative",
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r192",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetails",
      "http://nexalin.com/role/ConcentrationOfCreditRiskDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of antidilutive shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investments owned by investment company.",
        "label": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r54",
      "r55",
      "r434",
      "r435",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of amortized cost, unrealized gains"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r30",
      "r31",
      "r33",
      "r34",
      "r49",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration of credit risk"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/ConcentrationOfCreditRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveGainLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nexalin.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedUtilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.",
        "label": "Accrued settlement liabilities"
       }
      }
     },
     "localname": "SettlementLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Weighted Average Exercise Price, Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Warrants Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted Average Exercise Price, Warrants Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life In Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Warrants Expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.",
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r94",
      "r95",
      "r621"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r118",
      "r127",
      "r128",
      "r129",
      "r152",
      "r168",
      "r169",
      "r171",
      "r172",
      "r175",
      "r176",
      "r198",
      "r207",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r244",
      "r245",
      "r248",
      "r251",
      "r257",
      "r297",
      "r374",
      "r375",
      "r376",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r409",
      "r430",
      "r454",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r615",
      "r629",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r21",
      "r119",
      "r140",
      "r141",
      "r142",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r174",
      "r199",
      "r200",
      "r259",
      "r269",
      "r270",
      "r271",
      "r280",
      "r281",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r316",
      "r365",
      "r366",
      "r367",
      "r382",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r174",
      "r330",
      "r372",
      "r393",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r432",
      "r433",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://nexalin.com/role/Cover",
      "http://nexalin.com/role/LoansPayableDetailsNarrative",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r174",
      "r330",
      "r372",
      "r393",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r432",
      "r433",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://nexalin.com/role/Cover",
      "http://nexalin.com/role/LoansPayableDetailsNarrative",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock issued for services rendered, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r61",
      "r62",
      "r84",
      "r374",
      "r454",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock issued for cash, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r61",
      "r62",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r61",
      "r62",
      "r84",
      "r382",
      "r454",
      "r538",
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock issued for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r44",
      "r61",
      "r62",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r80",
      "r411",
      "r427",
      "r455",
      "r456",
      "r582",
      "r594",
      "r631",
      "r642",
      "r651",
      "r666"
     ],
     "calculation": {
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets",
      "http://nexalin.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r151",
      "r243",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r293",
      "r457",
      "r459",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "STOCKHOLDERS\u2019 EQUITY (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/Non-consolidatedJointVentureAndRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r107",
      "r108",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://nexalin.com/role/NatureOfOrganizationAndBusinessDetailsNarrative",
      "http://nexalin.com/role/SummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDetails3"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org//330/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-40/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r613": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r614": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001829126-23-003245-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-23-003245-xbrl.zip
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M;&QN-O.E[&&QP86F]XAL@A8PML@#^0/B 0]&P*NJ/8UDG0ZZT!=8#'XQ3)Y
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ME.>VK/M6]>2,+V03I3P_=U%6(,965Y^O",GI))]^"9+SZ40AFPD/R<L=G]9
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M%Y?[R1M0R5\Q%8*2F*B"VJ"#3*:#4!<U,_7.<_&Z4BVD_OX4<U)$C/KJV<P
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M0_?LU2"CTFQ4:XU6K7I\!!];S>MZM=RN85MJ^.>FUFBWN.8%U[RMW97;=7B
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MM6Q\M4((O%/'4F]BF)[D6L/NM"_)-)B]S$F=YZI6X/4_H\<OUYOX(;O<4W(
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M#I[)O%2>_WR0LK5N3A9(Q VF \8X<OSC0?#60Y%$::.]A:U'(J$C+32)RQ;
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MN?>$H:R,/RX;G#YK@.YD:YE 8#/*Z(7+3H*DT:6[7SBN>VK6<7=NK0\/EO:
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M.% AKNV/P1:IXBGW#J4KG?K4^,;9#]$O^$_ON4?!H+$.N*802#5%4^L2G2&
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MNJ<OZ8)JV)DZ:DH<M!)8KJ;W!55^9CBF$.(K ^H]8.)U*GMR?.27/IE!09<
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M)&*OP%$GWJQR'V(:7;4WL$$*43?0&,Q>KJ.*!H)A#SZ>*G; & RA!"FV9_$
MZ7@+="'T-*9-)8G0\@&:K1QI+%24,,B0P?^EGABK,3(&\HAY3-]EC!0J*&C7
M+$P^]?F.8_J%;O5[AK/3DL='L\CWY-)9]@]!+!N8BSR?.#HT38LH4ZGTTW[X
M%$?4+YKD,7 (U%0>G'K./%2:W^K5)%\"=QMFP4HS=P\("]#11>+&!/X'ZXLG
M72(P&9E@H$XRGW9/62RA817,^+A!%,67Q1PHD89= BZ]H^^QTP"C&IYV9_R'
MRP5T./>)24XAB5.U80]^RMW:M3EL;BSV&!%MI-@5(G0>W;T\P.9>6>>&V*V
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M'V Q!6C[9,L0:I]Z[3']G8Z!,V?1'-'PWG&-#2#76'W?%[?8EY$:=,LF84!
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M->29-B&+EHIHB&8+W%CD(T1." ^Q!9!MENEWW9;MR 8#5D;X))?(#5@]<VB
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M7,">F1F /3--KUHJ_OQV4[PYFY)X]U%Q/2N+XGH6FYZ5*?YV<ZZ2<85$VFW
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M.:63!_NB,:CXVP/EHKH\@BP#:"_&CQD35:?<\8AM.[%EX*S="&.:\TU_,&[
MW6PF=P"<2L#KHM/X)2!G%?O4)[1:CMU7<MV ,O_?IRD@P$*?VYCOC>?2?/I:
M]:]$C5R)F1K+CHV\94L.V+WTC=SZOV+-06KK,I:[ZN;!R>TB$SRW;[NRL>M%
MQ4[B.MTFLKW=;%;4WGJ%6@U3NXKY?^(D1R/6O(^NG*MN_TSN:>P_-FOOXDH
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MIZ%'+4C&X$<*/X)DZ$(@Q. >8;QV HN0!^0.0CB3[1,??'^/8L4IY&6B9XU
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M+^^4A5.96O<B2QTBS&@\MQV<722D"R<L33A@OR0C>%!(QKEE5G,?#5F4>\*
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MQBDO%I-7$ST*<*C1,.^(B>AT+LU$=":=9:K^+4C5R\ZIH6@OFN+*.I7$U P
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MV($M: L\9:OH[3NC3BAT@.XX[UHX[^:)>J:+Y*)M928TOH_(<'*5;4?PI4^
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M = LPZ%0.,)0)NR/Z@H16!05U^\B59?SM:N&+X_7\.5L)&)T,E9-7AX/['?
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M +5[0M 8T!#]+K(')AI>T]!C])<<1[Z@5 ""7OGAOI90;= GT2<@K;4KF5&
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M*CVAX @A,<'>$.&:_A#\B[5Q=X2><#>WM(M. M":T1!'1B\YI+;!P7X)L_Z
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MX!$VF%Z8["SMP2$P]-!SV2[H <]01AOE>9FWE\?<9;I9R:M!1?'#,7^;VS8
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MZH!A^O>\>#A&#2"+^K'MZL1[JLJ3>0"8X\9)7U(&P.IAEL#;HPQL.4K+UT6
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M(K.=B(B_7>]_H&!_Z%U]S3KR C=KC<8,V9>>Q$.!6*3=KV_4ZHWV;[O]%1"
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M?,Q23YAS1GG@+$U+<^#$X=<QC3YT!G0U\&,^)X _7Q"74%,DW"PNS"K32_.
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ME087ES;5BX)J>6D\\)S!='40RC[9LP #>QF\A218V"M(I2HY>V$9@38 #\$
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M%'W/X1&K6>(%(BFN" (?'L4K3=9P&J)ERZ+;:>1,&%<"5U9\4C(HU4,^ "<
MRI3Z4^,+=>\&6Y4M%@Z0<M=''B =CF3/")%3FEHJS\B8U"H/PAS$A]GHZ80
M]9(D4\-6X?!)WT45!LO Y8UCGR-Z*UYI%MB9ZU'[WA";V"5<W6BT]975[72T
M\('L.Q_BBFJH.^7,VRYR$?Z:<&"(]E2Q%#(!NO+=PBEWL<A/%3%J=+&Q/-KJ
MASPQ%8L L9135UP^B+'0U91VVP\#> #K+&=']6ZV"\2_O%3>1Z-L_JU!_@O'
MK1=8R'!);9C01(8 'HU28]!78Z,F&XFET\RN66LUVC28&?DBQPU;ZYNU9KN.
MU_N.,K38(0#@'A+3\*USGJ%[)J<_6RNX+K+X9OUO^<SRTM1#]'7C[V?($6RD
M9:;//]?7&FT+& 8!('O K-4;])%\/>6!(1]&188F$-<V&O7:9K-5Y,#$7+&_
MFAI+S;7<%(K]LU&K;VS6ZIM;4W,_K3^WX+.M]A;^FWJ2C$'ZX'<T %LQ/NK%
MSUTHMK9JL%%F+E@!K8K;)7^;<T@5/3P6/>C"_2#$ZFN>!XUZ1(",M@\2*T"A
M*:]K2D&Q5 T$?.T*'QZ.D:(\NF<J&)?"F+0OP.4L0)LG$2+(\61H@RB(O410
MNP*;,QR7EU"8"N"_&:,+"B^M]3$U</92P)*8\6U C0-9QKC\RJYP["PQ?F!6
MC++?CE%P:DH[4O$4:R"V,*T:)F:!AY8@!<XOA0=J7"#ID]Z$522M KE*;<MK
MQ'2GPP#NWTI!=QEIM175!H9"RVZ7FA'TI I0)H KBGH\JW(7>:*#;%W.-$%T
M.@?]R%$%AI>& 7.4N?VASD/9ERTC*M/SL?NXE"BVUOUZ+><:"6Y5*GN"QFY>
M)RK[IN \'7(/LI]0(05(=E@Q\H6RN):7V.2R3(N+U[=-IO6-P!K=9< T0R4(
M#(M$<9Y$=O08VC< B&I>PC_[I+&4N*I-*1JR%RO&.'!?0^Z&BIHNC8BJF8,<
M:U(!,'6$FAZ#E4,C[1 \'G,B%\W;,08<R:#+-YT#M43IVB@48(E\G\BH0=4!
M@QK+[Q#(V$-_'O!\[/("%Q2+P)5;&.D3'8'T @- &I:8?D]5@-3;!=X#<A$>
M)D31+60$*T\LD;S8R88))<(E-=7>-O/Y)+EO#E8L,WH V)[*]:<1@OG%V-TP
MXRMQ0!4D8PWEIS!N9.88^3)C,O<0/)<F/T6(SJA*DH%*V](>!3@Z)98Y"E;$
M$]0AAI'T<9 >' 9LE1'D:Q;0&GH',NY@1-M$#<#U4.[R&UF*Y>OR6?$3<@!9
M_HZ8K$^I!%12[I' ?C?P?'G_4\XXS=JTO(MQE%?BQ%Z76>0PI$]2V_/QSU/L
M-]="OO/-! U<(HJ$36J;\!,A6TH%W,CI (A'VG;UU3<UDR@)_9%BC(C,G"V
MGIR@"I: EB?EN]**-0FR%]E 7-DB._V.3+Q"\<=3Y"[8B%E>NA!.V ^(QU1Z
MV2-/%%.F5LQW\$7DQB5E@*,M)9MZL&4(9EQ?>ME)!2._N/9LDS>VBQ8H&V.>
M<*GG&^H<V% .'2,BFG'N8C\Y].FA<Q@3T*7Q*7_";Y*4GCAA1&K,]N6N=15&
M8%1NU#>4JA-H\9D4%\D2U?XS9T8]]!@GJ8B2OZR5QC/+PZDA<,BJ=$?^5'<D
M4=O\VUIIYD\S_RD_(GBR]<S2>^,@20PVN\TURN1[@H?6GUF@Q8:.G<X\0RT0
M'=WE;>Z+\ !6VL_RBRS>XPKZK9)GW""/VR2H&\))E.7+3CG%P\ O110)&F K
MZ@\JX."AFSSLLB^9%*&",%,_QO^-$V#"%*! 12ET''(<P ]42T&!0P@JWOPS
M& -YBE0("R0V"%+5@!$4=IN\,.B?M.Q^+,SZV2)C4!X7PUET*FZQ4L[:HRB7
ME.1>+#M/.A0-NB)EU5@ZM_B(U2!AD0:.I7(3#.?0N^T,7@LH[ !Z!6(,V 5,
M176\+'B"4/D8"O;V*A,+FRI&;#\47HY5PL#= $]!>R!WD3^9"KSY24@].),\
M'67*)TNE,XG44V2,<#KV1PO@^>V5!P !D)D((.V@[-7$]\+IPY<K%U\\H*FT
M%^'$]H$_;*N-<Q/1[D3&1'7SE9C<V66>2X&9>@"%D"TM(YM&-LN%B^Y.Y5+'
MV/$J7:&<.=(5@/.487P$[[3CB50S.8(@@V=T91H.!3KP'LP])AVR6?^7VC0_
MG>NEYE[0J1C284OP2HY8(;$*]!'7TUO]1?C3O5E*C2I+R<Q2ZE192I7L- <D
M:[OF$@7DL)J2_+-4%V!"F%22MU<F_Q?*5=9C"HH%B#=G0+""<J.DNZ'PH(JC
M^+^;Y:X&$A5JF2F%N1P 5#\X\Z4[T0V[[;S1O!<  7LNBB]#CM)T$3N5@;"N
MSX*JJ&"A?-?6BE2OEI=8U!<E/6CQP@1-NP99MFE]0R8^*3UD;OX1UQ(7UC Z
M'6A%!"RK*4T$W3ZENLC4V5FDFB@-@BY#O8T@746/LUN4Z'@DQ@F25"*7$3DU
M ]DG2A_8M!+#)T!M&WX1T?[TP0;V>9Z;HLM+9[F)6['1QP/[Q$@5D'X.3X7\
MDZR;D)*3&MQ142E:$&B*S?<GP KE7]+X N4T0G+WL?N\G7!D)G^5]LN "0?F
M7()A&,^5V7;D0&!O"QI=S%)FP<3F^:SN:T-.+:#]&ZY,#PH]RE&DB05P&H$,
M&E&& *_!@Q?0L @+?J**:SP!=*4@FI:XWQU/R;E6M /UR! 2F>@R2 9>%.4N
M (T?&.Z3J9N4& /H-N8\LPF&]Z:6Y5:F)"D7[H9^0<0J>K\>CECSOBOB519)
M!"BD5"'_T<JA!H!BP;K?"BJR2BNL$.4)( H5LQJ*Z_="D:*(U*_0QLCRTH,E
MI/IMF7S4'*Z@6]ONR$MDD$6I[-JOIN0B[A2#0<M+E7C\R4HU^]0Q:V[_%D01
ML8I*HW[$5. $&U_%J8I<;M0W9LM;;#>D'+8$8V)Z!I=*E^)+RP<T_;5PAU -
M6WH P-6PI?M!KYIFR*,P4IV7E_+9M,A40,4 F4O>K.;?F)8E+0TN#%.QR*&7
MZ.12F1R:8&<_6_=0ER/UJ-X.4QT+4?Q\UJJC7@G"WJ,$7368D2KORA- I+Z@
M W[I&%-'2.,8RRP(-HLTI/TP=,D44J'3::U"-R^461SJX\B>J"BTK8<XZO&
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ML&1'L.6E8>BJL#AP27M2 ,J&8YA@55E>ENOEB%2SNAE5E;F>2PX $@*VA97
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MWM!Z"0@>6<?'N_]^83\^01$R/65R:@$Y5=3T^-3TK<14W^QL;)C$% "B]2=
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M14CL7BY1&7^ EOPB#7^X]C]02P,$%     @ 4(JJ5E?CQ9(6"   TC8  !@
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MSW%#B/TKE/WRSXMJY=>Z3GTC)?$8MF40<+@\T:<&@EU"%3-H!_#RD6 (2L+
MQ4:"ZQ!'8+<)I"U,77CM<^T)J1,8APE-26%1/U728SXT@].< ,I]!FYCH=SY
M[H4T&C/2A%QQEPBF%Y4@+5;.3YC5I7+NVRM[R;$FC:S/X2P$LTK&%:UKH$;/
MS);/;9XN6)LN@.G0YL=N"CV03[Y, 7=5 1VN 'I+)=P)/<WGVDR#?-AI0U5^
M#$8':91'$[W]$*0S(P:02F>R!$DF"@1 J'[@&A, I 9)6&0$876\2A[9!*28
MH :D*45:0<Q)DQ/>Y)!'0!DM!?=I;#0=:>YSJ,71 FZ)G$F)$4I*- %N99P;
MO VIF$D84C/0*(8$A:.F%"-I(B@F.C#,:+%B:3#"<KXL5X5O(X8=(17!>.;O
M"S!'Q&^%^!$@_N26*CI6=!J:<@#A,4V43C!, 1:&G1:Y8T#+8?/[4I=(K5:\
MJ-8NSFKOBN]^_7#QWJ ;&VL?JJ;Q0ZU2.SUN[$$WUH.-[3Q0D1AW1[=D00",
MDS^P"&JZI\1QF=*WB%_V<C.7-'$,!D+HP3 &X8..9!(_K\(V(98N>S,DY,&&
M:I"L%X-DA%P?CV-,4&9V*4"A.B@4^4=P'A*</N99N^U/\8.G%RF=,W<V@G1[
M\F92I_2\1"%(,FGJJ=1\;B)U##?P]PH0IJ%,6)SPD9-G- D [W'XN'>JN8=!
M$T]>\% F2I:*G5JU0JJ761UR*#7NP7Q(_< IS(I0+2.@RG,B^#T3Z3G,HP'.
M7UZD.OD[NL2Q^MQU]7G^YJI/<V3O+T*-L\H*F*6RWKY*$.BO/_ <5"9U'><I
M\5ZJ1X%\QU+9=(9]3 /(G!B:Q5Y(PB-)E4ET/@<%C9 3B F0\C2> L$GE@ P
MOSU 8M\2#@:8L)5$GCDJ.CV6EJ\HY6%IV12"8,G' :1(KO%,P>,,()5RJF6%
M-V/T'CD2TXM,8HM%<V2_. S< JB9/&AK,2BY$+P;T@KU8:1FRZSR+*A'7/#8
M# %D2@5.99B:!NMU,H$5!K.--6D^WWAP>F1AAX<DUGY-(%N!@KCD $"8":<
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M)XDK)&ZP_N O/8JP2KUE2%:;-VW[X!;ZR1/_6M-ER-I29"6+JR2KX1\D-S\
M/\ES<0^[[#/.<\EVHF(=!-FSNNVXEAXZ6A#BVN#ST39A@-!).51^P\Z:HAV1
M\0QIIH7Q7FSX9V&P8)EZ;=9@'U5V(<%2'&F/T+N;QXGT<B"TYT$83V"X,-$#
MC%:%2C%B=&HQ@$ZE L324R4\UN/F: P=B-T(#X L&/.C 9-+#)^N5'Q$]%8)
M)^)&"#?[C,4LQB5-)8;#F50<:'JI9/=1".^!MYFRP2%W&,]A*)@TA9C%4'HC
M%:425E )O)6 O*)&E8Q?%*E4M_)Z*R.Z2P9L8R+-<#;%;D($+S8^ATV-)%^
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MC=!39\R4B';:<'NI"0"*5( '&7*0#D/+V1AAQW<(G9.$O[O)=SC199.,I4.
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MH?V(LBX!RL):-F5 .LOC<SR.C(F\/G+'';^)YFZ(/"6'LF)E70N4B3>E N
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MEF=\K.J9.D )TM3^8%R_*A?,;#6F+NEUDGTR'8/7J[@=!LW@NQ^U6AZ,$;4
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MD#*]3X*/7!%EMH36=@C],DZRB&QQ0^LLW>M^5I6:G]M9]960W\TJU_'.OH%
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MK3U&1)+D5%1EHFQN_VOP!U?LPRQ<AMG5:>#DAR_9UC@F=/K !+LAR[OM_EE
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MRZ-%?BC*?IN>N12\BI\<+^ ^1;$%\A7, IG.V!\WO2&S/D;7K=&X-VG/^JQ
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MB&"3B'A/ZOL:L-K8[NP*M.AXE8/TRF;^F))'Q].GP-371'>(-S ,Q.B\LB'
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M^%/![(7J\Z]*IF'QR>F_?7=Q_FWAS>FL):24T- 'I6UY.7J?!QX!9S1A#)I
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MA4.]1IJT8<>D.H(;1"A]P:&/3[?NTH.HK!WTF0]:!6=-JH@W=!1%Z@<']HI
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M(9]5V@U=4P5L:-J"NEXD2R9"P1;FT]6;\X2ZK(-9F@TR'QG[#2#-0/FTV',
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M=?+G4?EO^'_NG(BPG_Q_4$L! A0#%     @ 4(JJ5H78!Z\+,@$ J/P* !4
M             ( !     &YE>&%L:6YT96-H;F]?,3!Q+FAT;5!+ 0(4 Q0
M   ( %"*JE:&K0)H=0P  ')$   9              "  3XR 0!N97AA;&EN
M=&5C:&YO7V5X,3 M,30N:'1M4$L! A0#%     @ 4(JJ5BX=N+L2"   OS8
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M &YX;"TR,#(S,#,S,5]C86PN>&UL4$L! A0#%     @ 4(JJ5EYY?T+T(
M2?$! !0              ( !Q'4! &YX;"TR,#(S,#,S,5]D968N>&UL4$L!
M A0#%     @ 4(JJ5D.)CB^Y0@  !;0# !0              ( !ZI8! &YX
M;"TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ 4(JJ5M"Z"",7,P  FC$#
M !0              ( !U=D! &YX;"TR,#(S,#,S,5]P<F4N>&UL4$L%!@
0   +  L Z (  !X- @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
